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Adequate respiratory control is vital, but is disrupted by stressors such as 
inflammation or opioids. Additionally, early-life stressors may have long-lasting 
consequences for adult breathing, increasing the risk of disease. This dissertation focuses 
on how acute inflammation impairs adult respiratory control mechanisms and explores 
the consequences of two early life stressors, neonatal inflammation and perinatal opioids. 
Respiratory plasticity is a key feature of respiratory control, commonly studied in 
the form of phrenic long-term facilitation (LTF), evoked by acute intermittent hypoxia. 
Two distinct molecular pathways evoke LTF: the Q-pathway which is impaired by low-
level inflammation, and the S-pathway which is inflammation-resistant. Chapters II and 
III further our mechanistic understanding of how inflammation impacts respiratory 
plasticity. 
Chapter II demonstrates spinal activation of the interleukin-1 (IL-1) receptor is 
necessary for impairing Q-pathway LTF after inflammation. However, IL-1, the 
endogenous ligand of IL-1R, is not sufficient to impair LTF in healthy animals, 




While LPS or simulated sleep apnea induces inflammation and impairs Q-
pathway-evoked LTF, chapter III demonstrates these impairments are generalizable to 
viral-mimetic induced inflammation which impairs Q-pathway, but not S-pathway-
evoked pLTF.  
Chapter IV demonstrates the long-lasting impairment of adult respiratory 
plasticity following a single bout of LPS-induced early-life inflammation. Early-life 
inflammation impaired both Q-pathway and S-pathway-evoked LTF in male and female 
rats. Despite a lack of adult pro-inflammatory gene expression, Q-pathway LTF was 
restored by adult anti-inflammatory treatment, demonstrating ongoing inflammatory 
signaling after neonatal inflammation. S-pathway-evoked LTF was revealed by adenosine 
receptor agonism, suggesting upstream impairment in adenosine release. 
Chapter V investigates the impact of maternal opioid use, another common 
perinatal stressor. Maternal methadone increases neonatal apneas and mitigates acute 
methadone-induced respiratory depression, demonstrating perinatal opioids destabilize 
neonatal respiratory control in rats.  
These studies demonstrate neurorespiratory control is disrupted by acute 
inflammation, neonatal inflammation, and perinatal opioids. The research contributes to 
our fundamental understanding of how inflammation impairs adult respiratory plasticity, 
both acutely and after a single early-life exposure. Further, it lays the foundation for 
future studies investigating how perinatal opioids alter the developing respiratory control 
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INTRODUCTION AND BACKGROUND 
 This chapter includes previously published co-authored material (Hocker et al., 
2017). F. Powell, J. Stokes, and A.G. Huxtable contributed to writing and provided 
editorial input. 
 Appropriate ventilatory control is critical for preserving life and must adapt to 
ensure adequate breathing after diseases, disorders, and injuries. The respiratory control 
system modulates breathing to maintain homeostasis under changing physiological and 
environmental conditions, but also utilizes adaptive control mechanisms (e.g. respiratory 
plasticity) to maintain adequate breathing in the face of disease or injury. Furthermore, 
respiratory plasticity can be used therapeutically to enhance breathing when respiratory 
function is compromised. However, theses therapeutic benefits are thought to be limited 
by inflammation. This dissertation examines how two stressors, inflammation and opioids, 
alter the neural control of breathing and undermine the system’s capacity to adapt. I will 
examine 1) how acute inflammation, which is common in injury and diseases, undermines 
adult respiratory plasticity 2) how early-life inflammation can have lasting consequences 
for adult respiratory control and 3) the effects of perinatal opioids, which inhibit respiratory 
control centers in the brain, and how they influence the development of the respiratory 
control system.  
 The first chapter of this thesis reviews the neural control of breathing and how it 




the respiratory control networks and their capacity for plasticity, as well as how acute 
inflammation and opioids alter these functions. 
 
Neurorespiratory Control System 
 The respiratory system is a vital homeostatic system for maintaining blood gasses 
and appropriate pH. The respiratory system must be robust, yet highly adaptable to 
changes in the environment, metabolic demand, and injury or disease. This adaptability is 
created through both modulation and, a less well appreciated form of adaptation in the 
respiratory control system, neuroplasticity.  
 The neural network controlling breathing is comprised of regions in the pons, 
medulla, and spinal cord that integrate sensory feedback and shape inspiratory and 
expiratory muscle activation patterns to control ventilation. These respiratory-related 
regions contain a heterogenous population of excitatory and inhibitory neurons, named 
according to how the firing patterns correspond with inspiration and expiration. However, 
most regions have a generally agreed upon function supported by lesion, 
pharmacological, and optogenetic experiments.  
 
Neural Circuitry Controlling Breathing 
The primary site of respiratory control is the ventral respiratory column (VRC) in 
the medulla (Feldman, 1986), a long column of regions responsible for respiratory 







Figure 1.1. Brainstem and spinal cord circuitry controlling breathing. Respiratory 
networks in the pons, medulla, and spinal cord control breathing. Rhythmogenic regions 
send excitatory outputs to bulbospinal neurons innervating phrenic motor neurons, which 
innervate the diaphragm, the primary inspiratory muscle. Ventral Respiratory Column 
(VRC), Bötzinger complex (BötC), preBötzinger complex (preBötC), ventral respiratory 
group (VRG), rostral VRG (rVRG), caudal VRG (cVRG), facial nucleus (VII), 
hypoglossal motor nucleus (XII), retrotrapezoid nucelus (RTN), parafacial respiratory 
group (pFRG/RTN), nucleus of the solitary tract (NTS), nucleus ambiguous (NA), area 
postrema (AP), post-inspiratory complex (PICO), phrenic motor nucleus (PMN), lateral 
parabrachial region (LPBr), Kölliker Fuse nucleus (KF). (Adapted from Smith, Abdala, 
Borgmann, Rybak, & Paton, 2013; Smith, Abdala, Rybak, & Paton, 2009; Tan, 
Pagliardini, Yang, Janczewski, & Feldman, 2010)  
 
The most rostral component of the VRC is the parafacial respiratory group/retrotrapezoid 
nucleus (pFRG/RTN) containing Phox2b-positive neurons (Thoby-Brisson et al., 2009) 




early rhythmic activity shifts in adults to tonic activity (Mulkey et al., 2004), regulated by 
CO2/pH and inputs from peripheral chemoreceptors (Gourine et al., 2010; Takakura et 
al., 2006), and may be responsible for expiratory abdominal muscle activation during 
active expiration (Huckstepp et al., 2018). The Bötzinger complex (BötC) is caudal to the 
RTN and is primarily made up of inhibitory interneurons which fire primarily during 
expiration and project to the preBötC (Smith et al., 2009) (Fig. 1.1). Caudal to the BötC 
is the preBötzinger complex (preBötC), which has been widely studied because of its 
critical role in inspiratory rhythm generation (Smith et al., 1991). It is composed of 
inhibitory and excitatory propriobulbar neurons projecting to the BötC, rostral ventral 
respiratory group (rVRG), and suprapontine regions (Yang and Feldman, 2018).  These 
connections coordinate rhythmic activity between regions and may mediate the emotional 
and other complex behaviors that can be altered by breathing (Tan et al., 2010b; Yang 
and Feldman, 2018). Importantly, this region can autonomously produce rhythmic 
bursting output via multiple potentially overlapping mechanisms, discussed in more 
detail below. The ventral respiratory group makes up the caudal aspect of the VRC and 
can be subdivided into rostral and caudal portions. Both the rVRG and caudal VRG 
(cVRG) contain premotor bulbospinal neurons which transmit respiratory activity from 
the medulla to cranial and spinal respiratory motor neurons driving respiratory muscles 
(Smith et al., 2013). Neurons in the rVRG are primarily inspiratory, while neurons in the 
cVRG are primarily expiratory (Smith et al., 2013) (Fig. 1.1).  
Other brainstem areas contain important respiratory modulating regions, but are 
not required for rhythmic respiratory motor output. The pontine respiratory groups 




(Smith et al., 2009) (Fig. 1.1). The dorsal respiratory group (DRG) is located in the 
nucleus of the solitary tract (NTS) and relays afferent input from peripheral and central 
chemoreceptors, as well as stretch receptors in the lung (Hamnid et al., 2005). Lesions to 
the DRG greatly diminishes the hypoxic ventilatory response in rats (Cheng et al., 2002). 
The NTS is also involved in cardiovascular reflexes and contributes to cardiorespiratory 
coupling. A diagrammatic view of the major pontine, medullary, and spinal regions 
controlling breathing is shown in Figure 1.1. 
 
Rhythm Generation 
 Respiratory rhythm is generated from bilateral preBötC interneurons in the VRC 
of the medulla (Gray et al 2001, Gray et al., 1999, Smith et al 1991). Single cell, laser 
ablation studies demonstrate approximately 80% of the 700 preBötC neurons are 
necessary for rhythm generation (Hayes et al., 2012). These cells are networked with 
nearby respiratory-related medullary regions and work together to produce coordinated, 
rhythmic output to premotor neurons, which relay signals to respiratory motor neurons 
and the muscles responsible for breathing. Despite significant advances in the last 30 
years, the precise cellular mechanisms underlying rhythm generation remain unclear. 
Proposed mechanisms include the pacemaker hypothesis (Rekling and Feldman, 1998), 
group pacemaker hypothesis (Feldman and Del Negro, 2006), and burstlet hypothesis 
(Feldman and Kam, 2015). 
 The pacemaker hypothesis posits that a group of synaptically connected 
pacemaker neurons independently generate rhythm and is modulated by other neural 




two types of endogenously bursting pacemaker neurons identified in the preBötC. 
However, these intrinsic pacemaker cells are not required for respiratory rhythm 
generation in all conditions (Del Negro et al., 2002; Feldman et al., 2013; Pace et al., 
2007; Paton et al., 2006; Peña et al., 2004). It is likely that in different in vitro 
experimental preparations, including either more or less respiratory circuitry, each region 
contributes to distinct breathing patterns such as sighs, gasps, and eupenic breathing 
(Peña et al., 2004) 
 The group pacemaker hypothesis suggests that rhythm is generated through 
emergent network properties (Feldman and Del Negro, 2006), in contrast to rhythm being 
driven by groups of intrinsically rhythmic neurons. While the network contains cells 
capable of endogenous bursting, they are not necessary for rhythmic respiratory motor 
activity. The network contains synaptically coupled excitatory neurons which provide 
positive feedback to excite each other. Excitatory inward currents amplify this feedback 
and drive high frequency bursting activity (Feldman and Del Negro, 2006). The ability 
for emergent bursting from synaptically coupled excitatory neurons can be easily 
modeled as two synaptically coupled leaky, integrate-and-fire neurons (Rubin et al., 
2009). These emergent bursting properties, because they are driven by positive feedback 
between excitatory cells, require activity dependent, inhibitory outward currents to 
depress their activity (Rubin et al., 2009).  Additionally, synaptic depression between 
preBötC interneurons occurs during physiologically relevant firing patterns and could 
also contribute to deactivation of group pacemaker activity (Kottick and Del Negro, 
2015). In vivo, this likely occurs through synaptic inhibition, though inhibition is not 




 More recent models focus on the properties of microcircuits within the preBötC to 
understand how groups of neurons contribute to the entire circuit output (Feldman and 
Kam, 2015). The burstlet hypothesis suggests a small population (a microcircuit) of 
preBötC cells can generate small burstlets, which recruit larger populations of neurons to 
create a full population burst (Feldman and Kam, 2015). Burstlets occur rhythmically at 
the shortest inter-burst interval and are thought to set the rhythm of respiratory networks. 
Specifically, when the excitability of the network is decreased experimentally, inspiratory 
bursts are sometimes absent, but burstlets persist at the same rhythm (Kam et al., 2013a). 
This slowing of full population bursts is described as “quantal” slowing because the 
periods between full population bursts are integer (or quantal) multiples of the basal 
burstlet rhythm (Kam et al., 2013a). A recent study, using light-activated release of 
glutamate, showed activation of only nine randomly selected preBötC neurons 
reproducibly triggered a burst triggering a XII nerve burst (Kam et al., 2013b). As 
preBötC neurons are a heterogenous group of excitatory and inhibitory neurons with pre-
inspiratory, inspiratory, and post-inspiratory firing patters, the random selection of cells 
in this study suggests a smaller microcircuit is sufficient to induce burstlets driving 
breathing rhythm. Thus, it is possible a small subset of preBötC neurons create burstlets 
and are the source of respiratory rhythm generation. 
 Taken together, it is likely there are overlapping mechanisms within the 
respiratory network producing rhythmic breathing-related activity. Redundancy of these 
mechanisms is beneficial because it makes respiratory output robust in the face of 
potential insults. It also has made the search for the smallest necessary unit of rhythm 




rely on different rhythm generating mechanisms. For example, as mentioned above, some 
endogenous rhythmic bursting mechanisms are necessary for gasping in situ, but not 
eupneic respiratory output (Paton et al., 2006). Therefore, the mechanisms responsible for 
respiratory rhythm generation may change under different conditions making them 
difficult to fully elucidate. 
Though the preBötC is the accepted kernel of respiratory rhythm generation, there 
are at least two other distinct rhythmogenic regions in the medulla involved in rhythm 
generation. The parafacial respiratory group/retrotrapezoid nucleus (pFRG/RTN) is the 
most rostral component of the VRC, contains endogenous pacemaker neurons, and can 
fire before and drive preBötC rhythm early in development (Onimaru and Homma, 
2003). The pFRG is important early in life for driving inspiratory rhythm as it is 
hypothesized to maintain breathing shortly after birth when the preBötC is inhibited by 
an endogenous opioid surge (Jacquin et al., 1996). Additionally, these two synchronous 
pacemakers in the developing respiratory network create the conditions required for 
quantal slowing of breathing.  This occurs when the preBötC is inhibited by opioids and 
the pFRG rhythm maintains the rhythm of breathing, but transmission failure through the 
preBötC leads to reductions in inter-burst intervals in predictable integers of the basal 
frequency (Mellen et al., 2003). Importantly, this phenomenon demonstrates the 
interactions between these two oscillators (Wittenmeir et al., 2008). However, the 
pFRG/RTN is only involved in inspiratory rhythm generation early in life (Janczewski 
and Feldman, 2006). Later in adolescence, the pFRG/RTN shifts to predominantly 
driving expiratory motor output during exercise or hypercapnia (Huckstepp et al., 2016a, 




 A separate, rhythmic post-inspiratory oscillator has been described dorsal and 
caudal to preBötC called post-inspiratory complex (PICO) (Anderson et al., 2016).  PICO 
is an excitatory network thought to regulate the post-inspiratory phase of breathing and is 
autonomously rhythm generating in phase with respiratory motor output (Anderson et al., 
2016). This discovery suggests the possibility that three distinct oscillatory regions 
control separate phases of the respiratory cycle: preBötC for inspiratory rhythm, PICO 
for post-inspiratory rhythm, and pFRG for expiratory rhythm. However, it remains 
unclear if the role of PICO changes during early post-natal development similar to the 
pFRG.  
 
Feedback Control Mechanisms 
 The rhythmic respiratory control centers also must be capable of considerable 
adaptability to compensate for changes in activity and environment, and thus respond to 
inputs to maintain homeostasis. Afferent inputs from central and peripheral 
chemoreceptors mediate the hypoxic and hypercapnic ventilatory responses to maintain 
appropriate blood gasses, and vagal inputs from the lung relay information about lung 
stretch and irritation (Feldman, 1986).   
 The hypoxic ventilatory response (HVR) is a triphasic response to reflexively 
ensure adequate oxygen delivery. Peripheral chemoreceptors located in the carotid body 
rapidly detect changes in arterial oxygen (PaO2) and are responsible for the initial rapid 
phase of hypoxic ventilatory response. The initial phase consists of a rapid increase in 
breathing frequency and increasing tidal volume within the first two minutes of hypoxic 




secondary phase of the HVR is evident as a decrease and eventual plateau of ventilation 
termed hypoxic ventilatory depression (HVD) (Powell et al., 1998). This secondary 
depression is primarily mediated by changes in frequency (Powell et al., 1998) and may 
be attributed to central mechanisms (Gourine and Funk, 2017). Lasting hypoxic exposure 
for days leads to ventilatory acclimatization, the third phase of the HVR (Powell et al., 
1998). 
 The HVR develops significantly during the early post-natal period. Very young 
neonatal animals have significant HVD which depresses breathing below baseline levels 
within a few minutes of exposure to hypoxia (Liu et al., 2006; Moss et al., 1987; Rajani 
et al., 2018; Thoby-brisson and Greer, 2010; Wong-Riley and Liu, 2008). During the first 
two weeks of life, HVD becomes less severe, such that hypoxic responses remain above 
baseline ventilation levels and animals can more adequately maintain oxygen saturation. 
The precise mechanisms underlying this change in the HVD remains unclear, but it likely 
reflects central shifts in neurochemical signaling. Shifting adenosine receptor expression 
and alterations in the expression of glutamate receptors contribute to HVD (Funk, 2013). 
Additionally, changes in hypoxia induced hypometabolism may contribute to the 
development of the HVR (Liu et al., 2006). The significant HVD in young animals makes 
them more vulnerable to hypoxia. Thus, appropriate development of the HVR after birth 
is critical.  
 Central chemoreceptors sense CO2 indirectly through changes in local pH 
(Guyenet and Bayliss, 2015). CO2 is able to cross the blood-brain barrier and is converted 
to changes in pH by reaction with carbonic acid. pH sensitive neurons in the ventrolateral 




central chemoreception (Guyenet et al., 2008; Nattie, 1999). However, the RTN is more 
sensitive to physiological ranges of pH and contributes to the majority of the hypercapnic 
ventilatory response making it a strong candidate for physiological control of PaCO2 
(reviewed in Guyenet and Bayliss, 2015). Further, some medullary regions may increase 
the gain of pH sensitivity in other regions and together multiple regions may have 
cumulative effects on breathing under physiological conditions (Nattie and Li, 2009). It is 
likely that overlapping pH sensitive mechanisms in the medulla work together to mediate 
physiological responses to changes in PaCO2, and that the overlapping mechanisms add 
malleability and create a more robust network response.  
 The carotid bodies, which primarily sense PaO2, also contribute to the HCVR. 
Thus, not all of the HCVR is due to central mechanisms. Remarkable studies in dogs 
demonstrate locally perfused carotid bodies determine the pH sensitivity of central 
responses to increasing PaCO2 (Blain et al., 2010; Smith et al., 2015). A hypercapnic 
carotid body can double or triple the central response to PaCO2 (Blain et al., 2010; Smith 
et al., 2015). Thus, cumulative effects of simultaneous activation of distinct CO2 sensing 
regions, both peripheral and central, are important for the ventilatory response to 
changing CO2/pH.  
 
Respiratory Motor Plasticity 
Respiratory plasticity is a fundamental feature of the respiratory control circuitry. 
Plasticity, defined as a change in future behavior based on prior experience (Mitchell and 
Johnson, 2003), can occur at any point within the respiratory circuitry, including the 




pools innervating respiratory muscles. Respiratory plasticity is thought to be critical for 
maintaining adequate breathing in the face of lung and neural control disorders by 
affording adaptability of the respiratory system to changing internal and external 
environments (Fuller and Mitchell, 2017; Mitchell and Johnson, 2003).  
The most well-studied model of respiratory plasticity is phrenic long-term 
facilitation (pLTF), a long-term increase in phrenic burst amplitude induced by acute 
intermittent hypoxia (AIH, Fig. 1.2). pLTF occurs in or around phrenic motor neurons in 
the cervical spinal cord (Baker-Herman et al., 2004; Dale et al., 2017; Devinney et al., 
2015a) and is induced by at least two distinct cellular signaling pathways: the Q-pathway 
and the S-pathway (Dale-Nagle et al., 2010) (Fig. 1.3). The Q-pathway is serotonin-
dependent and induced by moderate AIH (mAIH, 3x5 minute hypoxic episodes, PaO2 35-
45 mmHg) (Baker-Herman and Mitchell, 2002), while the S-pathway involves activation 
of adenosine receptors and is induced by severe AIH (sAIH, PaO2 25-35 mmHg) 
(Nichols et al., 2012) (Fig. 1.3). The cellular mechanisms of Q- and S-pathway plasticity 
are distinct (Turner et al., 2018), but evoke a similar lasting facilitation of phrenic motor 
output. The mechanisms leading to prolonged phrenic motor output after AIH (Fig. 1.1) 
are hypothesized to involve phosphorylation of phrenic motor neuron glutamate receptors 
(Turner et al., 2018). In support of this hypothesis, multiple reports have demonstrated 
that a NMDA receptor antagonist prevents development of pLTF after mAIH (McGuire 
et al., 2005, 2008). Furthermore, after S-pathway activation with intermittent adenosine 
receptor agonism, NMDA receptor antagonism inhibits the development of pLTF 
(Golder, 2009), suggesting Q-pathway and S-pathway-evoked plasticity converge by 







Figure 1.2. Acute intermittent hypoxia elicits long-term facilitation of phrenic burst 
amplitude. Integrated phrenic ( Phr) nerve recording from an anesthetized, ventilated, 
paralyzed, and vagotomized adult rat. Phrenic long-term facilitation (pLTF) is evident as 
the progressive increase in phrenic burst amplitude 60 minutes after acute intermittent 
hypoxia (AIH, 3, 5-minute bouts of hypoxia). pLTF is quantified as the percent change of 















Figure 1.3. Distinct cellular pathways induce pLTF after either moderate or severe 
AIH. The working mechanistic model of pLTF in phrenic motor neurons. Moderate AIH 
activates Gq-coupled receptors leading to Q-pathway-evoked pLTF, while severe AIH 
activates a Gs-coupled S-pathway-evoked pLTF. (Adapted from Turner et al., 2018). 
 
 In disease and injuries compromising ventilation, plasticity within the respiratory 
system is thought to compensate and stabilize breathing (Fuller and Mitchell, 2017). 
However, AIH-induced motor plasticity is not limited to respiratory-related motor output. 
AIH facilitates motor output from all studied spinal motor pools (Baker-Herman and 




Mitchell, 2002; Christiansen et al., 2018; Hayes et al., 2014; Mitchell and Johnson, 2003; 
Trumbower et al., 2017), suggesting it has significant therapeutic value for patients with 
motor limitations. In fact, multiple clinical trials have now demonstrated AIH-induced 
improvements in upper and lower limb motor function in patients with incomplete spinal 
cord injuries (Hayes et al., 2014; Trumbower et al., 2012, 2017). Therefore, 
understanding the mechanisms underlying AIH-induced motor plasticity may have 




 Undermining the respiratory control system poses a significant threat to 
maintaining homeostasis. Multiple studies have examined how pharmacological agents 
(like opioids) or diseases (like sleep apnea) cause dysfunction in the respiratory system, 
but more recent studies have begun to investigate the interplay between the immune 
system and the respiratory system. A common attribute of almost all diseases and 
disorders, respiratory or other, is inflammation. Increasing evidence supports a dynamic 
role for inflammation in promoting or inhibiting different forms of neuroplasticity (Di 
Filippo et al., 2008; Liu et al., 2011; Stemkowski and Smith, 2012; Watkins and Maier, 
2002; Woolf and Salter, 2000). Since the therapeutic benefits of AIH-induced motor 
plasticity may be impaired by underlying inflammation, many investigations into the role 
of inflammation in the respiratory system have focused on plasticity. Understanding how 
inflammation alters the respiratory system is vital for development of better therapeutic 





Models of Systemic Inflammation 
Since LPS activates endogenous inflammatory pathways and much is known 
about its signaling cascade, it serves as a relevant ligand to induce systemic inflammation 
experimentally. LPS is a component of gram-negative bacterial cell walls and activates 
the innate immune response via Toll-like Receptor 4 (TLR4). TLR4 activation induces 
pro-inflammatory gene expression through activation of MAPKs JNK, ERK, p38 MAPK, 
and the transcription factor NF-ĸB (Kuzmich et al., 2017). Many endogenous ligands also 
activate TLR4 including proteins released from dead or dying cells, heat shock proteins, 
and modified low-density lipoproteins (Erridge, 2010; Lehnardt et al., 2008; Ohashi et 
al., 2000). As both bacterial and endogenous activation of TLR4 are possible sources of 
inflammation throughout our lives, LPS serves as a relevant model to understand the 
impact of inflammation.  
 Viral infections are also common models of inflammation and induce similar 
inflammatory signaling pathways to LPS-induced inflammation. RNA viruses induce 
inflammation through activation of TLR3, TLR7, and TLR8 (Carrithers, 2014). The most 
common model of viral infections is the viral mimetic, polyinosinic:polycytidylic acid 
(polyIC), a synthetic dual-stranded RNA (dsRNA) molecule activating TLR3. TLR3 
activation elicits overlapping inflammatory profiles to other TLRs, including activation 
of NF-kB and MAPKs, and increased pro-inflammatory gene expression (Konat et al., 
2009; Krasowska-Zoladek et al., 2007; Yamato et al., 2014). However, the inflammatory 
cascade and gene expression profile from viral inflammation is distinct from bacterial 
inflammation (Hu et al., 2013). Furthermore, polyIC can compromise the blood-brain 




inflammatory transmission are similar between polyIC and LPS. Importantly, polyIC-
induced inflammation induces temporally slower onset of inflammatory genes in the CNS 
compared to LPS (Konat et al., 2009; Krasowska-Zoladek et al., 2007; Yamato et al., 
2014), and therefore, it has the potential to have different effects on pLTF. Overall, both 
bacterial and viral-induced inflammation are common (Obasi et al., 2014) and elicit 
overlapping, but distinct, inflammatory profiles.  
 
CNS Inflammation  
 The mechanisms of peripheral to CNS transmission of inflammation are still an 
active area of investigation, but at least four possible routes of inflammatory transmission 
have been demonstrated. Peripheral immune cells and pro-inflammatory molecules can 
cross the BBB under certain conditions or induce inflammatory signaling within the CNS 
via cross-talk between endothelial cells, neurons, and glia (Lampron et al., 2013). 
Circumventricular organs also play a role in CNS responses to inflammation by allowing 
either LPS or cytokines to interact directly with neurons and glia. The area postrema 
contains cells activated by LPS, TNFα, and IL-1β (Wuchert et al., 2008; Wuchert et al., 
2009). However, the capacity for LPS penetration across the BBB is low (Banks and 
Robinson, 2010), yet even low-dose LPS (intraperitoneal or intratracheal) is sufficient to 
induce inflammatory gene and protein expression in the CNS without LPS crossing the 
BBB (Balan et al., 2011; Banks and Robinson, 2010; Laye et al., 1995). Vagal afferents 
moderate communication of low-level systemic inflammation to the CNS, since 
vagotomy eliminates the febrile response associated with sickness and inflammation after 




alternative routes for transmission and induction of CNS inflammation (Romanovsky et 
al., 1997), as evident by subdiaphragmatic vagotomy inhibiting CNS gene expression of 
IL-1β after i.p. LPS (Laye et al., 1995), and cervical vagotomy inhibiting medullary IL-
1β after intratracheal LPS (Balan et al., 2011).  
 Therefore, there is considerable communication between the peripheral and 
central immune responses. In the experiments below, I use bacterial and viral 
inflammatory stimuli to induce systemic inflammatory responses, which are then 
transmitted to the CNS to mediate neurophysiological effects. These paradigms represent 
physiologically relevant stimuli for inducing central inflammatory responses compared to 
direct immune stimulation in the CNS, which is rare. Additionally, the doses of 
inflammation used in the following experiments are relatively low in most cases and do 
not evoke sepsis. Therefore, the models of inflammation used here are relevant for 
understanding low-level inflammation, such as would be expected in diseases and 
injuries. 
  
Inflammation and Respiratory Motor Plasticity 
Q-pathway-evoked respiratory motor plasticity is exquisitely sensitive to even 
low-levels of inflammation. In adults, Q-pathway-evoked plasticity is undermined by low 
levels of acute, systemic inflammation induced by a TLR4 agonist (lipopolysaccharide, 
LPS) (Huxtable et al., 2011; Vinit et al., 2011) or 8 hours of intermittent hypoxia 
(Huxtable et al., 2015, 2017) and restored by the non-steroidal anti-inflammatory, 
ketoprofen (Huxtable et al., 2013, 2015). On the contrary, S-pathway-evoked adult 




therefore it has the potential to serve as a “backup” pathway to preserve plasticity after 
inflammation. 
 Since AIH-induced plasticity is being translated to clinical populations (e.g. after 
spinal cord injury) (Hayes et al., 2014; Trumbower et al., 2012, 2017) with low-levels of 
systemic/neuroinflammation, interest in the impact of inflammation on motor plasticity is 
growing. Previous studies on inflammation-induced impairments in pLTF have focused 
on lipopolysaccharide (LPS, bacterial induced-inflammation) (Huxtable et al., 2013; 
Vinit et al., 2011)  or simulated sleep apnea induced by nocturnal intermittent hypoxia 
(Huxtable et al., 2015, 2017). LPS induces systemic inflammation, increases brain 
inflammatory cytokines, and undermines pLTF within 3 hours (Huxtable et al., 2013), 
while nocturnal intermittent hypoxia is a relevant physiological perturbation (Huxtable et 
al., 2015). However, the signaling mechanisms by which inflammation undermines 
respiratory motor plasticity are not yet fully understood. The anti-inflammatory, 
ketoprofen, restores Q-pathway-evoked pLTF after LPS or nocturnal intermittent hypoxia 
(Huxtable et al., 2013, 2015). Ketoprofen inhibits both COX and NF-κB (Cashman, 
1996; Yin et al., 1998). However, as COX inhibition alone does not restore Q-pathway-
evoked pLTF after inflammation, the restoration of pLTF from ketoprofen is likely due to 
NF-κB inhibition (Huxtable et al., 2017). Additionally, after nocturnal intermittent 
hypoxia, spinal p38-MAPK inhibition restores pLTF (Huxtable et al., 2015). Thus, 
inflammation is responsible for impairing pLTF and activates inflammatory signaling via 
p38 MAPK within phrenic motor neurons. However, the inflammatory signaling 
molecules responsible for inducing inflammation in the phrenic motor pool remain to be 




Though studies to date have focused on LPS or intermittent-hypoxia induced 
impairments in pLTF, viral infections are also common (Obasi et al., 2014) and induce an 
overlapping, but unique, inflammatory profile. As inflammation comes from diverse 
stimuli during our lives, understanding the effects of viral-induced inflammation on 
respiratory motor plasticity broaden our understanding of the impact of inflammation on 
respiratory control. Additionally, while the inflammatory impairment of Q-pathway-
evoked plasticity has been confirmed in multiple models, S-pathway-evoked plasticity 
has only been studied after LPS-induced inflammation (Agosto-Marlin et al., 2017, 
2018). Therefore, my second aim will investigate the effects of viral-induced 
inflammation on Q- and S-pathway-evoked pLTF. Because S-pathway plasticity may 
serve important roles as a backup pathway during inflammation, this study will 
significantly contribute to our understanding of how respiratory motor plasticity 
manifests during inflammation and potential strategies for therapeutic use.  
 
Lasting Consequences of Neonatal Inflammation 
We are beginning to understand the potential for long-term physiological 
consequences after early life inflammation, including impairments of adult immune 
function (Bilbo et al., 2010; Mouihate et al., 2010; Spencer et al., 2011), adult stress 
reactivity (Grace et al., 2014; Shanks et al., 2000; Wang et al., 2013), adult learning and 
hippocampal plasticity (Bilbo, 2005; Bilbo et al., 2006), age-related cognitive decline 
(Bilbo, 2010), and increased risk of neuropsychiatric disorders (Hornig et al., 1999; 




et al., 2002, 2004), little is known about the long-lasting consequences of neonatal 
inflammation on adult neurorespiratory control. 
At birth, neonates transition from a sterile maternal environment into an 
environment filled with pathogens and inflammatory stimuli and must simultaneously 
begin robust, rhythmic breathing. Respiratory problems represent a significant clinical 
problem for neonatologists (Martin et al., 2012), especially in preterm infants where 
breathing is unstable (Poets et al., 1994; Poets and Southall, 1994) and infections are 
common (Stoll et al., 2002, 2004). Further, inflammation appears to augment respiratory 
dysfunction in neonates, whereby inflammation depresses hypoxic responses (Olsson et 
al., 2003; Rourke et al., 2016) and induces recurrent apneas (Hofstetter et al., 2007). 
Despite the prevalence of early life inflammation, little is known about the long-lasting 
consequences of neonatal inflammation on adult neurorespiratory control. Furthermore, 
few studies have investigated sex-differences in pLTF (Behan et al., 2002; Dougherty et 
al., 2017) and we know even less about sex-differences in respiratory control in response 
to inflammation. However, there are sex differences in inflammatory responses whereby 
females are typically protected from some negative consequences of inflammation due to 
more rapid resolution of inflammation (Rathod et al., 2017) and the protective effects of 
female sex hormones (Bouman et al., 2005; Rathod et al., 2017). Furthermore, females are 
less susceptible to long-term effects of neonatal inflammation on adult behaviors (Kentner 
et al., 2010). Given the profound effects of neonatal inflammation on other physiological 
systems, the third aim of this dissertation will examine the hypothesis that neonatal 







 Opioids are among the most potent analgesics, yet their use is limited by 
significant side-effects such as sedation, dizziness, nausea, constipation, itching, 
allodynia, physical dependence, tolerance, and respiratory depression (Benyamin et al., 
2008). The misuse of opioids has become a national and public health crisis with more 
than 118 US residents dying from opioid overdoses daily in 2016, representing a 27% 
increase from the previous year and accounting for two thirds of drug-overdose deaths in 
the USA (CDC WONDER, 2018). Not only is this a major public health concern, but it 
carries a significant economic burden, estimated to be >$78.5 billion in 2013 (Florence et 
al., 2016). 
 Repeated opioid use induces tolerance leading to the use of higher opioid doses 
which cause profound respiratory depression, thought to be the most life-threatening side-
effect of opioids (reviewed in Hutchinson et al., 2011). Since the respiratory control 
system does not develop opioid-induced tolerance (Emery et al., 2016; Levitt and 
Williams, 2018), respiratory depression is a potentially lethal risk of opioid misuse.  
 
Opioids and Respiratory Rhythm Generation 
 The physiological effects of opioids are complicated by opioid receptor (OR) 
subtypes, interactions with other non-opioid receptors, divergent signal transduction 
cascades, and interactions between opioids and inflammatory signaling (Hutchinson et 
al., 2009). Three main types of ORs (, , and ) are largely responsible for mediating 




al., 2011). ORs are primarily inhibitory Gi-protein-coupled receptors hyperpolarizing 
neurons through activating protein kinase A (PKA), inhibiting voltage-dependent Ca2+ 
channels, reducing Na+ conductance, and activating inward-rectifying K+ channels 
(Montandon et al., 2011, 2016). Within the respiratory control circuitry, MOR are 
expressed in the ventral respiratory column with the highest density of receptor 
expression near the preBötC and very little receptor expression in the more rostral 
pFRG/RTN (Kennedy, 2014). In vitro and in vivo data from rodents demonstrate the 
major effect of opioids is to depress breathing through the preBötC (Montandon et al., 
2011), while the pFRG/RTN is relatively opioid insensitive (Mellen et al., 2003; Takeda 
et al., 2001). The organization of these two coupled oscillators and their differential 
sensitivity to opioids creates the conditions for opioid-induced quantal slowing of 
respiratory rhythm. Quantal slowing indicates a reduction in frequency at integer 
multiples of the control period. The proposed mechanism for this effect is the opioid-
insensitive pFRG/RTN continues to oscillate at the control period, but there is 
transmission failure through the inhibited preBötC, causing some breaths to be skipped 
(Mellen et al., 2003). The appearance of quantal slowing demonstrates preBötC and 
pFRG activities are coordinated and suggests the pFRG could act as a backup in the 
presence of opioids to promote breathing.  
 
Perinatal Opioids and Respiratory Control 
 Recently, there has been a disproportionate rise in opioid use during pregnancy 
(Epstein et al., 2013; Krans et al., 2015; Stover and Davis, 2015). Maternal opioid use 




nystagmus, sleep disturbances, respiratory deficits, and even death (McQueen and 
Murphy-Oikonen, 2016). Clinically these infants (55-94%, Finnegan et al., 1975; Hudak 
et al., 2012) are diagnosed with neonatal abstinence syndrome (NAS), described as 
dysfunction in the central and autonomic nervous systems, and gastrointestinal system, 
though the pathophysiology and treatments for these infants remains unclear. The 
increase maternal use of opioids and risk of NAS leads to a significant need to develop 
better treatments for neonates born from mothers using opioids (Kraft et al., 2016). 
However, discrepancies are abundant regarding how neonates with NAS should be 
treated clinically (McQueen and Murphy-Oikonen, 2016). Current treatments for NAS 
include methadone, morphine, or buprenorphrine (Kocherlakota, 2014); however, ideal 
dosing guidelines are not clear (McQueen and Murphy-Oikonen, 2016). Overall, as 
maternal opioid use increases, understanding the impacts of gestational opioids and how 
to best treat infants represents a critical clinical need (McQueen and Murphy-Oikonen, 
2016). 
 As maternal opioids cross the placenta (Hauser and Knapp, 2018; Kopecky et al., 
1999) and suppress respiratory rhythm generation in the preBötC, they may inhibit 
appropriate development of the respiratory control system. The respiratory system must 
be fully functional at birth and capable of robust, rhythmic breathing. Rhythmic neural 
activity, initiating at the preBötzinger complex (preBötC, the kernel for respiratory 
rhythmogenesis) is required for adequate development of neural circuitry, respiratory 
muscles, and the lungs (Greer, 2012; Pagliardini et al., 2003). In rats, development of 
respiratory neural networks begins around embryonic day 17 (E17) and continues until 




the medulla, they begin rhythmic activity which activates respiratory motor neurons and 
drive fetal breathing movements (Greer, 2012; Pagliardini et al., 2003). Importantly, the 
preBötC is exceptionally sensitive to opioids and is responsible for many of the 
respiratory depressant effects of neonatal opioids (Montandon et al., 2011, 2016; Stucke 
et al., 2015). Therefore, in the presence of prenatal opioids, the respiratory control 
networks need to compensate to maintain adequate development and appropriate 
respiratory function at birth (Gourévitch et al., 2017). However, controlled studies on 
neonatal breathing after maternal opioids are extremely limited. One study demonstrated 
medullary respiratory network reorganization after maternal opioid exposure in neonatal 
rats (Gourévitch et al., 2017) and another study in guinea pigs demonstrates hypercapnic 
ventilatory responses are enhanced in pups exposed to prenatal opioids (Nettleton et al., 
2008), suggesting changes in chemosensitivity after maternal opioids. To our knowledge, 
the study presented in Chapter V will be the first investigating changes in neonatal 
breathing after maternal opioid use in rats. Additionally, since NAS infants are typically 
treated with exogenous opioids to alleviate withdrawal symptoms (Pryor et al., 2017), the 
final aim of this dissertation will also assess neonatal ventilatory responses after maternal 
opioid use and repeated, acute, neonatal methadone exposure. 
As maternal opioid use increases, understanding the acute and long-term effects 
will be critical to effectively treating neonates exposed to perinatal opioids. Additionally, 
understanding how maternal opioid use alters the respiratory effects of acute opioid 
exposure in neonates will contribute to our understanding of how to best treat neonates to 






  This dissertation focuses on furthering our understanding of how inflammation or 
opioids undermine the neurorespiratory control system. These studies provide novel 
findings on the mechanisms of inflammatory impairment of respiratory plasticity and 
how maternal opioids impact neonatal breathing. The first aim will focus on the effects of 
acute inflammation and the mechanisms by which they impair adult respiratory plasticity. 
These mechanistic insights may help in developing clinical strategies to promote 
plasticity after inflammation. Next, I compare the generalizability of inflammation-
induced impairments in respiratory plasticity between bacterial and viral sources of 
inflammation. These studies suggest distinct inflammatory stimuli can impair respiratory 
plasticity and suggest inflammation, regardless of the source, could limit respiratory 
control mechanisms. The remainder of the dissertation focuses on perinatal challenges 
when the respiratory system is vulnerable and relatively unstable. Chapter IV will 
describe the lasting effects of a single bout of early life inflammation on adult respiratory 
motor plasticity and broadens our understanding of motor plasticity to both males and 
female rats. Chapter V of this dissertation investigates the respiratory consequences of 
perinatal opioids to better understand how maternal opioid use alters the neurorespiratory 
control system and how neonatal opioids affect breathing after in utero exposure. These 
studies lay a solid foundation for future work understanding and treating neonates 






INTERLEUKIN-1 SIGNALING AFTER ACUTE, SYSTEMIC INFLAMMATION 
UNDERMINES ADULT RESPIRATORY MOTOR PLASTICITY 
 
 This chapter includes co-authored material previously published in the Journal of 
Applied Physiology (Hocker and Huxtable 2018). I designed and implemented the 
experiments, collected and analyzed data, and wrote the manuscript. Dr. Adrianne 
Huxtable designed, contributed to writing, provided guidance and editorial assistance.  
Introduction 
Our understanding of how systemic inflammation alters CNS function has 
accelerated with the identification of peripheral cytokines inducing CNS inflammation by 
crossing the blood brain barrier, entering the CNS at circumventricular organs, activating 
vagal afferents (Hosoi et al., 2000; Laye et al., 1995), or activating blood brain barrier 
endothelial cells and glia (Ching et al., 2007; Iwase et al., 2000; Quan et al., 2003). In 
turn, this peripheral to central inflammatory signaling alters CNS function by modulating 
glia (Liddelow et al., 2017) and significantly affecting neuroplasticity (Di Filippo et al., 
2008). The inflammatory deficits in plasticity can limit neural control mechanisms and 
impair physiological regulatory processes. 
A complicated relationship exists between inflammatory signaling and 
neuroplasticity. Inflammatory signaling in the CNS promotes and inhibits distinct forms 
of neuroplasticity in different CNS regions through the actions of the interleukin-1 (IL-1) 
signaling cascade. CNS IL-1β and its corresponding IL-1 receptor (IL-1R) are 




(LPS) (Di Filippo et al., 2008; Huxtable et al., 2013; Turrin et al., 2001). IL-1β is 
sufficient to inhibit hippocampal-dependent memory formation and long-term 
potentiation, a form of plasticity important for learning and memory formation (Katsuki 
et al., 1990). However, a genetic knockout of the IL-1R undermines hippocampal-
dependent memory formation and abolishes plasticity in the form of long-term 
potentiation (Avital et al., 2003; Di Filippo et al., 2013; Schneider et al., 1998), 
demonstrating IL-1 signaling both contributes to and undermines hippocampal plasticity. 
Conversely, spinal pain hypersensitivity, a form of neuroplasticity in the spinal dorsal 
horn, is induced by inflammatory stimuli involving IL-1R activation (Cunha et al., 2008; 
Maier et al., 1993; Zhang et al., 2008). Thus, IL-1β and IL-1Rs have complicated effects 
on neuroplasticity, whereby IL-1R signaling can either promote or inhibit plasticity 
depending where in the CNS region plasticity is occurring. 
The respiratory control system, like other CNS regions, undergoes plasticity to 
confer stability and adaptability to respiratory output (Devinney et al., 2015b; Mitchell 
and Johnson, 2003). Phrenic long-term facilitation (pLTF) is a frequently studied model 
of neuroplasticity in the respiratory control system (Mitchell and Johnson, 2003). pLTF is 
induced by acute intermittent hypoxia (AIH: three 5-min hypoxic episodes, separated by 
5 min normoxic periods) and manifests as a progressive increase in phrenic nerve burst 
amplitude following AIH. Previously, we have shown pLTF is abolished by systemic 
inflammation and IL-1β gene expression increases after systemic inflammation in the 
cervical spinal cord (Huxtable et al., 2013, 2015). However, the inflammatory signaling 





 Given the central role for IL-1R signaling in other forms of plasticity and 
increased IL-1β gene expression in the cervical spinal cord (where purportedly pLTF 
occurs (Baker-Herman et al., 2004; Dale et al., 2017)) after systemic inflammation, we 
investigated the necessity and sufficiency of IL-1 signaling to undermine pLTF after 
systemic inflammation. We demonstrate that IL-1R activation, both systemically and 
centrally, undermines pLTF after LPS-induced systemic inflammation. Yet, in healthy 
rats, acute, exogenous IL-1β spinally was not sufficient to undermine pLTF. Overall, our 
findings further our mechanistic understanding of how plasticity in the neural control of 
breathing is abolished by systemic inflammation. 
 
Methods 
All experiments were approved by the Institutional Animal Care and Use 
Committee at the University of Oregon and conformed to the policies of the National 
Institute of Health Guide for the Care and Use of Laboratory Animals. Male Sprague 
Dawley Rats (300-400g; 3-4 months; Envigo Colony 217 and 206) were housed under 
standard conditions with a 12:12h light/dark cycle with food and water ad libitum. 
Drugs and Materials 
Lipopolysaccharide (LPS; 0111:B4, Sigma Chemical) was dissolved and 
sonicated in sterile saline to a working concentration of 100 g/mL given via 
intraperitoneal (i.p.) injections. The IL-1R antagonist, AF-12198 (Toronto Research 
Chemicals) was dissolved in 10% ethanol and sterile saline for peripheral injections (0.5 
mg/mL) or in fresh artificial cerebrospinal fluid (aCSF; 120mM NaCl, 3mM KCl, 2mM 




(1 mM). Recombinant rat IL-1β (rIL-1, BioVision 4130) was dissolved in aCSF for i.t. 
injections (0.25-10 ng/L). 
Experimental Groups 
To investigate the necessity of peripheral IL-1R activation in undermining pLTF, 
we used the following experimental groups: 1) LPS (100 µg/kg i.p., 24 hours before AIH) 
+ AF-12198 (0.5 mg/kg i.p., 24 hours before AIH) (n = 5); 2) LPS + Vehicle (10% 
ethanol in sterile saline) (n = 5); 3) Saline (i.p.; LPS Vehicle) + AF-12198 (n = 6); 4) 
Saline + Vehicle (n = 5); 5) Time control (TC), which consists of rats from each of the 
previous treatment groups (LPS + AF-12198 (i.p.), n=4; Saline + AF-12198 (i.p.), n=5; 
LPS + Vehicle (i.p.), n=4; Saline + Vehicle (i.p.) n=4). 
To investigate the necessity of spinal IL-1R activation in undermining pLTF after 
systemic inflammation, we used the following experimental groups: 1) LPS (100 µg/kg 
i.p., 24 hours before AIH) + AF-12198 (1 mM, 15 L, i.t., 20 min before AIH) (n = 4); 2) 
LPS + Vehicle (10% ethanol in sterile saline, i.t.) (n = 5); 3) Saline (i.p.) + AF-12198 
(i.t.) (n = 4); 4) Saline + Vehicle (i.t.) (n = 4); 5) TCs, which consist of rats from each of 
the previous treatment groups (LPS + AF-12198 (i.t.), n=4; Saline + AF-12198 (i.t.), n=3; 
LPS + Vehicle (i.t.), n=4; Saline + Vehicle (i.t.), n=4). 
To investigate the sufficiency of acute, exogenous, spinal rIL-1 to undermine 
pLTF, we performed a dose-response with exogenous rIL-1 (i.t.) at 1 ng (n = 3), 10 ng 
(n = 3), 100 ng (n = 4), and 300 ng  (n = 4). AIH was performed 20 minutes after spinal 
rIL-1 injections. 
To investigate the effects of acute, exogenous, spinal rIL-1 on phrenic burst 




300 ng (n = 3)) was applied over the cervical spinal cord and phrenic neural output 
monitored over the next 105 minutes. 
Electrophysiological studies 
Electrophysiological studies have been described in detail previously (Huxtable et 
al., 2015). Rats were anesthetized with isoflurane, tracheotomized, ventilated (Rat 
Ventilator, VetEquip®) and bilaterally vagotomized. A venous catheter was placed for 
drug delivery and fluid replacement, and a femoral arterial catheter was used for arterial 
blood analysis and monitoring blood pressure. Arterial blood samples were analyzed 
(PaO2, PaCO2, pH, base excess; Siemens RAPIDLAB® 248) before AIH, during the first 
hypoxic response, and 15, 30 and 60 minutes post-AIH. Temperature was measured with 
a rectal temperature probe (Kent Scientific Corporation) and maintained between 37 and 
38°C with a heated table. Using a dorsal approach, hypoglossal and phrenic nerves were 
dissected, cut distally, and desheathed. Rats were converted to urethane anesthesia (1.8 
g/kg i.v.; Sigma-Aldrich), allowed to stabilize over the next hour, and paralyzed with 
pancuronium dibromide (1 mg/rat; Selleck Chemicals). 
In rats receiving i.t. injections, a laminectomy was performed at cervical vertebrae 
2 (C2) and a primed, silicone catheter was inserted two millimeters through a small 
incision in the dura. The catheter tip extended toward the rostral margin of C4 (Baker-
Herman and Mitchell, 2002). AF-12198 (1 mM) or vehicle (aCSF) was injected (15 µL) 
20 minutes before AIH. rIL-1β was applied i.t. 20 minutes before the start of AIH at 
doses of 1ng (4 µL of 0.2 ng/µL), 10ng (10 µL of 1 ng/µL), 100ng (10 µL of 10 ng/µL), 
and 300ng (30 µL of 10 ng/µL in 10 µL boluses over 3 minutes). In rats receiving rIL-1β 




Nerves were bathed in mineral oil and placed on bipolar silver wire electrodes. 
Raw nerve recordings were amplified (10k), filtered (0.1-5 kHz), integrated (50 ms time 
constant), and recorded (10 kHz sampling rate) for offline analysis (PowerLab and 
LabChart 8.0, AD Instruments). Apneic and recruitment CO2 thresholds were determined 
by changing inspired CO2 with continuous end-tidal CO2 monitoring (Kent Scientific 
Corporation). End tidal CO2 was set 2 mmHg above the recruitment threshold and arterial 
blood samples were used to establish baseline PaCO2, which was maintained within 1.5 
mmHg of the baseline value throughout. Blood volume and base excess were maintained 
(±3 MEq/L) by continuous infusion (1-3 mL/h i.v.) of hetastarch (0.3%) and sodium 
bicarbonate (0.99%) in lactated ringers. Experiments were excluded if mean arterial 
pressure deviated more than 20 mmHg from baseline versus 60 minutes after AIH.  
All rats (except for TC rats) received three, 5 minute bouts of hypoxia (~10.5% 
O2, PaO2 35-45 mmHg) separated by 5 minutes of normoxia. The average amplitude and 
frequency of 30 consecutive integrated phrenic bursts were analyzed at baseline, during 
the first acute hypoxic response, and 15, 30, and 60 minutes after AIH and made relative 
to baseline amplitude. Physiological variables and phrenic nerve activity data for each 
experimental group were compared using two-way, repeated measures ANOVA with 
Fisher LSD post hoc tests. Time control data were grouped for each experimental design 
since no significant differences between experimental groups were found (ANOVA RM, 
Fisher LSD post-hoc). Mean arterial pressure is reported from baseline, the end of the 
final hypoxic exposure, and 60 minutes after AIH. Acute hypoxic responses were 






Peripheral IL-1R activation is necessary for undermining pLTF after peripheral LPS. 
 Saline + AF-12198 Vehicle (i.p.) and saline + AF-12198 (i.p.) rats exhibited 
pLTF 60 minutes after AIH (57 ± 25%, p < 0.0001, n=6; 44 ± 14%, p < 0.0001, n=5, 
respectively, Fig. 2.1A and B). As expected (Huxtable et al., 2013), pLTF was eliminated 
in LPS + Vehicle (i.p.) rats (12 ± 18%, p < 0.05, n=6, Fig. 2.1A and B). pLTF was 
restored by peripheral antagonism of IL-1Rs (LPS ± AF-12198 i.p.; 63 ± 13%, p < 
0.0001, n=5, Fig. 2.1) and was not evident in any TC groups (-1 ± 9 % p = 0.24, n=17).  
No significant differences in the magnitude of pLTF was evident between LPS + AF-
12198 (i.p.) and saline + AF-12198 (i.p.) groups. 
The acute hypoxic phrenic response was unaffected by LPS or IL-1R antagonism 
(Saline + Vehicle (i.p.); 133 ± 39%, LPS + Vehicle (i.p.); 129 ± 49%, Saline + AF-12198 
(i.p.); 104 ± 46%, LPS + AF-12198 (i.p.); 129 ± 30%, Fig. 2.1C); no significant 
differences were present between groups.  
LPS caused a small, but significant, increase in baseline phrenic burst frequency 
compared to saline controls (LPS + Vehicle (i.p.), 51 ± 6 bursts/min; Saline + Vehicle 
(i.p.), 43 ± 8 bursts/min; p = 0.021). However, AF-12198 had no effect on baseline burst 
frequency between groups (LPS ± AF-12198 (i.p), 49 ± 5 bursts/min; Saline + AF-12198 







Figure 2.1. Peripheral IL-1R antagonism restores pLTF after systemic 
inflammation. Representative integrated phrenic neurograms (A) for acute intermittent 
hypoxia (AIH)-treated rats receiving Saline + Vehicle (i.p.), LPS (100 g/kg; i.p.) + 
Vehicle (i.p), Saline + AF-12198 (i.p.), LPS + AF-12198 (i.p.), and a time control (no 
AIH). pLTF is evident as the progressive increase in phrenic nerve amplitude from 
baseline (dashed line) over 60 minutes following AIH. Group data (B) demonstrate pLTF 
is abolished by LPS (Vehicle treated, dark bars) and restored by peripheral IL-1R 
antagonism (AF-12198 treated, grey bars). Acute hypoxic responses (C) were not 
significantly altered by any treatment (ANOVA). *** p < 0.0001 significant difference in 
phrenic amplitude from baseline; # different from Saline + Vehicle (p < 0.001), Saline + 
AF-12198 (p < 0.05), and LPS + AF-12198 (p < 0.001); ## p < 0.001 different from 
Saline + Vehicle, Saline + AF-12198, and LPS + AF-12198 (ANOVA RM, Fisher LSD). 
 
 
Small variations were evident in physiological parameters (Table 1), but remained 
within experimental limits. As expected, all experimental groups displayed significantly 
decreased MAP and PaO2 during hypoxia (Huxtable et al., 2015). Temperature 60 
minutes after AIH was significantly different in Saline + Vehicle and LPS + AF-12198 
(i.p.) groups relative to baseline, but remained within experimental limits noted above. 
Similarly, 60 minutes after AIH, small differences were evident between groups in PaO2 





Table 1.1. Physiological parameters during electrophysiology experiments with systemic 
AF-12198 (0.5 mg/kg, i.p.) treatment. 
Experimental Group Temperature PaO2 PaCO2   pH MAP 
Baseline AF12198 + LPS 37.4 ± 0.3 315.4 ± 17.3 44.6 ± 3.3 7.34 ± 0.04 c 145 ± 5 
 AF12198 + Saline 37.6 ± 0.3 281.9 ± 29.1
d 43.3 ± 3.5 7.34 ± 0.02 c 115 ± 13 d,e 
 Vehicle + LPS 37.5 ± 0.2 
c 295.8 ± 19.7 43.5 ± 3.3 7.36 ± 0.01 146 ± 7 
 Vehicle + Saline 37.7 ± 0.1 295.8 ± 22.9 41.7 ± 2.7 7.38 ± 0.03 126 ± 12 
 Grouped TC 37.6 ± 0.3 295.0 ± 24.8 42.4 ± 3.1 7.36 ± 0.03 131 ± 23 
       
Hypoxia AF12198 + LPS 37.5 ± 0.2 39.9 ± 3.0 a,b 44.9 ± 3.2 7.33 ± 0.05 a,b 101 ± 24 a,b 
 AF12198 + Saline 37.4 ± 0.2 40.9 ± 3.7 
a,b 43.0 ± 3.4 7.34 ± 0.02 a 63 ± 12 a,b,d 
 Vehicle + LPS 37.6 ± 0.2 41.1 ± 1.5 
a,b 43.4 ± 3.7 7.36 ± 0.03 a 106 ± 15 a,b,c 
 Vehicle + Saline 37.5 ± 0.2 39.1 ± 2.4 
a,b 42.0 ± 2.8 7.37 ± 0.03 73 ± 26 a,b,d 
 Grouped TC 37.5 ± 0.2 298.2 ± 25.0 42.1 ± 3.3 7.36 ± 0.03 127 ± 27 
       
60 min AF12198 + LPS 37.7 ± 0.1 a 297.3 ± 13.5 a 44.8 ± 2.7 7.37 ± 0.04 132 ± 12 a 
 AF12198 + Saline 37.4 ± 0.2 277.0 ± 27.8 44.0 ± 2.7 7.37 ± 0.03 115 ± 9
 e 
 Vehicle + LPS 37.6 ± 0.3 299.9 ± 20.8 
c 44.1 ± 3.5 7.39 ± 0.01 140 ± 9 
 Vehicle + Saline 37.5 ± 0.2 
a 273.7 ± 26.1 a,b 42.5 ± 2.4 a 7.38 ± 0.02 119 ± 20 
 Grouped TC 37.5 ± 0.2 297.1 ± 22.4 42.6 ± 3.4 7.38 ± 0.03
 a 128 ± 21 
 
MAP, mean arterial pressure, a p < 0.05 different from baseline within group, b p < 0.05 different from grouped TC 
within time point, c p < 0.05 different from Vehicle + Saline within time point, d p < 0.05 different from AF-12198 + 
LPS within time point AF12198 + LPS; n=5, AF12198 + Saline; n=6, Vehicle + LPS; n=5, Vehicle + Saline; n=6, 
Grouped TC; n=17 
 
 
Spinal IL-1R activation is necessary for undermining pLTF after peripheral LPS. 
We next tested the hypothesis that acute, spinal IL-1R activation is necessary to 
undermine pLTF 24 hours after peripheral LPS (Fig 2A and B). Saline + Vehicle (i.t.) 
rats exhibited pLTF 60 minutes after AIH (60 ± 18%, p < 0.0001, n=4). AF-12198 (i.t.) 
did not significantly increase the magnitude of pLTF in saline treated rats (Saline + AF-
12198 (i.t.); (72 ± 26%, p < 0.0001, n=4). As expected, LPS (100 µg/kg; i.p.) eliminated 
pLTF (LPS + Vehicle (i.t.), 11 ± 10%, p = 0.165 from baseline, n=5). pLTF was restored 
after spinal IL-1R antagonism (LPS + AF-12198 (i.t.), 53 ± 15%, p < 0.0001 from 
baseline, n=4). pLTF was not apparent in the TC group (6 ± 17%, p = 0.241, n=15). 
The acute hypoxic phrenic response was not significantly affected by LPS or 
spinal IL-1R antagonism (Saline + Vehicle (i.t.); 117 ± 23%, LPS + Vehicle (i.t.); 169 ± 




Baseline phrenic burst frequency was not significantly different between any 
group (Saline + Vehicle (i.t.); 45 ± 6 bursts/min, Saline + AF-12198 (i.t.); 45 ± 3 
bursts/min, LPS + Vehicle (i.t.); 44 ± 4 bursts/min, LPS ± AF-12198 (i.t); 47 ± 10 
bursts/min, p = 0.9528). Frequency LTF was evident in Saline + AF-12198 (i.t.) rats 60 
minutes after AIH (4 ± 2 bursts/min, p = 0.0138), but not in any other group. 
 
 
Figure 2.2. Spinal IL-1R antagonism restores pLTF after systemic inflammation. 
Representative integrated phrenic neurograms (A) for AIH-treated rats receiving Saline + 
Vehicle (i.t.), LPS (100 g/kg; i.p.) + Vehicle (i.t.), Saline + AF-12198 (1 mM, 15 L; 
i.t.), LPS (i.p.) + AF-12198 (i.t.), and a time control (no AIH). pLTF is evident as the 
progressive increase in phrenic nerve amplitude from baseline (dashed line) over 60 
minutes following acute intermittent hypoxia (AIH). Group data (B) demonstrate pLTF is 
abolished by LPS + Vehicle (dark bars) and restored by intrathecal IL-1R antagonism 
(AF-12198 treated, grey bars). Acute hypoxic responses (C) were not significantly 
affected by any treatment. *** p < 0.0001 significant difference in phrenic amplitude 
from baseline; # p < 0.001 different from Saline + Vehicle, Saline + AF-12198, and LPS 
+ AF-12198 (ANOVA RM, Fisher LSD). 
 
Small variations were evident in physiological parameters (Table 2), but they 




significantly decreased MAP and PaO2 during hypoxia. There were no significant 
differences in temperature, PaCO2, or pH at baseline between groups. The significant 
decrease in PaO2 at 60 min in the saline + Vehicle (i.t.) group was within normal limits. 
At baseline, LPS treatment increased MAP relative to saline-treated groups with AF-
12198 or vehicle (Table 2).  
 
 
Table 2.2. Physiological parameters during electrophysiology experiments after spinal 
AF-12198 (1 mM, 15uL). 
 
 
MAP, mean arterial pressure, a p < 0.05 different from baseline within group, b p < 0.05 different from 
grouped TC within time point, c p < 0.05 different from Vehicle + Saline within time point, AF12198 + 
LPS; n=4, AF12198 + Saline; n=4, Vehicle + LPS; n=5, Vehicle + Saline; n=4, Grouped TC; n=15 
 
 
Spinal exogenous rIL-1β does not abolish AIH-induced pLTF in healthy rats. 
pLTF remains after spinal, exogenous rIL-1β (1ng ± AIH; 66 ± 26%, n=3, p = 
0.012, 10ng ± AIH; 102 ± 49%, n=4, p < 0.0001, 100ng + AIH; 93 ± 51%, n=3, p < 
0.0001, 300ng ± AIH; 37 ± 40%, n=3, p = 0.028). However, after 300ng rIL-1β, AIH 
elicited pLTF with lower magnitude than 10ng (p = 0.008) and 100ng doses (p = .014, 
Fig. 2.3A and B). Thus, rIL-1β is not sufficient to abolish pLTF in healthy rats.  
Experimental Group Temperature PaO2 PaCO2   pH MAP 
Baseline AF12198 + LPS 37.5 ± 0.3 294.2 ± 31.0 47.5 ± 2.5 7.35 ± 0.03 145 ± 19 
 AF12198 + Saline 37.4 ± 0.3 276.9 ± 22.1 45.1 ± 2.2 7.37 ± 0.03 127 ± 20
 b 
 Vehicle + LPS 37.5 ± 0.3 284.6 ± 29.0 44.0 ± 2.7 7.37 ± 0.01 144 ± 11
 c 
 Vehicle + Saline 37.7 ± 0.3 288.9 ± 33.5 43.5 ± 3.2 7.38 ± 0.02 102 ± 11
 b 
 Grouped TC 37.5 ± 0.2 278.7 ± 16.1 44.8 ± 3.2 7.35 ± 0.04 125 ± 25        
Hypoxia AF12198 + LPS  37.5 ± 0.2 37.6 ± 2.1 a,b 47.6 ± 3.4 7.33 ± 0.02 106 ± 37 a,c 
 AF12198 + Saline 37.6 ± 0.1 39.1 ± 2.0
 a,b 44.1 ± 2.3 7.37 ± 0.02 66 ± 14 a 
 Vehicle + LPS 37.4 ± 0.1 37.5 ± 2.1
 a,b 44.5 ± 3.8 7.37 ± 0.02 95 ± 10 a 
 Vehicle + Saline 37.7 ± 0.2 38.6 ± 8.0
 a,b 43.4 ± 3.8 7.36 ± 0.03 56 ± 12 a 
 Grouped TC 37.6 ± 0.2 283.7 ± 33.8 44.9 ± 3.2 7.36 ± 0.03 122 ± 25 
       
60 min AF12198 + LPS 37.4 ± 0.3 289.5 ± 18.8 47.2 ± 2.3 7.37 ± 0.02 137 ± 15 
 AF12198 + Saline 37.6 ± 0.2 272.5 ± 19.0 45.4 ± 3.3 7.37 ± 0.03 115 ± 18 
 Vehicle + LPS 37.5 ± 0.3 283.7 ± 20.3 43.9 ± 2.3 7.39 ± 0.02 132 ± 13 
 Vehicle + Saline 37.5 ± 0.1 260.5 ± 20.9
 a 43.6 ± 2.8 7.40 ± 0.03 99 ± 23 




Furthermore, rIL-1β had no effect on the acute hypoxic phrenic responses at any 




Figure 2.3. Exogenous, spinal rIL-1β does not abolish pLTF in healthy animals. 
Representative integrated phrenic neurograms (A) after intrathecal rIL-1β (1ng, 10ng, 
100ng, 300ng; indicated by  ) 20 minutes before acute intermittent hypoxia (Hx). pLTF 
is evident as the progressive increase in phrenic nerve amplitude from baseline (dashed 
line) over 60 minutes following acute intermittent hypoxia. Intrathecal rIL-1β does not 
abolish pLTF at any dose. Group data (B) demonstrate pLTF at all doses of intrathecal 
rIL-1β, but the magnitude of pLTF at high doses (300 ng) is reduced compared to lower 
doses (10 and 100 ng). Acute hypoxic phrenic responses (C) were not significantly 
affected by any treatment. * p < 0.05; ** p < 0.01; *** p < 0.001 significantly different 
from baseline; a, p < 0.05 significantly different from 10ng + AIH and 100ng + AIH 
(ANOVA RM, Fisher LSD). 
 
 
Minor changes in physiological variables occurred in animals receiving 
intrathecal rIL-1β and AIH (Table 3). Temperature was decreased at 60 minutes in the 
1ng + AIH group, but remained within acceptable ranges. There were no significant 




AIH and 300ng + AIH groups. PaO2 and MAP were significantly decreased during 
hypoxia (Table 3). 
 
Spinal exogenous rIL-1β facilitates phrenic amplitude in healthy rats. 
Since exogenous IL-1β is sufficient to induce plasticity in the spinal dorsal horn 
in the form of pain hypersensitivity (Cunha et al., 2008), we next tested the hypothesis 
that spinal rIL-1β was sufficient to facilitate phrenic nerve amplitude. Low doses of rIL-
1β (1 ng and 10 ng) did not significantly alter phrenic amplitude (1 ng; -3 ± 5%, n=3, p = 
0.738, 10 ng; 8 ± 22%, n=3, p = 0.380); however, higher doses of rIL-1β induced 
progressive phrenic amplitude facilitation (100 ng; 31 ± 12%, p = 0.005 relative to 
baseline, n=4, 300 ng; 51 ± 17%, p <0 .0001 relative to baseline, n=4). Therefore, high 
doses of rIL-1β are sufficient to facilitate phrenic amplitude. 
 
Figure 2.4. Exogenous, spinal rIL-1β induces dose-dependent facilitation of phrenic 
amplitude. Representative integrated phrenic neurograms (A) for rats receiving 
intrathecal rIL-1β (1ng, 10ng, 100ng, 300ng; indicated by ). Phrenic amplitude 
facilitation is evident as the progressive increase in phrenic nerve amplitude from 
baseline (dashed line) following intrathecal rIL-1β. Group data (B) demonstrate a dose-
dependent increase in phrenic nerve amplitude 60 minutes after intrathecal rIL-1β. ** p < 
0.01; *** p < 0.001 significantly different from baseline; a, p < 0.05 significantly 
different from 1ng + TC; b, p < 0.01 significantly different from 1ng + TC and 10ng + 




Physiological variables were stable throughout electrophysiology experiments 
without any significant changes (Table 3).   
 
Table 2.3. Physiological parameters during electrophysiology experiments after spinal 
rIL-1β. 
Experimental Group Temperature PaO2 PaCO2  pH MAP 
Baseline 1 ng + AIH 37.7 ± 0.3  272.9 ± 34.8 42.8 ± 2.0  7.38 ± 0.01 117 ± 12 
 10 ng + AIH 37.5 ± 0.2 267.9 ± 11.1 40.0 ± 4.8 7.40 ± 0.05 111 ± 21 
 100 ng + AIH 37.6 ± 0.1 258.7 ± 11.1 43.9 ± 2.8 7.37 ± 0.01 115 ± 18 
 300 ng + AIH 37.6 ± 0.4 289.0 ± 6.2 41.5 ± 2.9 7.40 ± 0.03 103 ± 10 
Hypoxia 1 ng + AIH 37.4 ± 0.3 38.0 ± 3.5 a 42.9 ± 3.7 7.36 ± 0.04 a 69 ± 17 a 
 10 ng + AIH 37.4 ± 0.3 38.2 ± 4.0
 a 38.8 ± 5.8 7.40 ± 0.05 72 ± 21 a 
 100 ng + AIH 37.4 ± 0.2 
f 42.6 ± 1.4 a 43.4 ± 2.8 7.36 ± 0.02 60 ± 25 a 
 300 ng + AIH 37.6 ± 0.3 37.6 ± 4.3
 a 42.2 ± 3.7 7.40 ± 0.01 a 62 ± 15 a 
60 min 1 ng + AIH 37.3 ± 0.1 a 247.7 ± 45.2 a 42.9 ± 1.3 7.37 ± 0.02 120 ± 5 
 10 ng + AIH 37.3 ± 0.2 281.3 ± 18.4 40.5 ± 4.9 7.39 ± 0.05 123 ± 17 
 100 ng + AIH 37.4 ± 0.2 249.5 ± 16.3 44.2 ± 2.3 7.37 ± 0.02 107 ± 20
 a 
 300 ng + AIH 37.5 ± 0.4 262.4 ± 15.0
 a 42.1 ± 3.2 7.37 ± 0.01 115 ± 14 
       
Experimental Group Temperature PaO2 PaCO2  pH MAP 
Baseline 1 ng  37.6 ± 0.4 282.1 ± 26.1 42.5 ± 1.2 7.38 ± 0.02 127 ± 27 
 10 ng  37.5 ± 0.2 255.3 ± 19.0 42.4 ± 2.2 7.37 ± 0.01 117 ± 12 
 100 ng 37.6 ± 0.3 264.4 ± 23.6 45.4 ± 2.4 7.37 ± 0.01 135 ± 9 
 300 ng 37.7 ± 0.3 258.8 ± 24.3 40.5 ± 6.5 7.40 ± 0.04 123 ± 11 
60 min 1 ng 37.6 ± 0.3 279.6 ± 15.0 43.0 ± 0.7 7.39 ± 0.03 132 ± 17 
 10 ng 37.7 ± 0.3 254.6 ± 7.2 42.8 ± 1.8 7.38 ± 0.02 120 ± 17 
 100 ng  37.4 ± 0.2 263.0 ± 25.2 45.7 ± 2.5 7.36 ± 0.01 131 ± 7 
 300 ng 37.6 ± 0.2 234.2 ± 22.6 40.2 ± 7.2 7.38 ± 0.01 134 ± 18 
        
MAP, mean arterial pressure, a p < 0.05 different from baseline within group, b p < 0.05 
different from all AIH experimental groups within time point,1 ng + AIH; n=3, 10 ng + 
AIH; n=4, 100 ng + AIH; n=3, 300 ng + AIH; n=3, 1 ng + TC; n=3, 10 ng + TC; n=3, 
100 ng + TC; n=4, 300 ng + TC; n=4, 
 
Discussion 
Here, we demonstrate a role for IL-1R activation, both peripherally and centrally, 
in systemic inflammation-induced impairment of respiratory motor plasticity. In healthy 
rats, however, activation of IL-1Rs with exogenous rIL-1β is insufficient to abolish AIH-
induced pLTF, yet it induces phrenic amplitude facilitation in the absence of AIH. Thus, 




sufficient to abolish pLTF in healthy rats. These data demonstrate IL-1R activation is an 
important signaling step in abolishing respiratory plasticity after systemic inflammation. 
 CNS responses to IL-1β have been widely studied because IL-1β plays a role in 
modulating many physiological systems, including thermoregulation and behavioral 
responses (Matsuwaki et al., 2017; Zhu et al., 2010), and IL-1β is rapidly upregulated in 
the CNS after LPS-induced systemic inflammation (Rothwell and Luheshi, 2000). More 
recently, IL-1 signaling in the CNS has been shown to modulate different forms of 
neuroplasticity, including hippocampal dependent learning and pain sensitivity in the 
dorsal spinal cord (Cunha et al., 2008; Maier et al., 1993; Zhang et al., 2008). We now 
demonstrate a role for IL-1R activation in undermining respiratory plasticity in the 
cervical spinal cord.  
The restoration of pLTF by peripheral IL-1R antagonism suggests IL-1R 
activation is necessary for transmitting relevant inflammatory information to the CNS 
after LPS-induced inflammation. Additionally, since IL-1R signaling likely contributes 
significantly to time-dependent changes in serum cytokine levels (Terrando et al., 2010), 
peripheral IL-1R antagonism may indirectly mitigate CNS inflammation by inducing 
changes in other cytokines and restore plasticity. While we did not assess CNS 
inflammation directly in these experiments, others have shown peripheral IL-1R 
activation is required for brain inflammatory responses after i.p LPS (Giles et al., 2015; 
Maier et al., 1993) and peripheral and spinal IL-1β gene expression is upregulated after 
peripheral LPS (Huxtable et al., 2013). Thus, we suggest the primary action of peripheral 
IL-1R antagonism is to inhibit peripheral inflammatory responses induced by LPS. It 




directly reduces CNS inflammatory responses. Since AF-12198 is a small peptide, we 
believe it is unlikely to cross the blood-brain barrier at sufficient concentrations to 
directly reduce CNS inflammation. Thus, the actions of peripheral IL-1R antagonism are 
most likely by inhibiting peripheral inflammatory responses. Together, we propose 
peripheral IL-1R antagonism indirectly reduces relevant spinal inflammation, and thus, 
restores pLTF. 
Our data demonstrating restoration of pLTF by spinal IL-1R antagonism is 
consistent with the hypothesis that persistent IL-1 signaling around the phrenic motor 
pool is necessary for undermining pLTF. IL-1R signaling in phrenic motoneurons could 
directly alter their properties to eliminate pLTF or could promote the release of other 
inflammatory cytokines from nearby cells (such as microglia) which undermine pLTF. 
IL-1R signaling can activate diverse intracellular pro-inflammatory pathways, including 
NF-kB and stress activated protein kinases (Dinarello, 2009), which may inhibit pLTF. 
Additionally, in a separate model of systemic inflammation, spinal p38-MAPK 
activation, a kinase downstream of IL-1R (Molina-Holgado et al., 2000), is necessary to 
undermine pLTF after systemic inflammation (Huxtable et al., 2015). Future 
investigations should assess the link between spinal IL-1 signaling and activation of p38-
MAPK in undermining pLTF. 
 Though we demonstrate the necessity of IL-1R activation in undermining 
plasticity, the effects of direct application of rIL-1β are more complicated. Here, no rIL-
1β dose abolished plasticity after AIH in healthy rats. The 300ng rIL-1β dose did reduce 
the magnitude of pLTF compared to other doses. Thus, it is possible higher doses of rIL-




due to solubility and volume limitations for intrathecal injections. Exogenous rIL-1β may 
be insufficient to undermine pLTF if complementary inflammatory molecules are 
necessary to completely undermine pLTF or if systemic inflammation primes the CNS to 
augment the response to IL-1β. IL-1R expression is upregulated after peripheral LPS 
(Turrin et al., 2001), such that healthy animals not exposed to LPS have a blunted 
response to exogenous rIL-1β. Alternatively, the cellular mechanisms undermining pLTF 
may take longer to develop than 20 minutes after spinal, exogenous rIL-1β. However, in 
hippocampal slices, rIL-1β inhibits long-term potentiation within 10 minutes of exposure 
(Bellinger et al., 1993), demonstrating rIL-1β can have rapid effects. In the absence of 
AIH, high doses of rIL-1β facilitated phrenic burst amplitude, demonstrating rIL-1β 
evoked a lasting increase in phrenic amplitude after rIL-1β is likely degraded (Reimers et 
al., 1991). While the mechanisms mediating this plasticity are unknown, other reports 
show dose-dependent IL-1β changes in synaptic strength or cell excitability in response 
to IL-1R activation, such as increased calcium-dependent glutamate release from 
hippocampal neurons, upregulated NMDA receptor activity (Galic et al., 2012), and 
increased dorsal root ganglion neuron excitability after IL-1β (Binshtok et al., 2008; 
Takeda et al., 2007). Taken together, rIL-1β exerts dose-dependent alterations of phrenic 
motor output, capable of both inducing facilitation and reducing the magnitude of, but not 
abolishing, pLTF. 
  Though our study demonstrates an important role of IL-1 signaling in spinal 
motor respiratory plasticity, IL-1 signaling is likely not the only inflammatory molecule 
involved in modulating respiratory neural activity. For example, inactivity-induced 




the activation of TNF receptor 1, an inflammatory cytokine receptor (Broytman et al., 
2013). Additional inflammatory molecules, such as prostaglandins, have also been shown 
to modulate central respiratory networks. While prostaglandins mediate profound 
respiratory modulation (Forsberg et al., 2016; Koch et al., 2015; Olsson et al.; Siljehav et 
al., 2012), they are unlikely to play a significant role in undermining respiratory motor 
plasticity after systemic inflammation since inhibition of cyclooxygenase, the rate-
limiting enzyme in the production of prostaglandins, does not restore pLTF (Huxtable et 
al., 2017). However, the relationship between the various types of inflammatory 
cytokines and their downstream effects in respiratory control remains mostly unknown. 
Improving our understanding of the actions of individual and combined inflammatory 
signaling molecules, as well as their cellular sources, in neural respiratory control will be 
the topic of future investigations. 
Our study builds on these and other recent studies investigating the effects of IL-1 
signaling in respiratory control networks (Aleksandrova and Danilova, 2010; Ribeiro et 
al., 2017).  Similar to previous reports (Aleksandrova and Danilova, 2010; Gresham et 
al., 2011), we found a tendency for systemic inflammation to increase baseline phrenic 
burst frequency. While the mechanisms mediating the increased frequency after systemic 
inflammation are unclear, direct intracerebroventricular rIL-1β increases minute 
ventilation, suggesting a direct effect of IL-1β on respiratory frequency (Aleksandrova 
and Danilova, 2010). Additionally, acute hypoxic ventilatory responses are attenuated 
after intratracheal LPS due to spinal IL-1R activation (Ribeiro et al., 2017); however, no 
significant changes were seen in the acute hypoxic phrenic amplitude response after 




experimental group, which supports previous work suggesting frequency LTF is small 
and inconsistent (Baker-Herman and Mitchell, 2008). Less is known about the 
mechanisms underlying frequency LTF, which may be distinctly different from the 
amplitude change known as pLTF. Thus, we have focused our analyses on amplitude 
changes since much more is known about the mechanisms of pLTF using this 
experimental preparation and the AIH paradigm, where the consistent and significant 
changes are reflected in amplitude. In summary, IL-1 signaling seems to have widespread 
roles in the neural control of breathing. 
In conclusion, we demonstrate IL-1R activation peripherally and centrally is 
necessary for undermining respiratory plasticity after systemic inflammation. Our study 
is the first to investigate the effects of IL-1 signaling on spinal respiratory plasticity, and 
builds on other recent studies investigating the effects of IL-1 signaling in medullary 
respiratory networks (Aleksandrova and Danilova, 2010; Ribeiro et al., 2017). Taken 
together, inflammatory signaling through IL-1R attenuates chemosensitivity 
(Aleksandrova and Danilova, 2010) and respiratory plasticity. Furthermore, such results 
suggest uncovering how inflammation impacts the neural control of breathing is 
fundamental to understand changes in respiratory function during pathological 
conditions. Furthermore, for respiratory motor plasticity to be used clinically (Hayes et 
al., 2014; Trumbower et al., 2012, 2017), we must also understand the interaction 










VIRAL MIMETIC-INDUCED INFLAMMATION ABOLISHES  
Q-PATHWAY-EVOKED BUT NOT S-PATHWAY-EVOKED ADULT 
RESPIRATORY MOTOR PLASTICITY IN RATS 
 
 This chapter includes material previously published in the Frontiers in 
Physiology: Respiratory Physiology (Hocker et al., 2019) which was co-authored by 
Adrianne G. Huxtable. I designed and led these studies, collected and analyzed all data, 
and wrote the paper. Adrianne Huxtable designed, contributed to writing the manuscript, 




Neuroplasticity of the respiratory control system is an important feature of the 
control of breathing thought to confer stability and adaptation when the respiratory system 
is challenged (Fuller and Mitchell, 2017). One frequently studied model of adult respiratory 
neuroplasticity is phrenic long-term facilitation (pLTF), induced by acute intermittent 
hypoxia (AIH). At least two pathways to pLTF exist: the Q-pathway and the S-pathway 
(Reviewed in Turner et al., 2018). The Q-pathway is serotonin-dependent and induced by 
moderate AIH (mAIH, 3x5 minute hypoxic episodes, PaO2 35-45 mmHg) (Baker-Herman 
and Mitchell, 2002), while the S-pathway is induced by severe AIH (sAIH, PaO2 25-35 
mmHg) and involves activation of adenosine receptors (Nichols et al., 2012). The cellular 
mechanisms of Q- and S-pathway plasticity are distinct (Turner et al., 2018) and the two 




2017). Adult Q-pathway plasticity is abolished by low levels of acute, systemic 
inflammation induced by a TLR4 agonist (lipopolysaccharide, LPS) (Huxtable et al., 2011; 
Vinit et al., 2011) or 8 hours of intermittent hypoxia (Huxtable et al., 2015, 2017) and 
restored by the non-steroidal anti-inflammatory, ketoprofen (Huxtable et al., 2013, 2015). 
On the contrary, S-pathway-evoked adult respiratory motor plasticity is inflammation 
resistant (Agosto-Marlin et al., 2017), and therefore it has the potential to serve as a 
“backup” pathway to preserve plasticity after inflammation. 
Since AIH-induced plasticity is being translated to clinical populations (e.g. after 
spinal cord injury) (Hayes et al., 2014; Trumbower et al., 2012, 2017) with low-levels of 
systemic/neuroinflammation, interest in the impact of inflammation on motor plasticity is 
growing. Studies on inflammation-induced impairments in pLTF have focused on 
lipopolysaccharide (LPS, bacterial induced-inflammation) (Huxtable et al., 2013; Vinit et 
al., 2011) or simulated sleep apnea induced by nocturnal intermittent hypoxia (Huxtable et 
al., 2015, 2017). LPS is the most common model of acute, systemic inflammation, induces 
a rapid upregulation of brain inflammatory cytokines, and abolishes pLTF within 3 hours 
and for at least 24 hours (Huxtable et al., 2013), while nocturnal intermittent hypoxia is a 
clinically relevant physiological perturbation also abolishing pLTF (Huxtable et al., 2015). 
However, viral infections are very common (Obasi et al., 2014) and induce unique, but 
overlapping, inflammatory profiles through TLR3 activation (Reimer et al., 2008). 
Polyinosinic:polycitidylic acid (polyIC) is an agonist for TLR3 and is used experimentally 
to investigate the effects of systemic viral inflammation (Nicodemus and Berek, 2010). 
PolyIC-induced inflammation induces a temporally slower onset of inflammatory genes in 




et al., 2014), and therefore, it has the potential to have differential effects on pLTF. Since 
inflammation arises from diverse stimuli throughout our lives, understanding the effects of 
polyIC on respiratory motor plasticity broadens our understanding of the impact of 
inflammation on respiratory control. Additionally, while the inflammation sensitivity of Q-
pathway-evoked plasticity has been confirmed in two models of systemic inflammation 
(reviewed in Hocker et al., 2017), the sensitivity of S-pathway-evoked plasticity has only 
been investigated after LPS-induced inflammation (Agosto-Marlin et al., 2017). Here, we 
hypothesize polyIC will induce CNS inflammation and abolish Q-pathway, but not S-
pathway, evoked pLTF. Further, since we hypothesize slower neuroinflammation onset 
after peripheral polyIC, where Q-pathway-evoked LTF will be abolished at 24 hours, but 
not 3 hours. 
Methods 
All experiments were approved by the University of Oregon Institutional Animal 
Care and Use Committee and conformed to the policies of the National Institute of Health 
Guide for the Care and Use of Laboratory Animals. Male Sprague Dawley Rats (300-400g; 
3-4 months; Envigo, Colony 206) were housed under standard conditions (12:12h 
light/dark cycle) with food and water ad libitum. 
Drugs and Materials 
PolyIC (P9582, Sigma Chemical) was dissolved in sterile saline, heated to 50°C, 
cooled for re-annealing, and injected (intraperitoneal, i.p.) at doses ranging from 250 µg/kg 
to 2 mg/kg. S-(+) Ketoprofen (Keto, Sigma Chemical) was dissolved in ethanol (50% V/V, 





To investigate the temporal actions of polyIC and the sufficiency of polyIC to 
abolish Q-pathway-evoked pLTF, we used the following groups: 3 hr polyIC (750 µg/kg, 
n = 5), 24 hr polyIC (750 µg/kg, n = 4), 24 hr polyIC (500 µg/kg, n = 4), 24 hr polyIC (250 
µg/kg, n = 4). A time control group consisted of rats from each of the groups: 3 hr polyIC 
(750 µg/kg, n = 3), 24 hr polyIC (750 µg/kg, n = 2), 24 hr polyIC (500 µg/kg, n = 1), 24 hr 
polyIC (250 µg/kg, n = 1).  
To investigate if acute, anti-inflammatory treatment restores Q-pathway-evoked 
pLTF after polyIC, rats were treated ketoprofen (12.5 mg/kg, i.p.) three hours before 
electrophysiology experiments. We used the following experimental groups: 24 hr vehicle 
(saline) + Keto (n = 4), 24 hr polyIC (750 µg/kg) + Keto (n = 4), and time controls made 
up of two animals from each treatment group (n = 4).  
To investigate the impact of polyIC-induced inflammation on S-pathway-evoked 
respiratory pLTF, we used the following experimental groups: 24 hr vehicle (n = 4), 24 hr 
polyIC (750 µg/kg) (n = 5), and time controls made up of two animals from each treatment 
group (n = 4).  
Electrophysiological Studies 
Electrophysiological studies have been described in detail previously (Bach and 
Mitchell, 1996; Baker-Herman and Mitchell, 2002). Briefly, rats were anesthetized with 
isoflurane, tracheotomized, ventilated (Rat Ventilator, VetEquip®), and bilaterally 
vagotomized. A venous catheter was placed for drug delivery and fluid replacement, and a 




sampling. Arterial blood samples were assessed (PaO2, PaCO2, pH, base excess; Siemens 
RAPIDLAB® 248) during baseline, the first hypoxic response, and 15, 30 and 60 minutes 
post-AIH. Rectal temperature was measured (Kent Scientific Corporation) and maintained 
between 37°C and 38°C with a custom heated surgical table. Using a dorsal approach, 
phrenic nerves were isolated, cut distally, and de-sheathed. Rats were converted to urethane 
anesthesia (1.8 g/kg i.v.; Sigma-Aldrich), allowed to stabilize for one hour, and paralyzed 
with pancuronium dibromide (1 mg; Selleck Chemicals). Nerves were bathed in mineral 
oil and placed on bipolar silver electrodes. Raw nerve recordings were amplified (10k), 
filtered (0.1-5 kHz), integrated (50 ms time constant), and recorded (10 kHz sampling rate) 
for offline analysis (PowerLab and LabChart 8.0, AD Instruments). Apneic and recruitment 
CO2 thresholds were determined by continuous end-tidal CO2 monitoring (Kent Scientific 
Corporation) while changing inspired CO2. End-tidal CO2 was set 2 mmHg above the 
recruitment threshold, where baseline PaCO2 was established and then maintained within 
1.5 mmHg for the duration of the experiment. Blood volume and base excess were 
maintained (±3 MEq/L) by continuous infusion (0-3 mL/h, i.v.) of hetastarch (0.3%) and 
sodium bicarbonate (0.99%) in lactated ringers. Experiments were excluded if mean 
arterial pressure deviated more than 20 mmHg from baseline.  
Rats (excluding time control rats) received three, 5-minute bouts of either mAIH 
(~10.5% O2, PaO2 35-45 mmHg) or sAIH (~7% O2, PaO2 25-35 mmHg). The average 
frequency and amplitude of 30 consecutive integrated phrenic bursts were assessed during 
baseline, the first acute hypoxic response, and 15, 30, and 60 minutes after AIH. Data are 
presented as the percent relative to baseline and compared using two-way, repeated 




variables were compared using two-way, repeated measures ANOVA with Tukey’s post 
hoc test. Mean arterial pressure is reported for baseline, the end of the third hypoxic 
episode, and 60 minutes after AIH. Acute hypoxic phrenic responses were compared using 
an ANOVA with Fisher LSD post hoc test. Values are presented as mean ± SD. 
RNA isolation and Quantitative PCR Experiments 
Male rats were injected with either vehicle (saline) or polyIC (750 µg/kg, i.p.) 3 or 
24 hours (n = 6 per group) before tissue collection. Rats were anesthetized with isoflurane 
and perfused with transcardiac PBS (pH 7.4). Ventral cervical spinal cords (C3-C7), 
medullas, and spleens were dissected and flash frozen until homogenization in TRIzol 
Reagent (Invitrogen, Carlsbad, CA, USA). RNA was isolated with PureLink columns 
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. cDNA was 
reverse transcribed from 1 µg of total RNA using qScript cDNA Synthesis Kit (QuantaBio) 
reverse transcriptase and analyzed using qPCR with PerfeCTa SYBR Green FastMix 
(QuantaBio) on a CFX-384 system (BioRad). Inflammatory gene expression was analyzed 
in ventral cervical spinal cord, medullary, and spleen homogenates using the following 
primers: 
IL-6: 5’-GTG GCT AAG GAC CAA GAC CA and 5’-GGT TTG CCG AGT AGA CCT 
CA; 
IL-1β: 5’-CTG CAG ATG CAA TGG AAA GA and 5’-TTG CTT CCA AGG CAG ACT 
TT; 





TNF-α: 5’-TCC ATG GCC CAG ACC CTC ACA C and 5’-TCC GCT TGG TGG TTT 
GCT ACG; 
iNOS: 5’-AGG GAG TGT TGT TCC AGG TG and 5’-TCT GCA GGA TGT CTT GAA 
CG; 
18s: 5’-CGG GTG CTC TTA GCT GAG TGT CCC G and 5’-CTC GGG CCT GCT 
TTG AAC AC.  
Wherever possible, primers (purchased from ThermoFisher) were designed to span introns 
(Primer 3 software). Primer efficiency was assessed by use of standard curves, as 
previously reported (Crain and Watters, 2015). Expression of inflammatory genes was 
made relative to 18s ribosomal RNA calculated using the 2-ΔΔCT method (Livak and 
Schmittgen, 2001).  
Results 
PolyIC induces transient inflammatory gene expression in the ventral cervical 
spinal cord 
Ventral cervical spinal inflammatory gene expression 3 and 24 hours after polyIC 
(750 g/kg, i.p., Fig. 3.1A) was assessed since previous studies have demonstrated 
peripheral LPS abolishes Q-pathway-evoked pLTF within 3 hours and for at least 24 hours 
(Huxtable et al., 2013), and involves activation of spinal IL-1 receptors (Hocker and 
Huxtable, 2018). In ventral cervical spinal homogenates, IL-1β, IL-6, TNFα and iNOS 
gene expression were not significantly different from saline controls at 3 or 24 hours (Fig. 
3.1A). However, COX-2 gene expression transiently increased at 3 hours (n = 6, p < 0.001, 




TNFα and iNOS genes was significantly increased relative to 3-hour polyIC (p = 0.01 and 
p = 0.003 respectively), but they were not different from 24-hour saline controls (p > 0.05). 
Thus, inflammatory gene expression increases in regions of the central nervous system 
important for pLTF 3 hours after polyIC, with some regions remaining insignificantly 
elevated at 24 hours. Medullary gene expression (Fig. 3.1B) was also assessed to 
investigate regional differences in CNS inflammatory responses and splenic gene 
expression (Fig. 3.1C) as a marker of systemic inflammation. In medullary and splenic 
homogenates, no significant changes in inflammatory genes (IL-6, IL-1β, COX-2, TNF-α, 
iNOS) were evident at 3 or 24 hours (Fig. 3.1B and C), suggesting polyIC induces minimal 
systemic or medullary inflammation. 
Q-pathway-evoked pLTF is abolished 24 hours after polyIC 
Q-pathway-evoked pLTF is evident as the increase in integrated phrenic nerve 
activity 60 minutes after mAIH (PaO2 35-45 mmHg) in anesthetized rats (Bach and 
Mitchell, 1996) (Fig. 3.2A). PolyIC (750 g/kg) was sufficient to induce transient cervical 
spinal inflammatory gene expression, but was insufficient to abolish Q-pathway-evoked 
pLTF at 3 hours (67 ± 21% change from baseline, n = 5, p < 0.001, Fig. 3.2B). At 24 hours, 
a dose response to polyIC revealed 750 µg/kg was sufficient to abolish Q-pathway-evoked 
pLTF (17 ± 15% change from baseline, n = 5, p = 0.058, Fig. 3.2B). Lower doses of polyIC 
were insufficient to significantly abolish pLTF (500 µg/kg = 24 ± 33% change from 
baseline, n = 4, p = 0.019; 250 µg/kg = 63 ± 19% change from baseline, n = 4, p < 0.001, 
Fig. 3.2B). Variability in pLTF magnitude 24 hours after 500 µg/kg polyIC suggests this 





Figure 3.1. PolyIC (750 g/kg, i.p.) transiently increases inflammatory gene 
expression in ventral cervical spinal cord homogenates, but not in the medulla or 
spleen. Ventral spinal cord homogenate COX-2 mRNA significantly increased 3 hours 
after polyIC and returned to baseline by 24 hours (A). TNFα and iNOS mRNA significantly 
increased in the ventral spinal cord at 24 hours compared to 3 hours after polyIC (n = 6 per 
group), but mRNA was not different from saline controls (A). Other inflammatory genes 
were not significantly altered by polyIC in ventral cervical spinal cords (A), medullas (B) 
or spleens (C).  Horizontal dashed line indicates 1-fold change from 3hr saline control. 
(*** p<0.001 significant difference from saline control, † p<0.01 between groups, †† 




receiving mAIH) did not differ from baseline (6 ± 18% change from baseline, n = 6, p = 
0.466, Fig. 3.2B), demonstrating no effect of polyIC on experiment stability. Between 
groups, phrenic amplitude 60 minutes after mAIH was significantly reduced (p < 0.01) 
after 24 hour polyIC (500 µg/kg) and 24 hour polyIC (250 µg/kg, and time controls) 
compared to 3hr polyIC (750 µg/kg) and 24 hr polyIC (250 µg/kg) groups. Thus, polyIC-
induced impairment of pLTF occurs slower than LPS-induced impairment and after 
inflammatory gene expression has returned to baseline. Phrenic nerve responses to 
moderate hypoxia were not different among groups (Fig. 3.2C). 
Figure 3.2. The viral mimetic, polyIC, abolishes Q-pathway-evoked pLTF at 24 
hours, but not at 3 hours. Representative integrated phrenic neurograms after polyIC 
(250-750 g/kg, 3 or 24 hours, i.p.) (A). Q-pathway-evoked pLTF is evident as the 
progressive increase in phrenic nerve amplitude from baseline (dashed line) over 60 
minutes following moderate acute intermittent hypoxia (mAIH, 3 x 5 minute episodes, 
PaO2 35-45 mmHg). Group data (B) demonstrate 750 g/kg polyIC was insufficient to 
abolish Q-pathway-evoked pLTF at 3 hours (n = 5). However, Q-pathway-evoked pLTF 
is abolished 24 hours after 750 µg/kg polyIC (n = 4), but not at lower doses of polyIC 
(500 µg/kg, n = 4; 250 µg/kg, n = 4). Time controls (no AIH, n = 7) are not different 
from baseline, but were significantly reduced from 3hr polyIC (750 µg/kg) and 24 hr 
polyIC (250 µg/kg) groups. Acute hypoxic phrenic nerve responses (C) were not altered 
by polyIC at any dose.  *** p < 0.0001 significant difference in phrenic amplitude from 
baseline; ** p < 0.001 from baseline, † p < 0.01 different from 3hr polyIC 750 µg/kg and 




Ketoprofen restores Q-pathway-evoked pLTF after polyIC induced inflammation 
To test the hypothesis that inflammatory signaling after polyIC (750 µg/kg, 24 
hours) was undermining Q-pathway-evoked pLTF, the anti-inflammatory ketoprofen (12.5 
mg/kg, i.p., 3 hours) was used to acutely diminish inflammatory signaling (Fig. 3.3A). As 
expected, Q-pathway-evoked pLTF was evident in vehicle + ketoprofen treated rats 60 
minutes after mAIH (64 ± 24% change from baseline, n = 4, p < 0.001, Fig. 3.3B). 
Ketoprofen restored Q-pathway-evoked pLTF after polyIC (55 ± 13% change from 
baseline, n = 5, p < 0.001, Fig. 3.3B), suggesting polyIC-induced inflammation abolishes 
Q-pathway-evoked pLTF. pLTF was not apparent in time control rats (8 ± 10% change 
from baseline, n = 4, p = 0.431, Fig. 3.3B). Phrenic amplitude 60 minutes after mAIH was 
significantly greater (p < 0.001) in vehicle + Keto and polyIC + Keto groups relative to 
time controls. Phrenic nerve responses to hypoxia were not different among groups (Fig. 
3.3C). 
S-pathway-evoked pLTF is resistant to polyIC induced inflammation 
S-pathway-evoked pLTF was evident as the significant increase in integrated 
phrenic amplitude 60 minutes after sAIH (PaO2 25-35 mmHg, Fig. 3.4A) in adult rats 
treated with vehicle (65 ± 33% change from baseline, n = 4, p < 0.001, Fig. 3.4B). PolyIC 
at the same dose undermining Q-pathway-evoked pLTF (750 µg/kg, i.p., 24 hours) was 
insufficient to abolish S-pathway-evoked pLTF (72 ± 25% change from baseline, n = 5, p 






Figure 3.3. Acute, anti-inflammatory ketoprofen restores Q-pathway-evoked pLTF 
after polyIC-induced inflammation at 24 hours. Representative integrated phrenic 
neurograms after polyIC (750 g/kg, i.p., 24h) and acute, adult ketoprofen (12.5 mg/kg, 
i.p., 3 hrs) (A). Q-pathway-evoked pLTF is evident as the progressive increase in phrenic 
nerve amplitude from baseline (dashed line) over 60 minutes following moderate acute 
intermittent hypoxia (mAIH, 3 x 5 minute episodes, PaO2 35-45 mmHg). Group data (B) 
demonstrate Q-pathway-evoked pLTF is restored 24 hours after 750 µg/kg polyIC by the 
anti-inflammatory ketoprofen (n = 4). Time controls (no mAIH, n = 4) are not different 
from baseline and were significantly reduced from vehicle (n = 4) and 24h polyIC groups 
(n = 4). Acute hypoxic phrenic nerve responses (C) were not altered by polyIC or 
ketoprofen. *** p < 0.0001 significant difference in phrenic amplitude from baseline; †  p 
< 0.001 different from all other groups (ANOVA RM, Fisher LSD). 
 
inflammation. Phrenic amplitude did not change from baseline in time control rats (4 ± 9% 
change, n = 4, p = 0.670, Fig. 3.4B). Both vehicle and polyIC groups had significantly 
greater phrenic amplitude 60 minutes after sAIH (p = 0.027 and p = 0.002 respectively) 
compared to time controls. Phrenic nerve responses to severe hypoxia were not different 









Figure 3.4. S-pathway-evoked pLTF persists 24 hours after the viral mimetic, polyIC. 
Representative integrated phrenic neurograms after polyIC (750 g/kg, i.p., 24 hrs) (A). S-
pathway-evoked pLTF is evident as the progressive increase in phrenic nerve amplitude 
from baseline (dashed line) over 60 minutes following severe acute intermittent hypoxia 
(sAIH, 3 x 5 minute episodes, PaO2 25-35 mmHg). Group data (B) demonstrate S-pathway-
evoked pLTF remains 24 hours after 750 µg/kg polyIC (n = 5). Time controls (no sAIH, n 
= 4) are not different from baseline and were significantly reduced from vehicle (n = 4) 
and 24hr polyIC groups. Acute hypoxic phrenic nerve responses to severe hypoxia (C) 
were not altered by polyIC. *** p < 0.0001 significant difference in phrenic amplitude 
from baseline; † p < 0.001 different from all other groups (ANOVA RM, Fisher LSD). 
 
Physiological variables for all experimental groups were stable throughout 




















750 µg/kg polyIC (3hr) 37.3 ± 0.2 282 ± 26 44.4 ± 1.1 7.36 ± 0.03 121 ± 14 
750 µg/kg polyIC (24hr) 37.5 ± 0.4 268 ± 7 46.7 ± 2.4 7.35 ± 0.03 136 ± 24 
500 µg/kg polyIC (24hr) 37.5 ± 0.3 287 ± 25 42.5 ± 3.4 7.38 ± 0.04 125 ± 17 
250 µg/kg polyIC (24hr) 37.4 ± 0.3 279 ± 37 45.5 ± 3.9 7.34 ± 0.02 120 ± 26 
Time Controls 37.5 ± 0.3 252 ± 29 45.6 ± 1.7 7.37 ± 0.02 123 ± 11 
  
    
Vehicle + keto 37.5 ± 0.3 261 ± 28 43.8 ± 1.8 7.38 ± 0.02 123 ± 11 
polyIC + keto 37.6 ± 0.1 267 ± 43 44.9 ± 2.3 7.35 ± 0.03 120 ± 22 
Time Controls + keto 37.4 ± 0.4 246 ± 36 43.2 ± 2.0 7.37 ± 0.01 124 ± 28 
  
    
Vehicle + sAIH 37.4 ± 0.3 262 ± 18 44.6 ± 2.4 7.39 ± 0.02 117 ± 5 
polyIC + sAIH 37.3 ± 0.2 255 ± 29 44.9 ± 2.4 7.39 ± 0.03 118 ± 18 
Time Controls 37.8 ± 0.1 260 ± 11 41.8 ± 1.1 7.4.0 ± 0.03 94 ± 19 
Hypoxia      
750 µg/kg polyIC (3hr) 37.5 ± 0.2 42 ± 3 ab 43.6 ± 1.3 7.35 ± 0.02 98 ± 23 a 
750 µg/kg polyIC (24hr) 37.4 ± 0.4 41 ± 4 ab 46.3 ± 1.8 7.34 ± 0.03 98 ± 35 ab 
500 µg/kg polyIC (24hr) 37.3 ± 0.2 39 ± 2 ab 41.4 ± 4.3 7.38 ± 0.03 90 ± 30 a 
250 µg/kg polyIC (24hr) 37.5 ± 0.4 41 ± 4 ab 45.5 ± 4.1 7.33 ± 0.02 102 ± 27 
Time Controls 37.5 ± 0.3 260 ± 31c 44.5 ± 1.9 7.37 ± 0.02 78 ± 29 
 
     
Vehicle + keto 37.4 ± 0.4 35 ± 6 ab 42.4 ± 1.6 7.36 ± 0.01 78 ± 29 ab 
polyIC + keto 37.7 ± 0.2 41 ± 4 ab 44.1 ± 1.8 7.33 ± 0.02 80 ± 30 b 
Time Controls + keto 37.4 ± 0.4 260 ± 14 c 43.5 ± 2.0 7.38 ± 0.01 124 ± 28 
 
     
Vehicle + sAIH 37.4 ± 0.3 29 ± 2 ab 43.7 ± 3.0 7.37 ± 0.04 70 ± 14 ab 
polyIC + sAIH 37.4 ± 0.2 31 ± 4ab 43.8 ± 1.2 7.37 ± 0.04 85 ± 15 b 
Time Controls 37.8 ± 0.2 252 ± 8 c 41.0 ± 1.3 7.41 ± 0.01 94 ± 20 
60 minutes      
750 µg/kg polyIC (3hr) 37.4 ± 0.4 272 ± 10 44.3 ± 1.6 7.37 ± 0.01 130 ± 12 
750 µg/kg polyIC (24hr) 37.6 ± 0.2 238 ± 43 47.2 ± 2.8 7.34 ± 0.03 136 ± 32 
500 µg/kg polyIC (24hr) 37.8 ± 0.3 250 ± 35 42.7 ± 3.5 7.38 ± 0.03 126 ± 20 
250 µg/kg polyIC (24hr) 37.6 ± 0.3 247 ± 37 45.6 ± 3.9 7.33 ± 0.04 122 ± 21 
Time Controls 37.6 ± 0.2 266 ± 66 45.2 ± 2.3 7.39 ± 0.02 114 ± 7 
 
     
Vehicle + keto 37.5 ± 0.5 242 ± 40 44.9 ± 1.8 7.38 ± 0.02 114 ± 7 
polyIC + keto 37.4 ± 0.3 268 ± 18 45.2 ± 2.3 7.34 ± 0.02 109 ± 21 
Time Controls + keto 37.8 ± 0.0 236 ± 29 42.8 ± 1.8 7.39 ± 0.02 116 ± 28 
 
     
Vehicle + sAIH 37.7 ± 0.4 250 ± 17 44.3 ± 2.0 7.38 ± 0.02 112 ± 13 
polyIC + sAIH 37.6 ± 0.3 240 ± 19 44.9 ± 1.7 7.38 ± 0.03 115 ± 21 
Time Controls 37.5 ± 0.3 252 ± 19 42.0 ± 1.0 7.40 ± 0.02 93 ± 20 
 
MAP, mean arterial pressure; PaO2, arterial oxygen pressure; PaCO2, arterial carbon dioxide 
pressure. Statistical comparisons: ANOVA-RM, Tukey’s post hoc:  a different from 60 minutes 








To further our understanding of inflammation-induced impairment in adult 
respiratory motor plasticity, we investigated the impact of viral-mimetic-induced 
inflammation on Q- and S-pathway-evoked pLTF. Here, we demonstrate inflammatory 
impairment in respiratory motor plasticity is generalizable to viral-mimetic-induced 
inflammation. The viral-mimetic, polyIC, induced a transient increase in cervical spinal 
inflammatory gene expression and impaired Q-pathway-evoked pLTF. However, the time 
course of inflammatory impairment of pLTF is slower after polyIC compared to bacterial-
induced inflammation (Huxtable et al., 2013). Additionally, S-pathway-evoked pLTF is 
resistant to polyIC-induced systemic inflammation, suggesting preferentially targeting S-
pathway-evoked motor plasticity is an effective strategy to elicit a therapeutic benefit in 
conditions with coincident inflammation.  
PolyIC is a commonly used viral-mimetic binding to TLR3 (Nicodemus and Berek, 
2010) and is used here to induce systemic inflammation. In this study, 750 g/kg polyIC 
(i.p.) was sufficient to induce ventral cervical spinal homogenate inflammatory gene 
expression within 3 hours, resolving by 24 hours. However, splenic inflammatory gene 
expression (a marker of systemic inflammation) showed no significant increase in 
inflammatory genes 3 or 24 hours after polyIC, suggesting this dose of polyIC induces 
relatively low-grade inflammation and has region-specific effects. These regional 
differences could be a result of differing mechanisms of peripheral to central inflammatory 
transmission, such as vagal transmission (Balan et al., 2011; Laye et al., 1995) or 
transmission through the blood brain barrier (Siljehav et al., 2012). Additionally, the blood-




(Pan et al., 1997), suggesting increased spinal inflammation could be a result of faster 
peripheral inflammatory signal transmission from the periphery to the spinal cord relative 
to the medulla. However, our understanding of the detailed mechanisms underlying 
peripheral polyIC-induced central inflammation remain unclear (Dantzer, 2009; Konat et 
al., 2009) and warrant further investigation. 
The time course of inflammatory gene expression after peripheral polyIC presented 
here is similar to increased cervical spinal inflammatory gene expression observed after 
peripheral LPS, which is elevated at 3 hours and similarly resolved by 24 hours (Huxtable 
et al., 2013). However, the magnitude of gene upregulation in spinal homogenates was 
substantially less following polyIC compared to LPS (Huxtable et al., 2013), suggesting 
750 g/kg polyIC is likely inducing a lower level of CNS inflammation. Yet, an inherent 
difficulty in comparing distinct inflammatory stimuli is identifying comparable doses. 
PolyIC dose-response experiments in rats demonstrate 750 g/kg (i.p.) is sufficient to 
upregulate circulating cytokines and induce fever through an IL-1 dependent mechanism  
(Fortier et al., 2004). Therefore, 750 g/kg polyIC is comparable to 100 g/kg LPS since 
both induce similar febrile responses in rats (Boisse et al., 2005), and induce spinal 
inflammatory gene expression within 3 hours, but only LPS is sufficient to impair pLTF at 
3 hours.  
While LPS and polyIC both induce MAPKs, NF-κB, and increase pro-
inflammatory gene expression, peripheral polyIC induces a slower onset and longer lasting 
upregulation of inflammatory gene expression in the CNS compared to LPS (Konat et al., 
2009; Krasowska-Zoladek et al., 2007; Yamato et al., 2014). These differences may arise 




different TLR adaptor signaling (Matsumoto and Seya, 2008; Zhu et al., 2016) and TLR3-
independent targets of polyIC (Hu et al., 2013; Matsumoto and Seya, 2008; McCartney et 
al., 2009; Starkhammar et al., 2012; Zhu et al., 2016). Alternatively, a temporal delay in 
polyIC-induced inflammatory protein expression may result in delayed or insufficient 
inflammation to impair plasticity 3 hours after polyIC. Additionally, we cannot rule out 
inflammatory changes in isolated cell types being diluted in homogenate samples, such as 
the changes seen in isolated microglia after LPS (Huxtable et al., 2013), nor the possibility 
of unmeasured inflammatory molecules playing an important role(s) in undermining 
plasticity. Any or all of these differences likely contribute to different time scales of pLTF 
impairment after polyIC (24 hour) compared to LPS (3 and 24 hour). 
 Q-pathway-evoked pLTF was not impaired 3 hours after polyIC, yet COX-2 gene 
expression transiently increased at 3 hours. Despite inducing neuroinflammation in regions 
of the CNS relevant to respiratory plasticity, it was not sufficient to impair plasticity. These 
findings support previous work demonstrating the inflammatory impairment of Q-
pathway-evoked pLTF is COX-independent (Huxtable et al., 2017). However, 750 g/kg 
polyIC was sufficient to abolish Q-pathway-evoked pLTF at 24 hours, when all measured 
inflammatory genes returned to baseline. Such findings match the results of Fortier et al., 
(2004), demonstrating 750 g/kg polyIC was just above the threshold required to induce 
brain-mediated febrile responses. Thus, 750 g/kg polyIC is above the threshold dose 
inducing CNS inflammatory responses and abolishing Q-pathway respiratory motor 
plasticity. Overall, these findings are similar to those observed 24 hours after LPS-induced 
inflammation (Huxtable et al., 2013), demonstrating the inflammatory impairment in Q-




Acute ketoprofen after polyIC-induced inflammation restored Q-pathway-evoked 
pLTF, confirming the impairment of pLTF is inflammation-dependent. Ketoprofen inhibits 
both COX and NF-κB (Cashman, 1996; Yin et al., 1998). However, as COX inhibition 
does not restore Q-pathway-evoked pLTF after inflammation (Huxtable et al., 2017), the 
restoration of pLTF from ketoprofen is likely due to NF-κB inhibition, though we cannot 
rule out other off-target effects of ketoprofen. Regardless, our results indicate the viral 
mimetic polyIC induces cervical spinal inflammation and impairs Q-pathway-evoked 
pLTF in an inflammation-dependent manner. Previous work demonstrated the acute 
impairment of pLTF is downstream of serotonin receptors, upstream of BDNF signaling 
(Agosto-Marlin et al., 2018), and involves IL-1 receptors (Hocker and Huxtable, 2018) and 
p-38 MAPK activation (Huxtable et al., 2015). Future studies should further investigate 
more detailed cellular mechanisms by which inflammatory signaling impairs Q-pathway-
evoked respiratory motor plasticity after both LPS- and polyIC-induced inflammation 
(summarized in Fig. 3.5). 
S-pathway-evoked pLTF is a distinct molecular signaling pathway inducing 
facilitation of phrenic motor output and elicited by severe AIH through adenosine 2A 
receptor activation (Nichols et al., 2012). While Q-pathway-evoked pLTF is abolished by 
low-levels of inflammation from diverse stimuli (Huxtable et al., 2013, 2015), S-pathway-
evoked pLTF is resistant to LPS-induced inflammation (Agosto-Marlin et al., 2017). Here, 
we demonstrate the inflammation resistance of S-pathway-evoked pLTF after polyIC-
induced inflammation (Fig. 3.5). These findings contribute to the possibility S-pathway-
evoked pLTF can serve as a “backup” mechanism to motor plasticity during low-level 





Figure 3.5. Schematic summarizing diverse inflammatory stimuli impair Q-pathway, 
but not S-pathway, adult respiratory motor plasticity. Lipopolysaccharide (LPS), 
polyinosinic:polycitidylic acid (polyIC), and one night of intermittent hypoxia (IH-1) 
activate peripheral inflammatory pathways and abolish Q-pathway-evoked pLTF. LPS and 
polyIC activate TLR4 and TLR3, respectively, to induce NF-kB activation and impair Q-
pathway-evoked pLTF. IH-1-induced inflammation activates p38 MAPK and NF-kB to 
impair Q-pathway-evoked respiratory motor plasticity. Thus, multiple, diverse low-level 
inflammatory stimuli impair Q-pathway-evoked pLTF. S-pathway-evoked pLTF, 
however, is resistant to both LPS and polyIC-induced inflammation, suggesting it may act 
as a “backup” pathway after inflammation.  
 
In summary, polyIC impairs Q-pathway, but not S-pathway-evoked, respiratory 
motor plasticity. Further, the inflammatory impairment of Q-pathway plasticity after 
polyIC relative to LPS is temporally delayed, though we do not have a detailed regional, 
time course of the inflammatory response following either polyIC or LPS. Such time course 
studies would facilitate a mechanistic understanding of the inflammatory impairment of Q-
pathway plasticity. While the present studies were all performed in urethane-anesthetized 




ventilatory LTF in freely behaving animals (McGuire et al., 2004, 2005, 2008), suggesting 
findings may be generalizable to ventilatory LTF. The present study focused on the impact 
of polyIC in adult male rats, highlighting the need for additional studies in females. 
However, the lack of sex differences observed in adults after neonatal inflammation 
(Hocker et al., 2019), suggest females would respond similarly to polyIC-induced 
inflammation. It is important to note pLTF in females is altered by cycling estrogen levels 
(Dougherty et al., 2017), which may also influence CNS inflammatory responses (Arakawa 
et al., 2014). Thus, future studies should address potential sex differences in the acute 
inflammatory impairment of pLTF and the inflammatory resistance of S-pathway-evoked 
plasticity in females.  
In conclusion, this is the first study to evaluate the impact of viral-mimetic-induced 
inflammation on adult respiratory motor plasticity and demonstrates respiratory plasticity 
is profoundly sensitive to diverse inflammatory stimuli. Our results suggest the sensitivity 
of Q-pathway-evoked pLTF to inflammation is not stimulus specific and is impaired by 
viral, bacterial, and physiological inflammatory stimuli (Fig. 3.5). Further, S-pathway-
evoked pLTF is resistant to viral mimetic-induced inflammation, supporting the notion S-
pathway-evoked plasticity could compensate for Q-pathway impaired plasticity after 
inflammation (Fig. 3.5). Therefore, inflammation, which is common during disease and 
injury, can abolish the therapeutic potential of respiratory motor plasticity (Hayes et al., 
2014; Mateika and Komnenov, 2017; Trumbower et al., 2012, 2017) and leave patients 
vulnerable to respiratory failure. Stimuli which preferentially elicit S-pathway-evoked 







ONE BOUT OF NEONATAL INFLAMMATION IMPAIRS ADULT RESPIRATORY 
MOTOR PLASTICITY IN MALE AND FEMALE RATS 
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Introduction 
At birth, neonates transition from a sterile maternal environment into an 
environment filled with pathogens, microbes, and toxins and must simultaneously begin 
robust, rhythmic breathing. Respiratory problems represent a significant clinical problem 
for neonatologists (Martin et al., 2012), especially in preterm infants where breathing is 
unstable (Poets et al., 1994; Poets and Southall, 1994) and infections are common (Stoll 
et al., 2002, 2004). Further, inflammation appears to augment respiratory dysfunction in 




Rourke et al., 2016) and induces recurrent apneas (Hofstetter et al., 2007). Despite the 
prevalence of early life inflammation, little is known about the long-lasting consequences 
of neonatal inflammation on adult neurorespiratory control. 
  We are beginning to understand the potential for long-term consequences of early 
life inflammation in other physiological systems. Neonatal inflammation blunts adult 
immune function (Bilbo et al., 2010; Mouihate et al., 2010; Spencer et al., 2011), 
increases adult stress reactivity (Grace et al., 2014; Shanks et al., 2000; Wang et al., 
2013), impairs adult learning and hippocampal plasticity (Bilbo, 2005; Bilbo et al., 2006), 
increases the risk of neuropsychiatric disorders (Hornig et al., 1999; Rantakallio et al., 
1997), and worsens age-related cognitive decline (Bilbo, 2010). Yet, we know very little 
about the long-term effects of neonatal inflammation on adult neurorespiratory control.  
 Respiratory plasticity is an important feature of the neural control of breathing, 
providing adaptability and maintenance of breathing when the respiratory system is 
challenged (Fuller and Mitchell, 2017). Phrenic long-term facilitation (pLTF) is a 
frequently studied adult model of respiratory motor plasticity (Mitchell and Johnson, 
2003) and is elicited by at least two distinct cellular signaling pathways: the Q-pathway 
and the S-pathway (reviewed in Dale-Nagle et al., 2010). The Q-pathway is evoked by 
moderate acute intermittent hypoxia (mAIH; 3x5 minute hypoxic episodes, PaO2 35-45 
mmHg) and is serotonin dependent, while the S-pathway is evoked by severe AIH (sAIH, 
PaO2 25-35 mmHg) and is adenosine dependent (Nichols et al., 2012). Interestingly, Q-
pathway-evoked plasticity is undermined by even low levels of acute, adult, systemic 
inflammation and restored by the non-steroidal anti-inflammatory, ketoprofen (Hocker 




adult plasticity is inflammation resistant (Agosto-Marlin et al., 2017). Though we are 
beginning to understand more about the mechanisms of acute, adult inflammation on 
respiratory motor plasticity (Hocker et al., 2017; Hocker and Huxtable, 2018), we do not 
know how inflammation in early postnatal life impacts respiratory motor plasticity in the 
adult. Furthermore, few studies have investigated sex-differences in pLTF (Behan et al., 
2002; Dougherty et al., 2017) and we know even less about sex-differences in respiratory 
control in response to inflammation. Additionally, males are more sensitive acutely to 
neonatal inflammation leading to higher male mortality in neonates (Bouman et al., 2005; 
Kentner et al., 2010; Rathod et al., 2017), but our understanding of other sex-differences 
after neonatal inflammation are unknown. Given the profound effects of neonatal 
inflammation on other physiological systems, we tested the hypothesis that neonatal 
inflammation undermines Q-pathway, but not S-pathway, respiratory motor plasticity in 
adult male and female rats. 
Our results indicate that one, neonatal inflammatory challenge completely 
abolishes adult, AIH-induced Q-pathway and S-pathway respiratory motor plasticity. 
Despite no lasting increases in adult, inflammatory gene expression, Q-pathway 
impairment is inflammation-dependent and is restored by acute adult anti-inflammatory 
treatment. Conversely, S-pathway impairment is inflammation-independent, but can be 
evoked by intermittent adenosine receptor agonism, suggesting phrenic motor neurons 
are not impaired. Since astrocytes are a primary source of adenosine during hypoxia 
(Angelova et al., 2015; Takahashi et al., 2010), they are likely impaired by neonatal 
inflammation and contributing to impairment of respiratory plasticity. These studies are 




respiratory plasticity and suggest neonatal inflammation induces lasting-changes, 
increasing susceptibility to adult ventilatory control disorders.   
 
Results 
Neonatal inflammation acutely delays weight gain and increases male mortality.  
Male and female postnatal day 4 (P4) rats were injected with either LPS 
(Lipopolysaccharide; 1mg/kg, i.p.) or saline. The dose of LPS was based on previous 
studies demonstrating CNS inflammatory gene expression in neonates (Rourke et al., 
2016), as well as our unpublished data (N. Morrison, S. Johnson, J. Watters, A. Huxtable, 
unpublished observations). Within 24 hours of neonatal LPS injections, there was 
significantly greater mortality of male pups (8 of 67) than female pups (1 of 55, Fisher’s 
exact test, p = 0.04, Fig. 4.1A). No mortality was evident in the saline treated males (n = 
63) or females (n = 63). For the surviving pups, neonatal LPS males weighed 
significantly less at week 7 (no pairwise weight differences seen in females), but 
importantly, weights were not different in adults (Fig. 4.1B).  
 
Adult, Q-pathway-evoked pLTF was undermined by neonatal inflammation, and was 
restored by acute, adult anti-inflammatory treatment. 
Q-pathway-evoked pLTF is evident as the increase in integrated phrenic activity 
60 minutes after mAIH (PaO2 35-45 mmHg) in adult, anesthetized rats (Bach and 
Mitchell, 1996). As expected, in adult males treated with neonatal saline, Q-pathway- 
evoked pLTF was evident after mAIH (55 ± 33.2% change from baseline, n = 7, p = 





Figure 4.1. Neonatal inflammation increases mortality in neonatal males and 
transiently delays weight gain in male and female rats. After neonatal inflammation 
(P4, LPS 1 mg/kg, i.p.) male mortality (A) is increased within 24 hours (Fisher’s exact test, 
p = 0.006), but not in females (p = 0.466), relative to saline controls. Weekly male and 
female weights (B) after neonatal saline or LPS demonstrate a transient impairment in male 
weight gain, but are unchanged from neonatal groups in adulthood. (* p < 0.05, significant 
pairwise difference within sex) 
 
 
treated with neonatal LPS (14 ± 49%, n = 12, p = 0.2247 Fig. 4.2A and C). To control for 
the known effects of estrus cycle hormones on pLTF in females (Behan et al., 2002; 
Dougherty et al., 2017; Zabka et al., 2001), adult females were ovariectomized 7-8 days 
before electrophysiology studies. Similar to males, adult females treated with neonatal 
saline displayed Q-pathway-evoked pLTF (97 ± 63% change from baseline, n = 7, p < 




express pLTF (-15 ± 43%, n = 6, p = 0.4689, Fig. 4.2B and C). Phrenic amplitude did not 
change from baseline in the time control group (8 ± 6% change, n = 5, p = 0.6482), 
regardless of sex or neonatal LPS exposure and was significantly reduced compared to 
males or females treated with neonatal saline. Between groups, Q-pathway-evoked pLTF 
was significantly abolished in adults after neonatal LPS compared to adults after neonatal 
saline for both males (p = 0.0200) males and females (p < 0.0001). Thus, neonatal 
inflammation induces lasting impairment of adult, Q-pathway-evoked respiratory motor 
plasticity in both males and females.  
 
Figure 4.2. Neonatal systemic inflammation undermines adult, Q-pathway-evoked 
pLTF in male and female rats. Representative integrated phrenic neurograms from male 
(A) and female rats (B) after neonatal (P4) saline (top traces, black) or LPS (1 mg/kg, i.p.; 
bottom traces, grey). Q-pathway-evoked pLTF is evident in adults after neonatal saline as 
the progressive increase in phrenic nerve amplitude from baseline (dashed line) over 60 
minutes following moderate acute intermittent hypoxia (mAIH, 3 x 5 minute episodes, 
PaO2 35-45 mmHg). Group data (C) demonstrate Q-pathway-evoked pLTF 60 min after 
mAIH is abolished in adults by neonatal LPS in both males (circles) and females (triangles) 
and phrenic amplitude in male and female time controls is unchanged from baseline (** p 
< 0.01, *** p < 0.001 from baseline, # p < 0.05, ### p < 0.001 between groups, ‡ p < 0.05 





To test whether this lasting impairment of adult, respiratory motor plasticity was 
due to ongoing adult inflammation as a result of the neonatal inflammatory LPS 
challenge, we acutely treated adults with the non-steroidal anti-inflammatory, ketoprofen 
(12.5 mg/kg, i.p., 3 h), a high dose previously shown to restore plasticity after acute, adult 
inflammation (Huxtable et al., 2013). Ketoprofen treatment restored Q-pathway-evoked 
pLTF in adult males treated with neonatal LPS (58 ± 18% change from baseline, n = 4, p 
= 0.0004, Fig. 4.3A and C). Ketoprofen also restored Q-pathway-evoked pLTF in adult 
females treated with neonatal LPS (111 ± 44% from baseline, n = 5, p < 0.0001, Fig. 
4.3B and C). Adults treated with neonatal saline (male: 54 ± 17% from baseline, n = 4, 
0.0008; female: 89 ± 40%, n = 5, p < 0.0001) were unaffected by adult ketoprofen 
treatment. Additionally, phrenic motor amplitude did not change in adult time controls 
treated with ketoprofen (13 ± 14% change from baseline, n = 4, p = 0.3436) and was 
significantly reduced compared to all other groups. Between groups, pLTF was not 
different between adult males (p = 0.7605) or females (p = 0. 2932) after neonatal saline 
or neonatal LPS, demonstrating the impairment in Q-pathway-evoked pLTF is 
inflammation-dependent in both males and females.  
 
Neonatal inflammation did not induce chronic neuroinflammation in adult medulla or 
cervical spinal cords.  
 Because the lasting impairment of Q-pathway-evoked pLTF was inflammation-
dependent, we examined whether neonatal inflammation had lasting effects on adult 






Figure 4.3. Acute, adult anti-inflammatory (ketoprofen, Keto) restores Q-pathway-
evoked pLTF after neonatal systemic inflammation in adult male and female rats. 
Representative integrated phrenic neurograms for adult male (A) and female (B) rats after 
neonatal (P4) saline (top traces, black) or LPS (1 mg/kg, i.p.; bottom traces, grey) and 
acute, adult ketoprofen (12.5 mg/kg, i.p., 3 hr). Q-pathway-evoked pLTF is evident as the 
progressive increase in phrenic nerve amplitude from baseline (black dashed line) over 60 
minutes following moderate acute intermittent hypoxia (mAIH, 3 x 5 minute episodes, 
PaO2 35-45 mmHg). Group data (C) demonstrate adult ketoprofen restores Q-pathway-
evoked pLTF 60 min after mAIH in adults after neonatal LPS in both males (circles) and 
females (triangles). Phrenic amplitude in male and female time controls is unchanged 
from baseline. (*** p < 0.001 from baseline, ‡ p < 0.05 from all other groups). 
 
Since plasticity was abolished in both males and females, data from both sexes were 
combined for analysis of inflammatory genes. In medullary and cervical spinal 
homogenates, neonatal LPS did not significantly alter mRNA for adult inflammatory 
genes (IL-6, IL-1β, TNF-α, or iNOS; Fig. 4.4A and B). However, COX-2 gene 
expression was reduced in adult spinal cords after neonatal LPS (Fig. 4.4B, p = 0.001), 
suggesting a decrease in COX-dependent inflammatory signaling. Thus, there was no 
evidence for lasting increases in neuroinflammatory gene expression in adults after a 








Figure 4.4. Neonatal inflammation does not increase adult medullary or spinal 
inflammatory gene expression. Homogenate samples isolated from adult medullas 
showed no significant increase in inflammatory mRNA after neonatal inflammation (A). 
Similarly, homogenate samples from isolated adult cervical spinal cords (C) were not 
increased by neonatal inflammation, but COX2 gene expression was significantly 
decreased in adults after neonatal inflammation (* p < 0.05).  
 
 
Adult S-pathway-evoked pLTF was undermined by neonatal inflammation, not restored 
by adult anti-inflammatory treatment, but revealed by intermittent adenosine 2A receptor 
agonism. 
S-pathway-evoked pLTF is evident as the increase in integrated phrenic activity 
60 minutes after sAIH (PaO2 25-35 mmHg) in adult rats. As expected, in adult males 
after neonatal saline, S-pathway-evoked pLTF was evident after sAIH (61 ± 69% change 




pathway-evoked pLTF was abolished in adult males after neonatal LPS (7 ± 18% change 
from baseline, n = 4, p = 0.6770, Fig. 4.5A and C). In adult females after neonatal saline, 
S-pathway-evoked pLTF was evident (102 ± 47% change from baseline, n = 4, p < 
0.0001, Fig. 4.5B and C). Similar to adult males treated with neonatal LPS, S-pathway-
evoked pLTF was abolished in adult females after neonatal LPS (0 ± 33%, n = 4, p = 
0.9796, Fig. 4.5B and C). Phrenic amplitude in the time control group was significantly 
less than males (p = 0.0147) or females (p < 0.0001) treated with neonatal saline. 
Between groups, S-pathway-evoked pLTF was significantly reduced after neonatal LPS 
in both adult males (p = 0.0180) and females (p < 0.0001) compared to adults after 
neonatal saline. Thus, neonatal inflammation induces lasting impairment of adult, S-
pathway-evoked respiratory motor plasticity in both males and females.  
To test whether this lasting impairment of adult, S-pathway-evoked plasticity is 
due to ongoing inflammation in adults after neonatal LPS, we examined sAIH-induced 
plasticity after an acute, adult treatment with ketoprofen (12.5mg/kg, i.p., 3 h). 
Ketoprofen did not alter normal expression of S-pathway-evoked pLTF in adult males 
after neonatal saline (63 ± 22% change from baseline, n = 5, p = 0.0014, Fig. 4.6A and 
C). However, contrary to the Q-pathway results, adult ketoprofen did not restore S-
pathway-evoked pLTF in adult males after neonatal LPS (0 ± 65% change from baseline, 
n = 5, p = 0.9804, Fig. 4.6A and C). Similarly, adult females treated with neonatal saline 
also exhibited normal S-pathway-evoked pLTF after adult ketoprofen (130 ± 22% change 








Figure 4.5. Neonatal systemic inflammation undermines adult, S-pathway-evoked 
pLTF in male and female rats. Representative integrated phrenic neurograms for adult 
male (A) and female (B) rats after neonatal (P4) saline (top traces, black) or LPS (1 mg/kg, 
i.p.; bottom traces, grey). S-pathway-evoked pLTF is evident as the progressive increase in 
phrenic nerve amplitude from baseline (black dashed line) over 60 minutes following 
severe acute intermittent hypoxia (sAIH, 3 x 5 minute episodes, PaO2 25-35 mmHg) in 
adults after neonatal saline. Group data (C) demonstrate S-pathway-evoked pLTF 60 min 
after sAIH is abolished in adults by neonatal LPS in both males (circles) and females 
(triangles). Phrenic amplitude in male and female time controls is unchanged from 
baseline. (** p < 0.01, *** p < 0.001 from baseline ## p < 0.01, ### p < 0.001 between 
groups, ‡ p < 0.05 from male and female adults after neonatal saline). 
 
 
restored by ketoprofen in adult females after neonatal LPS (25 ± 30% change from 
baseline, n = 6, p = 0.0803, Fig. 4.6B and C). Adult males and females treated with 
neonatal LPS and adult ketoprofen were not different from time controls (males, p 
=0.4964; females p = 0.5227). Between groups, S-pathway-evoked pLTF after acute 
ketoprofen was significantly reduced in adults after neonatal LPS comapred to adults 




inflammation induces a lasting impairment of adult, S-pathway-evoked respiratory motor 
plasticity, which is not due to ongoing adult, inflammatory signaling. 
 
 
Figure 4.6. Adult, anti-inflammatory (ketoprofen, keto) does not restore S-pathway-
evoked pLTF after neonatal systemic inflammation in adult male and female rats. 
Representative integrated phrenic neurograms for adult male (A) and female (B) rats after 
neonatal (P4) saline (top traces, black) or LPS (1 mg/kg, i.p.; bottom traces, grey) and 
acute, adult ketoprofen (12.5 mg/kg, i.p., 3 hr). S-pathway-evoked pLTF is evident as the 
progressive increase in phrenic nerve amplitude from baseline (black dashed line) over 60 
minutes following severe acute intermittent hypoxia (sAIH, 3 x 5 minute episodes, PaO2 
35-45 mmHg) in adults after neonatal saline. Group data (C) demonstrate acute, adult 
ketoprofen does not restore S-pathway-evoked pLTF 60 min after sAIH after neonatal LPS 
in adult males (circles) and females (triangles). Phrenic amplitude in male and female time 
controls is unchanged from baseline.  (** p < 0.01, *** p < 0.001 from baseline, ## p < 




S-pathway-evoked plasticity elicted by sAIH is adenosine dependent (Golder et 
al., 2008; Nichols et al., 2012) and can be evoked by intermittent CGS-21680, an 
adenosine 2A receptor agonist. To test if neonatal inflammation is impairing phrenic 




21680 on the cervical spinal cord, around the phrenic motor pool. Intrathecal CGS-21680 
(100 µM, 3 x 10 µL) evoked phrenic motor plasticity in adult males after neonatal saline 
(110 ± 17% change from baseline, n = 4, p < 0.001, Fig. 4.7A and C) and females after 
neonatal saline (127 ± 47%, n = 4, p < 0.001, Fig. 4.7B and C). After neonatal LPS, 
intrathecal CGS-21680 also elicited plasticity in adult males (85 ± 64%, n = 6, p < 0.001, 
Fig. 4.7A and C) and adult females (147 ± 74%, n = 6, p < 0.001, Fig. 4.7B and C), 
demonstrating phrenic motor neurons are not impaired after neonatal inflammation and 
are capable of S-pathway-evoked plasticity. The vehicle control group was not different 
from baseline (-3 ± 5% change, n = 4, p = 0.8891) and significantly reduced compared to 
all other groups. Between groups, pLTF was not different between adult males (p = 
0.2841) or females (p = 0.4032) after neonatal saline or neonatal LPS. Thus, adult phrenic 
motor neurons are not impaired after neonatal inflammation and are capable of plasticity 
after neonatal inflammation. Therefore, the source of intermittent adenosine release is 
impaired during sAIH-induced pLTF after neonatal inflammation. 
 
Adult microglia and astrocyte density were not changed by neonatal inflammation. 
While there was no evidence for elevated neuroinflammation based on the 
inflammatory genes evaluated here, the anti-inflammatory drug ketoprofen successfully 
restored Q-pathway-evoked plasticity. Additionally, our results indicate the impairment 
in S-pathway-evoked plasticity was likely due to a lasting change in adenosine signaling, 
possibly as a result of altered astrocytes. Thus, we hypothesized a lasting change in 







Figure 4.7. Intermittent adult, adenosine receptor agonism reveals plasticity after 
neonatal systemic inflammation in male and female rats. Representative integrated 
phrenic neurograms for adult male (A) and female (B) rats after neonatal (P4) saline (top 
traces, black) or LPS (1 mg/kg, i.p.; bottom traces, grey). S-pathway-evoked phrenic motor 
plasticity is evident as the progressive increase in phrenic nerve amplitude from baseline 
(black dashed line) 90 minutes after intermittent CGS-21680 (100 µM, black arrows, 3 x 5 
minutes apart) in adults after neonatal saline. Group data (C) demonstrate adult CGS-21680 
reveals S-pathway-evoked plasticity after neonatal LPS in adult males (circles) and females 
(triangles). Phrenic amplitude in male and female vehicle controls is unchanged from 




impairing adult plasticity. We evaluated GFAP (astrocytes) and IBA1 (microglia) 
immunoreactivity in the adult preBötC, the site of respiratory rhythmogenesis (Smith et 
al., 1991), and in cervical spinal cords in the region of the phrenic motor nucleus, the 
presumptive site of pLTF (Baker-Herman et al., 2004; Dale et al., 2017; Devinney et al., 
2015a). Neonatal inflammation did not alter GFAP (p = 0.5969) or IBA1 (p = 0.6487) 
immunoreactivity in adult preBötC in either sex (Fig. 4.8A, B, and E), suggesting 






Figure 4.8. Neonatal inflammation does not alter GFAP or IBA1 immunofluorescence 
in adult preBötzinger Complex or ventral cervical spinal cords. After neonatal LPS (1 
mg/kg, i.p., P4), representative confocal images (40x) from adult preBötC (A and B) and 
cervical spinal cords (C and D) displayed no qualitative differences in immunoreactivity 
for GFAP (green, astrocytes) or IBA1 (green, microglia) in males (left panels) or females 
(right panels). PreBötC neurons are labeled with antibodies for NK1R (red, A and B) and 
motor neurons are labeled with antibodies for ChAT (red, C and D). Neonatal inflammation 
did not significantly change mean fluorescent intensity of either GFAP or IBA1 in the 
preBötC (E) or cervical spinal cord (F), suggesting no lasting differences in astrocytes or 





Furthermore, there were no changes in GFAP (p = 0.7195) or IBA1 (p = 0.9254) 
immunoreactivity in adult cervical spinal cords (Fig. 4.8C, D and F), suggesting no 
lasting changes in astrocyte and microglia density in the region of the phrenic motor 
nucleus. Additionally, no obvious differences in astrocyte or microglial morphology in 
adult phrenic motor nuclei or the preBötC were seen following neonatal LPS 
inflammation, suggesting other signaling mechanisms are responsible for impairing adult 
pLTF. 
 
Acute hypoxic phrenic responses were greater in females, but were unaffected by 
neonatal inflammation.   
Neonatal inflammation did not significantly alter moderate acute hypoxic phrenic 
amplitude responses within adult males (neonatal saline = 114 ± 41% change from 
baseline; neonatal LPS = 93 ± 36%) or females (neonatal saline = 185 ± 53%; neonatal 
LPS = 148 ± 63%, Table 4.1). Hypoxic phrenic amplitude responses were also unaffected 
by the anti-inflammatory ketoprofen in adult males (neonatal saline + Keto = 118 ± 36%; 
neonatal LPS + Keto, 118 ± 44%) or females (neonatal saline + Keto, 165 ± 52%; 
neonatal LPS + Keto, 189 ± 82%, Table 4.1). However, adult females exhibited 
significantly greater acute phrenic amplitude responses to moderate hypoxia (main effect, 
p = 0.0004).  
Phrenic amplitude in response to severe hypoxia was similarly unaltered by 
neonatal inflammation within adult males (neonatal saline = 139 ± 37% change from 
baseline; neonatal LPS = 106 ± 10%) or females (neonatal saline = 172 ± 125%; neonatal 




phrenic amplitude responses in adult males (neonatal saline = 151 ± 25% change from 
baseline; neonatal LPS, 174 ± 96%) or females (neonatal saline = 194 ± 45%; neonatal 
LPS = 235 ± 63%, Table 4.1). Similarly, adult females exhibited a significantly greater 
acute amplitude response to severe hypoxia than males (main effect, p = 0.021).  
 
 
Table 4.1. Acute, adult hypoxic phrenic responses. Group data for adult, acute hypoxic 
phrenic responses to moderate (PaO2 35-45 mmHg) and severe (PaO2 25-35 mmHg) 
hypoxia demonstrate no differences after neonatal (P4) saline or LPS (1 mg/kg, i.p), or 
after adult ketoprofen (12.5 mg/kg, i.p, 3 hr) within each sex. Significant differences 
between sexes demonstrate larger responses in females after moderate or severe hypoxia 
(† p < 0.05, ††† p < 0.001). a p <0.05 from male neonatal LPS. Moderate hypoxia: neonatal 
saline male (n = 7), neonatal LPS male (n = 10), neonatal saline female (n = 6), neonatal 
LPS female (n = 6). Keto + Moderate hypoxia: neonatal saline male (n = 4), neonatal LPS 
male (n = 4), neonatal saline female (n = 5), neonatal LPS female (n = 5). Severe hypoxia: 
neonatal saline male (n = 5), neonatal LPS male (n = 4), neonatal saline female (n = 4), 
neonatal LPS female (n = 4). Keto + Moderate hypoxia: neonatal saline male (n = 5), 











 Neonatal Saline Neonatal LPS Neonatal Saline Neonatal LPS 
Moderate 
hypoxia  114 ± 41 93 ± 36 185 ± 53
a 148 ± 63 
 
Keto + Moderate 





Female  †        
                    
 Neonatal Saline Neonatal LPS Neonatal Saline Neonatal LPS 
      
Severe hypoxia 139 ± 37 106 ± 10 172 ± 125 172 ± 26 
 
Keto + Severe 




Physiological parameters and frequency plasticity 
All physiological parameters remained within experimental limits (Table 4.1). 
Neonatal saline or LPS caused no significant changes in adult temperature, PaCO2, PaO2, 
or pH at baseline. There were no between group differences in baseline MAP, suggesting 
no long-lasting cardiovascular changes after neonatal inflammation. No significant 
changes occurred over time in temperature, pH, or PaCO2 for any group. As expected, 
MAP and PaO2 were significantly decreased during hypoxic episodes in experimental 
groups, but these changes were not evident in time control groups and were not different 
from baseline values at 60 minutes post-AIH. 
Baseline phrenic burst frequency was not significantly different between groups 
and frequency plasticity, an increase in burst frequency 60 minutes after AIH , was not 







Table 4.2. (next page) Physiological parameters during electrophysiology experiments. 
MAP, mean arterial pressure; PaO2, arterial oxygen pressure; PaCO2, arterial carbon 
dioxide pressure. Neonatal Saline + mAIH male (n = 7) female (n = 7); Neonatal LPS + 
mAIH male (n = 12) female (n = 6); Neonatal Saline + Keto + mAIH male (n = 4) female 
(n = 5); Neonatal LPS + Keto + mAIH male (n = 4) female (n = 5); Neonatal Saline + 
sAIH male (n = 5) female (n = 4); Neonatal LPS + sAIH male (n = 4) female (n = 4); 
Neonatal Saline + Keto + sAIH male (n = 5) female (n = 5); Neonatal LPS + Keto + 
sAIH male (n = 5) female (n = 6); Time Control (n = 5); Time Control + Keto (n = 4). 
Statistical comparisons: ANOVA-RM, Tukey’s post hoc:  a different from Time control 
within time point, b different from TC + Keto within time point, c different from baseline 
and 60 min, d different from baseline, e different from female neonatal LPS + Keto + 





 Temperature (°C) PaO2 (mmHg) PaCO2 (mmHg) pH MAP (mmHg) 
Baseline Male Female Male Female Male Female Male Female Male Female 
Neonatal Saline + mAIH 37.4 ± 0.2 37.4 ± 0.2 254 ± 19 259 ± 53 43.2 ± 5.6 48.9 ± 3.7 7.37 ± 0.06 7.36 ± 0.02 124 ± 9 121 ± 18 
Neonatal LPS + mAIH 37.6 ± 0.2 37.5 ± 0.2 266 ± 30 268 ± 24   42.8 ± 4.7e 45.0 ± 1.8 7.37 ± 0.04 7.37 ± 0.02   127 ± 10 123 ± 23 
Neonatal Saline + Keto + mAIH 37.3 ± 0.1 37.4 ± 0.3 249 ± 21 255 ± 28 41.7 ± 4.9 48.6 ± 3.5 7.38 ± 0.03 7.33 ± 0.02 132 ± 8 121 ± 12 
Neonatal LPS + Keto + mAIH 37.4 ± 0.2 37.4 ± 0.3 276 ± 40 283 ± 33 41.5 ± 3.2 47.9 ± 3.6 7.39 ± 0.03 7.34 ± 0.02   129 ± 16 117 ± 14 
Neonatal Saline + sAIH 37.6 ± 0.3 37.5 ± 0.2 295 ± 18 266 ± 9 43.3 ± 5.9 47.7 ± 3.1 7.37 ± 0.02 7.36 ± 0.00 133 ± 6 121 ± 19 
Neonatal LPS + sAIH 37.4 ± 0.1 37.4 ± 0.4 297 ± 28 264 ± 35 45.3 ± 4.2 47.7 ± 4.0 7.36 ± 0.02 7.36 ± 0.02   135 ± 20 132 ± 14 
Neonatal Saline + Keto + sAIH 37.4 ± 0.3 37.5 ± 0.1 256 ± 46 268 ± 29   41.6 ± 2.2e 49.9 ± 3.5 7.39 ± 0.03 7.34 ± 0.02   110 ± 12 113 ± 29 
Neonatal LPS + Keto + sAIH 37.5 ± 0.2 37.4 ± 0.2 243 ± 45 245 ± 39 42.3 ± 3.4 51.6 ± 6.8 7.37 ± 0.01 7.31 ± 0.04 121 ± 3 129 ± 13 
Neonatal Saline + CGS-21680 37.5 ± 0.2 37.3 ± 0.2 268 ± 21 237 ± 14 45.4 ± 5.3 46.2 ± 3 7.36 ± 0.04 7.34 ± 0.03   119 ± 24 121 ± 10 
Neonatal LPS + CGS-21680 37.6 ± 0.3 37.4 ± 0.3 247 ± 27 247 ± 21 46.2 ± 2.9 46.6 ± 2.7 7.37 ± 0.02 7.34 ± 0.02    114 ± 12 107 ± 15 
Time Controls 37.7 ± 0.1 250 ± 45 49.4 ± 4.0 7.36 ± 0.05 110 ± 10 
Time Controls + Keto 37.5 ± 0.3 250 ± 17 44.0 ± 9.1 7.37 ± 0.06 115 ± 39 
CGS-21680 Vehicle Controls 37.4 ± 0.3 237 ± 40 45.8 ± 0.8 7.37 ± 0.03 110 ± 17 
Hypoxia           
Neonatal Saline + mAIH 37.4 ± 0.2 37.3 ± 0.1 38 ± 2abc 40 ± 3abc  42.2 ± 5.1e 48.8 ± 3.8 7.35 ± 0.07  7.36 ± 0.03e    62 ± 23abc    65 ± 30abc 
Neonatal LPS + mAIH 37.5 ± 0.4 37.4 ± 0.1 39 ± 2abc 39 ± 4abc  43.0 ± 4.8e 45.4 ± 2.8  7.36 ± 0.04e  7.36 ± 0.02e    68 ± 19abc 80 ± 21c 
Neonatal Saline + Keto + mAIH 37.5 ± 0.2 37.4 ± 0.3 38 ± 1abc 39 ± 3abc 41.9 ± 3.5 48.6 ± 3.7  7.37 ± 0.03e 7.32 ± 0.04 62 ± 11c  56 ± 6abc 
Neonatal LPS + Keto + mAIH 37.5 ± 0.2 37.5 ± 0.3 40 ± 2abc 39 ± 4abc  40.9 ± 2.2e 47.8 ± 4.9 7.36 ± 0.04 7.32 ± 0.03 71 ± 14c 66 ± 19c 
Neonatal Saline + sAIH 37.6 ± 0.2 37.4 ± 0.3 29 ± 5abc 29 ± 2abc 43.5 ± 5.9 47.7 ± 2.3 7.35 ± 0.03 7.32 ± 0.06  58 ± 9abc    53 ± 11abc 
Neonatal LPS + sAIH 37.4 ± 0.3 37.5 ± 0.3 30 ± 4abc 31 ± 5abc 46.3 ± 4.2 47.3 ± 5.9 7.34 ± 0.03 7.31 ± 0.03 61 ± 20c    59 ± 20abc 
Neonatal Saline + Keto + sAIH 37.4 ± 0.2 37.5 ± 0.2 30 ± 2abc 32 ± 3abc  42.3 ± 2.2e 48.9 ± 3.7 7.36 ± 0.03 7.29 ± 0.03   34 ± 8abcf    45 ± 29abc 
Neonatal LPS + Keto + sAIH 37.3 ± 0.3 37.6 ± 0.2 31 ± 2abc 32 ± 1abc  42.2 ± 3.2e 52.2 ± 5.8 7.34 ± 0.03 7.28 ± 0.06     37 ± 11abcf    43 ± 21abc 
Time Controls 37.6 ± 0.3 226 ± 40 48.7 ± 4.7 7.35 ± 0.04 107 ± 13 
Time Controls + Keto 37.5 ± 0.2 258 ± 13 45.5 ± 9.3 7.37 ± 0.06e 109 ± 44 
60 minutes           
Neonatal Saline + mAIH 37.5 ± 0.4 37.3 ± 0.1 234 ± 28 259 ± 22 43.4 ± 5.7 48.6 ± 3.7  7.38 ± 0.05e 7.35 ± 0.02 114 ± 9 117 ± 27 
Neonatal LPS + mAIH 37.5 ± 0.3 37.4 ± 0.3 253 ± 19 268 ± 23a  42.9 ± 4.4e 45.2 ± 2.6  7.39 ± 0.04e 7.37 ± 0.01   116 ± 14 121 ± 25 
Neonatal Saline + Keto + mAIH 37.3 ± 0.2 37.3 ± 0.3 262 ± 14 257 ± 32 42.5 ± 4.9 48.7 ± 4.0 7.38 ± 0.01 7.33 ± 0.04   121 ± 13 115 ± 11 
Neonatal LPS + Keto + mAIH 37.6 ± 0.3 37.6 ± 0.3 257 ± 18 276 ± 40a 41.5 ± 2.7 47.8 ± 3.6 7.36 ± 0.02 7.34 ± 0.06   123 ± 11 112 ± 18 
Neonatal Saline + sAIH 37.5 ± 0.3 37.4 ± 0.2 262 ± 36 258 ± 19 43.7 ± 5.5 47.6 ± 2.9 7.37 ± 0.04 7.32 ± 0.03 135 ± 9 115 ± 24 
Neonatal LPS + sAIH 37.7 ± 0.2 37.4 ± 0.2 282 ± 16a 266 ± 18 46.2 ± 4.8 47.7 ± 4.5 7.36 ± 0.02 7.35 ± 0.02   127 ± 14 128 ± 17 
Neonatal Saline + Keto + sAIH 37.7 ± 0.3 37.4 ± 0.3 248 ± 42 262 ± 9 42.3 ± 2.6 50.2 ± 4.2 7.37 ± 0.03  7.32 ± 0.03d   105 ± 10 109 ± 36 
Neonatal LPS + Keto + sAIH 37.5 ± 0.2 37.4 ± 0.3 252 ± 24 245 ± 21 42.2 ± 3 51.2 ± 6.9 7.38 ± 0.02 7.31 ± 0.04   117 ± 14 125 ± 19 
Neonatal Saline + CGS-21680 37.3 ± 0.3 37.6 ± 0.1 270 ± 46 215 ± 48 45.7 ± 4.9 47 ± 3.3 7.34 ± 0.06 7.35 ± 0.04 112 ± 30 126 ± 21 
Neonatal LPS + CGS-21680 37.4 ± 0.4 37.4 ± 0.4 254 ± 26 256 ± 21 46.1 ± 3.2 46.5 ± 3.2 7.37 ± 0.01 7.33 ± 0.04 107 ± 16 101 ± 25 
Time Controls 37.5 ± 0.3 220 ± 25 48.4 ± 3.7 7.36 ± 0.04 102 ± 22 
Time Controls + Keto 37.6 ± 0.2 272 ± 21 44.3 ± 8.7 7.37 ± 0.07 111 ± 48 






 Although neonatal inflammation is common (Stoll et al., 2002, 2004), little is 
known concerning how neonatal inflammation alters ventilatory control. Here, we 
investigated the long-term consequences of neonatal systemic inflammation on adult 
respiratory motor plasticity, a key feature of the neural control of breathing providing 
adaptability to respiratory system challenges (Mitchell and Johnson, 2003). We show for 
the first time that a single inflammatory challenge to neonates completely abolishes AIH-
induced Q-pathway and S-pathway-evoked respiratory motor plasticity in adult males and 
females. Our results indicate a persistent change in adult inflammatory signaling 
contributes to this impairment since adult anti-inflammatory treatment restores Q-
pathway-evoked, but not S-pathway-evoked, pLTF. Further, this is the first evidence of 
impairment of S-pathway-evoked motor plasticity, suggesting neonatal inflammation 
likely leads to a further vulnerable adult as this pathway was thought of as a “backup 
pathway” after acute, adult inflammation (Agosto-Marlin et al., 2017). However, we 
demonstrate S-pathway plasticity can be revealed by intermittent, spinal adenosine 
receptor agonism, suggesting astrocyte dysfunction after neonatal inflammation since 
they are the likely source of adenosine during hypoxia (Angelova et al., 2015; Takahashi 
et al., 2010). These studies are the first steps toward understanding the lasting effects of 
neonatal inflammation on adult neurorespiratory control and suggest neonatal 
inflammation may increase susceptibility to adult ventilatory control disorders.   
LPS-induced neonatal inflammation transiently upregulates cytokines in regions 
involved in respiratory control and plasticity (N. Morrison, S. Johnson, J. Watters, A. 




regions (Bilbo and Schwarz, 2012; Jafri et al., 2013; Schwarz and Bilbo, 2011; Wang et 
al., 2006). Neonatal inflammation also increases male mortality, consistent with clinical 
male mortality after neonatal inflammation (Person et al., 2014) and is relevant to the 
increased risk of sudden infant death syndrome for males (Kinney and Thach, 2009). 
However, similar to other studies (Bilbo et al., 2005; Mouihate et al., 2010; Smith et al., 
2014), we found no measurable adult changes in cytokines, or glial number or 
morphology despite a lasting inflammation-dependent impairment in Q-pathway-evoked 
pLTF. While, we have previously demonstrated adult Q-pathway pLTF is sensitive to 
low levels of acute, systemic inflammation (Hocker and Huxtable, 2018; Huxtable et al., 
2011, 2013, 2015, 2017; Vinit et al., 2011), this is the first study to demonstrate neonatal 
inflammation induces lasting changes in inflammatory signaling to undermine adult Q-
pathway-evoked pLTF. Additionally, S-pathway-evoked pLTF is not restored by even the 
high dose of ketoprofen used here, but is revealed by intermittent adenosine 2A receptor 
agonism on phrenic motor neurons (Seven et al., 2018). While the adenosine 2A receptor 
agonist may affect other cell-types in the cervical spinal cord and complicate our 
findings, adenosine 2A receptors are primarily located on phrenic motor neurons in the 
cervical spinal cord (Seven et al., 2018) and their expression on phrenic motor neurons is 
required for pLTF (Seven et al., 2018). Thus, these results indicate phrenic motor neurons 
are not impaired after neonatal inflammation and the loss of S-pathway-evoked plasticity 
is likely due to impaired adenosine signaling during hypoxia. Furthermore, a likely 
source of adenosine during hypoxia is astrocytes (Angelova et al., 2015; Takahashi et al., 
2010), suggesting neonatal inflammation induces lasting astrocyte-specific changes in the 




mechanisms impairing distinct forms of respiratory motor plasticity is required to 
develop plasticity as a therapeutic tool, such as for spinal cord injury and amyotrophic 
lateral sclerosis (Gonzalez-Rothi et al., 2015; Mitchell, 2008). Additionally, considering 
the cross-talk between Q- and S-pathways (Dale-Nagle et al., 2010; Fields and Mitchell, 
2015; Perim et al., 2018), the response of the respiratory control system likely depends on 
the functional status of both Q- and S-pathways. Thus, future studies are needed to 
understand how inflammation modifies cross-talk between Q- and S-pathways and how 
respiratory motor plasticity can be exploited therapeutically (Gonzalez-Rothi et al., 
2015). 
The timing of neonatal inflammation is likely a significant factor in how neonatal 
inflammation impacts adult physiology. Low-levels of cytokines are important for 
neurodevelopment (Bilbo and Schwarz, 2009), and perturbing the balance of neonatal 
cytokines during development leads to lasting aberrant effects on neural circuits and 
developing cells (Reemst et al., 2016). Furthermore, while many components of the 
respiratory system begin developing in utero (Johnson et al., 2017; Mantilla and Sieck, 
2008; Pagliardini et al., 2003; Prakash et al., 2000), the respiratory control system 
undergoes significant postnatal maturation. In these studies, we induced systemic 
inflammation with LPS at P4, similar to other studies showing long-term consequences of 
neonatal inflammation in other physiological systems (Bilbo, 2010; Fan et al., 2008; 
Kohman et al., 2008; Shanks et al., 2000; Walker et al., 2006), supporting the idea that 
important neural changes occur within the first week of life. Yet, it remains to be 
determined whether there is a precise critical period where neonatal inflammation 




LPS are consistent with other critical developmental windows, including a male-specific 
sensitive period to LPS (Rourke et al., 2016), disproportionate male mortality from 
neonatal inflammation (Person et al., 2014), the increased risk of sudden infant death 
syndrome for males (Kinney and Thach, 2009), and increased incidence of obstructive 
sleep apnea in adults after neonatal inflammation (McNamara and Sullivan, 2000). Thus, 
these data have important implications for understanding the sex-specific impairment 
early in life and into adulthood. Additionally, we and others (Spencer et al., 2006) 
observed a short delay in weight gain after neonatal inflammation, which normalized by 
weaning, suggesting no lasting effects on growth. Future studies are needed to refine our 
understanding of the critical periods during development when early-life inflammation 
induces long-lasting physiological changes to improve our understanding of adult disease 
and better understand important developmental processes.  
While other reports have shown sex differences in neonatal programming of adult 
neuroinflammatory responses (LaPrairie and Murphy, 2007; Rana et al., 2012), we 
observed no sex-differences in the effects of neonatal inflammation on adult plasticity. 
Importantly, this is the first evidence of inflammation abolishing pLTF in females and the 
first to report sAIH-induced respiratory motor plasticity in females. Females exhibited 
greater acute hypoxic phrenic amplitude responses relative to males, consistent with 
previous findings (Bavis et al., 2004; Mortola and Saiki, 1996), despite variability in 
reports of sex differences in hypoxic ventilatory responses (Behan and Kinkead, 2011). In 
contrast to our results following neonatal inflammation, neonatal stress alters adult 
hypoxic responses in a sex-dependent manner, whereby male responses are enhanced and 




respiratory control may be dependent on the type of stressors in early life. Importantly, 
our experiments were performed in adult, ovariectomized females with exogenously 
restored estradiol levels to permit respiratory motor plasticity (Behan et al., 2002; 
Dougherty et al., 2017; Zabka et al., 2003). Therefore, as sex hormones are known to 
modulate respiratory control and hypoxic responses (Behan and Kinkead, 2011; Nelson et 
al., 2011), we cannot rule out a confounding role for exogenous estradiol 
supplementation after ovariectomy. Finally, after neonatal inflammation, we found no 
differences in adult hypoxic responses, suggesting no lasting change in carotid body 
responses due to neonatal inflammation. Accordingly, the deficit in adult respiratory 
motor plasticity after neonatal inflammation is likely a consequence of long-term changes 
in the spinal cord where pLTF occurs (Baker-Herman et al., 2004; Dale et al., 2017; 
Devinney et al., 2015a).  
 While adult anti-inflammatory treatment restored Q-pathway-evoked pLTF, we 
did not observe increases in inflammatory gene expression in adult medullary or cervical 
spinal cord homogenates. Thus, while inflammatory signaling contributes to the 
impairment of adult plasticity, the source of this signaling change remains unclear and 
will be the topic of future studies. Similarly, others demonstrated no changes in baseline 
CNS inflammatory markers after neonatal inflammation, but observed priming of glial 
responses to adult stimuli (Bilbo et al., 2005; Mouihate et al., 2010; Smith et al., 2014), 
suggesting lasting changes in glia have the potential to underlie impairments in adult 
respiratory plasticity. Contrary to other reports (Boisse et al., 2005; Kentner et al., 2010), 
we found spinal COX-2 gene expression was decreased in adulthood, suggesting a 




inflammation-dependent impairment in plasticity. Further, the acute inflammatory 
impairment of adult respiratory plasticity is COX-independent (Huxtable et al., 2017), 
emphasizing a role for other inflammatory molecules mediating the lasting impairment in 
respiratory motor plasticity. Unmeasured inflammatory genes or post-transcriptional 
changes in inflammatory proteins may be responsible for undermining adult pLTF after 
neonatal inflammation. Conversely, other perinatal stimuli involving inflammatory 
signaling, such as maternal care and diet, do have lasting programming effects on adult 
inflammatory cytokine expression (Bilbo and Schwarz, 2009), but are more complex 
stimuli than the acute neonatal inflammation in our study. We also observed no change in 
microglial or astrocyte density and no obvious qualitative changes in morphology in adult 
medullas or spinal cords after neonatal inflammation. Thus, there are no obvious signs of 
inflammation in regions contributing to pLTF despite the restoration of Q-pathway-
evoked pLTF with ketoprofen. Furthermore, the abolition of S-pathway-evoked pLTF is 
likely due to lasting changes in adenosine signaling from astrocytes, suggesting an 
astrocyte-specific change underlies this impairment. Thus, future studies are needed to 
identify inflammatory mechanisms undermining the Q-pathway and further details of the 
inflammation-independent mechanism responsible for undermining S-pathway-evoked 
motor plasticity.  
The adult respiratory control network is vulnerable to early life stressors (Bavis et 
al., 2004; Fournier et al., 2011; Genest et al., 2004), which may undermine the ability to 
compensate during adult ventilatory control disorders. Our study is the first to 
demonstrate lasting consequences of neonatal inflammation on adult respiratory control. 




other studies in which the physiological effects of early life inflammation are not 
revealed until after an adult stimulus (Bilbo, 2010; Bilbo et al., 2005). We found a single 
episode of neonatal systemic inflammation induced lasting impairment of both Q- and S-
pathway-evoked respiratory motor plasticity in adults. Our results demonstrate the adult 
impairment of Q-pathway plasticity is dependent on acute inflammatory signaling; 
however, we observed no lasting increase in adult inflammatory gene expression or the 
density of astrocytes and microglia. The pharmacological induction of S-pathway-evoked 
pLTF demonstrates phrenic motor neurons are capable of plasticity and suggest upstream 
impairment, such as the source of adenosine. While strong evidence supports astrocytes 
as the primary source of adenosine during hypoxia (Angelova et al., 2015; Takahashi et 
al., 2010), we cannot rule out other sources of adenosine. Identifying cell-type specific 
changes underlying lasting physiological impairments will be explored in future studies. 
Future studies will investigate the lasting effects of neonatal inflammation on isolated 
microglia and astrocytes to uncover potential mechanisms of adult impairments after 
neonatal inflammation. 
Together, these results indicate two mechanistic pathways to spinal motor 
plasticity induced by AIH are undermined by neonatal inflammation in rats. Our 
experimental approach assessed phrenic nerve output in anesthetized rats and may not be 
generalizable to respiratory control in freely behaving animals or to other forms of motor 
plasticity. However, AIH induces long-term facilitation of ventilation in humans 
(Mateika and Komnenov, 2017) and strengthens corticospinal pathways to non-
respiratory motor-neurons (Christiansen et al., 2018), suggesting our results likely have 




respiratory motor plasticity does not necessarily alter normal homeostatic control of 
ventilation, the general facilitation of spinal motor output has significant therapeutic 
potential for treating patients with respiratory and non-respiratory motor limitations 
(Hayes et al., 2014; Nichols et al., 2013; Trumbower et al., 2012, 2017) 
In conclusion, this basic science study has major implications for the 
understanding the neonatal origins of adult ventilatory control disorders. These studies 
are the first evidence that one neonatal inflammatory exposure induces long-term 
impairments in adult respiratory control with potential relevance to many respiratory 
disorders. These findings are particularly relevant since inflammation is common in 
neonates (Person et al., 2014), especially those born prematurely who are at higher risk 
for adult disease (Luu et al., 2016). Improving our appreciation of how early life 
inflammation can influence adult respiratory control will have important consequences 
for understanding adult disease and susceptibility to respiratory disorders. Additionally, 
AIH-induced spinal motor plasticity is also a promising therapy to enhance motor 
recovery after spinal injury (Trumbower et al., 2012). However, not all patients respond 
to AIH (Hayes et al., 2014; Trumbower et al., 2017) and our findings suggest neonatal 
inflammatory exposure could contribute to these therapeutic limitations and 
understanding the mechanisms undermining plasticity will increase the therapeutic 
potential of AIH-induced spinal motor plasticity. 
 
Methods 
All experiments were approved by the Institutional Animal Care and Use 




conformed to the policies of the National Institute of Health Guide for the Care and Use 
of Laboratory Animals. Male and female Sprague Dawley rats (Envigo Colony 217 and 
206) were housed under standard conditions (12:12h light/dark cycle) with food and 
water ad libitum. 
Drugs and Materials 
LPS (0111:B4, Sigma Chemical) was dissolved and sonicated in sterile saline for 
neonatal intraperitoneal (i.p.) injections (1 mg/kg). S-(+) Ketoprofen (Keto, Sigma 
Chemical) was dissolved in ethanol (50%) and sterile saline for acute, adult injections 
(12.5 mg/ml/kg, i.p., 3 hr). 17-  estradiol was dissolved in sesame oil (Tex Lab Supply, 
Texas, USA) for acute injections (40 g/mL/kg, i.p.,3 hr) in adult females after 
ovariectomy. 
The adenosine 2A receptor agonist CGS-21680 was dissolved in fresh artificial 
cerebrospinal fluid (aCSF: 120mM NaCl, 3mM KCl, 2mM CaCl2, 2mM MgCl2, 23mM 
NaHCO3, and 10mM glucose) with DMSO (10%) for intrathecal injections. 
Neonatal treatments 
Timed pregnant rats (E14-17 upon arrival) were purchased in pairs from a 
commercial vendor (Envigo) and monitored daily. To control for between litter effects, 
litters were stratified such that each dam fostered similar numbers of male and female 
pups. On postnatal day 4 (P4), all of the stratified pups with one dam were injected with 
LPS (1 mg/kg, i.p.), while pups with the control dam were injected with sterile saline 
(i.p.). The dose of LPS was based on previous studies demonstrating CNS inflammatory 
gene expression in neonates (Rourke et al., 2016), as well as our unpublished data (N. 




CNS inflammation following LPS (1mg/kg). Pups were weighed weekly and weaned at 
P21. Electrophysiology experiments were conducted once males reached 300g. Females 
were ovariectomized at approximately 250g, 7-8 days prior to electrophysiology 
experiments.  
Ovariectomy 
Ovariectomies were performed as previously described (Dougherty et al., 2017) to 
control for the known effects of estrus cycle hormones on pLTF (Behan et al., 2002; 
Dougherty et al., 2017; Zabka et al., 2001). Adult rats were anesthetized with isoflurane 
and maintained on a nose cone (2.5% in O2) during surgery. Depth of anesthesia was 
confirmed by the absence of toe-pinch responses. Bilateral dorsolateral incisions exposed 
ovarian fat pads. Ovaries were ligated and removed, muscle layers were approximated, 
and skin incisions were closed with a single dissolvable suture. A single dose of 
buprenorphine (0.05 g/kg, s.c.) was administered at the end of surgery for pain control 
and rats recovered in individual cages for 7-8 days before electrophysiology studies. 
Since pLTF exists in females only when estradiol is high (Dougherty et al., 2017), 
estradiol levels were restored by injection of 17-  estradiol (40 g/mL/kg, i.p.) three 
hours before electrophysiology experiments. 
Experimental Groups 
All experimental groups consisted of adult male and female rats after a single 
injection of either neonatal LPS or neonatal saline. To investigate the impact of neonatal 
systemic inflammation on adult Q-pathway-evoked respiratory motor plasticity, the 




neonatal LPS + mAIH (n = 12), female neonatal saline + mAIH (n = 7), female neonatal 
LPS + mAIH (n = 6). 
To investigate if acute anti-inflammatory treatment restores Q-pathway-evoked 
respiratory motor plasticity after neonatal inflammation, adults were treated with 
ketoprofen (12.5 mg/kg, i.p.) three hours before electrophysiology experiments: male 
neonatal saline + Keto + mAIH (n = 4), male neonatal LPS + Keto + mAIH (n = 4), 
female neonatal saline + Keto + mAIH (n = 5), female neonatal LPS + Keto + mAIH (n = 
5). 
To investigate the impact of neonatal systemic inflammation on adult S-pathway-
evoked respiratory motor plasticity, we used the following experimental groups: male 
neonatal saline + sAIH (n = 5), male neonatal LPS + sAIH (n = 4), female neonatal saline 
+ sAIH (n = 4), female neonatal LPS + sAIH (n = 4). 
To investigate if acute anti-inflammatory treatment restores S-pathway-evoked 
respiratory motor plasticity after neonatal inflammation, adults were treated with 
ketoprofen (12.5 mg/kg, i.p.) three hours before electrophysiology experiments: female 
neonatal saline + Keto + sAIH (n = 5), male neonatal LPS + Keto + sAIH (n = 5), female 
neonatal saline + Keto + sAIH (n = 5), female neonatal LPS + Keto + sAIH (n = 6). 
To investigate if intermittent, intrathecal CGS-21680 reveals S-pathway-evoked 
respiratory motor plasticity, we used the following experimental groups: male neonatal 
saline + CGS-21680 (n = 4), male neonatal LPS + CGS-21680 (n = 6), female neonatal 
saline + CGS-21680 (n = 4), female neonatal LPS + CGS-21680 (n = 6).  
To reduce use of additional animals, and because time control experiments were 




animals from each experimental condition. The time control group for studies 
investigating the Q-pathway (Fig. 4.2) and S-pathway (Fig. 4.5) consisted of adults after 
neonatal saline (male: n=1; female n=2), neonatal LPS (n = 1 male, 1 female). The time 
control + Keto group (Figs. 3 and 6) consisted of adults after neonatal saline + Keto (n = 
1 male, 1 female) and neonatal LPS + Keto (n = 1 male, 1 female). Vehicle controls for 
intrathecal CGS-21680 experiments (Fig. 4.7) consisted of adults after neonatal saline (n 
= 1 male, 1 female) and neonatal LPS (n = 1 male, 1 female).  
Electrophysiological studies 
Electrophysiological studies have been described in detail previously (Bach and 
Mitchell, 1996; Baker-Herman and Mitchell, 2002; Huxtable et al., 2013). Rats were 
anesthetized with isoflurane, tracheotomized, ventilated (Rat Ventilator, VetEquip®), and 
vagotomized bilaterally. A venous catheter was placed for drug delivery and fluid 
replacement, and a femoral arterial catheter was used to monitor blood pressure and for 
arterial blood sampling. Arterial blood samples were analyzed (PaO2, PaCO2, pH, base 
excess; Siemens RAPIDLAB® 248) during baseline, during the first hypoxic response, 
and 15, 30 and 60 minutes post-AIH. Temperature was measured with a rectal 
temperature probe (Kent Scientific Corporation) and maintained between 37°C and 38°C 
with a custom heated table. Using a dorsal approach, hypoglossal and phrenic nerves 
were cut distally, and de-sheathed. Rats were converted to urethane anesthesia (1.8 g/kg 
i.v.; Sigma-Aldrich), allowed to stabilize for one hour, and paralyzed with pancuronium 
dibromide (1 mg; Selleck Chemicals). 
In rats receiving intrathecal injections, a laminectomy was performed at cervical 




small incision in the dura. The catheter tip extended toward the rostral margin of C4 
(Baker-Herman and Mitchell, 2002). CGS-21680 (100 M) or vehicle (10% DMSO in 
aCSF) was injected around the phrenic motor pool in three boluses (10 µL) separated by 
5 minutes.  
Nerves were bathed in mineral oil and placed on bipolar silver wire electrodes. 
Raw nerve recordings were amplified (10k), filtered (0.1-5 kHz), integrated (50 ms time 
constant), and recorded (10 kHz sampling rate) for offline analysis (PowerLab and 
LabChart 8.0, AD Instruments). Apneic and recruitment CO2 thresholds were determined 
by changing inspired CO2 with continuous end-tidal CO2 monitoring (Kent Scientific 
Corporation). End tidal CO2 was set 2 mmHg above the recruitment threshold, whereby 
arterial blood samples were used to establish baseline PaCO2, which was maintained 
within 1.5 mmHg of the baseline value throughout. Blood volume and base excess were 
maintained (±3 MEq/L) by continuous infusion (1-3 mL/h, i.v.) of hetastarch (0.3%) and 
sodium bicarbonate (0.99%) in lactated ringers. Experiments were excluded if mean 
arterial pressure deviated more than 20 mmHg from baseline.  
All rats (excluding time control rats) received three, 5-minute bouts of either 
mAIH (~10.5% O2, PaO2 35-45 mmHg) or sAIH (~7% O2, PaO2 25-35 mmHg). The 
average amplitude and frequency of 30 consecutive integrated phrenic bursts were taken 
during baseline, the first acute hypoxic response, and 15, 30, and 60 minutes after AIH 
and made relative to baseline amplitude. Phrenic nerve activity data for each 
experimental group were compared using two-way, repeated measures ANOVA with 
Fisher LSD post hoc tests. Sample sizes were selected based on similar, previous studies 




2017, 2018). Physiological variables were compared using two-way, repeated measures 
ANOVA with Tukey’s post hoc test. Mean arterial pressure is reported for baseline, the 
end of the third hypoxic exposure, and 60 minutes after AIH. Acute hypoxic responses 
were compared using an ANOVA with Fisher LSD post hoc test. Values are means ± SD. 
RNA isolation, cDNA synthesis and quantitative PCR experiments 
Neonatal rats (P4) were injected with either vehicle (saline) or LPS (1 mg/kg, i.p.) 
and allowed to mature to ~12 weeks. Adult male and female rats were anesthetized with 
isoflurane and perfused with PBS (transcardiac). Medulla and cervical spinal cords (C3-
C7) were dissected and flash frozen until they were homogenized in Tri-Reagent (Sigma, 
St. Louis, MO, USA). Glycoblue reagent (Invitrogen, Carlsbad, CA, USA) was used to 
isolate total RNA, according to the manufacturer’s protocol. cDNA was reverse 
transcribed from 1 µg of total RNA using MMLV reverse transcriptase together with a 
cocktail of oligo dT and random primers (Promega, Madison, WI, USA), as previously 
described (Crain et al., 2009), and analyzed using qPCR with PowerSYBR green PCR 
master mix on an ABI 7500 Fast system. Inflammatory gene expression was analyzed in 
medulla and spinal cord homogenates using the following primers: 
IL-6: 5’-GTG GCT AAG GAC CAA GAC CA and 5’-GGT TTG CCG AGT AGA CCT 
CA;  IL-1β: 5’-CTG CAG ATG CAA TGG AAA GA and 5’-TTG CTT CCA AGG CAG 
ACT TT;  COX-2: 5’-TGT TCC AAC CCA TGT CAA AA and 5’-CGT AGA ATC 
CAG TCC GGG TA;  TNF-α: 5’-TCC ATG GCC CAG ACC CTC ACA C and 5’-TCC 
GCT TGG TGG TTT GCT ACG;  iNOS: 5’-AGG GAG TGT TGT TCC AGG TG and 
5’-TCT GCA GGA TGT CTT GAA CG;  18s: 5’-CGG GTG CTC TTA GCT GAG TGT 




Wherever possible, primers were designed to span introns (Primer 3 software) and 
were purchased from Integrated DNA Technologies (Coralville, IA, USA). Primer 
efficiency was assessed by use of standard curves, as previously reported (Crain and 
Watters, 2015). Expression of inflammatory genes was made relative to 18s ribosomal 
RNA calculated using the 2-ΔΔCT method (Livak and Schmittgen, 2001). Gene transcripts 
were considered undetectable, and not included in statistical analyses if their CT values 
fell outside of the linear range of the standard curve for that primer set, which in most 
cases was ≥34 cycles.  
Immunohistochemistry methods 
Upon completion of electrophysiology experiments, rats were perfused 
(transcardiac) with cold phosphate buffered saline (PBS, pH 7.4), followed by 4% 
paraformaldehyde (pH 7.4). All brains were removed and immersed in paraformaldehyde 
until sectioning (Leica VT 1200S vibratome). For immunohistochemistry, transverse 
medullary and coronal cervical spinal cord sections (40 µm) were washed (PBS) and 
blocked (PBS, 0.3% Triton, 1% BSA, 2 hours, room temperature) to prevent non-specific 
antibody binding. For medullary sections, two combinations of primary antibodies were 
used (PBS, 0.3% Triton, 0.01% BSA, room temperature, 24 hours): (1) rabbit anti-GFAP 
(1:1000, Millipore AB5804) to label astrocytes and guinea pig anti-NK1R (1:500, 
Millipore AB15810) to label preBötzinger Complex (preBötC) neurons (Gray et al., 
1999), and (2) rabbit anti-IBA1 (1:1000, Wako 019-19741) to label microglia and guinea 
pig anti-NK1R (1:500, Millipore AB15810) to label preBötC neurons. For the spinal 
cord, two different combinations of primary antibodies were used (PBS, 0.3% Triton, 




AB5804) to label astrocytes and goat anti-ChAT (1:300, Millipore AB144p) to label 
motor neurons, (2) rabbit anti-IBA1 (1:1000, Wako 019-19741) to label microglia and 
goat anti-ChAT (1:300, Millipore AB144p) to label motor neurons. After primary 
antibody incubation, sections were rinsed (PBS) and incubated with secondary antibodies 
(PBS, 0.3% triton, 0.01% BSA, room temperature, 3 hours): donkey-anti-rabbit 647 IgG 
(1:1000, Life Technologies A31573) to label GFAP and IBA1 primary antibodies, 
donkey-anti-goat 555 IgG (1:1000, Life Technologies A21432) to label ChAT primary 
antibody and donkey-anti-guinea pig 488 IgG (1:1000, Alexa Fluor 706-545-148) to label 
NK1R primary antibody. Sections were washed and mounted onto charged microscope 
slides, air dried and covered with prolong gold (Life technologies, P36930) to preserve 
the fluorescence. A glass cover slip was placed over the samples and sealed with clear 
nail polish. Slides were stored in the dark at 4°C until imaged. All immunohistochemistry 
experiments contained adult male and female tissues after neonatal saline (medulla: n = 5 
males, 7 females; spinal cord: n = 5 males, 6 females) or neonatal LPS (medulla: n = 6 
males, 4 females; spinal cord: n = 6 males, 3 females). 
Image analysis methods 
All immunofluorescent images (1024 x 1024 pixels, 40x magnification) were 
acquired using a Leica Microsystems CMS GmbH confocal microscope using the LAS X 
acquisition and viewing software (0.5 µm z-stack step increments). All images were 
taken using identical laser and gain settings and identically adjusted for 
contrast/brightness using ImageJ open source software to allow for comparisons across 
all groups. To quantify the density of microglia and astrocytes, maximum intensity 




analyzed. Mean fluorescent intensity for each image within a single batch was made 
relative to the average fluorescent intensities of adults after neonatal saline samples 
within each sex (Paizs et al., 2009). Data are presented as percent change from adults 
after neonatal saline within each sex. 
Statistical Analysis 
GraphPad Prism 7.0 software was used for statistical analyses. Differences in 
mortality between treatments and between sexes was evaluated with Fisher’s exact test. 
Phrenic nerve activity data for each experimental group were compared using two-way, 
repeated measures ANOVA with Fisher LSD post hoc tests. Physiological variables were 
compared using two-way, repeated measures ANOVA with Tukey’s post hoc test. Mean 
arterial pressure is reported from baseline, the end of the third hypoxic exposure, and 60 
minutes after AIH. Acute hypoxic phrenic responses were compared using an ANOVA 
with Fisher LSD post hoc test. Microglial and astrocytic density comparisons were made 
between groups using a one-way ANOVA with multiple-comparisons post hoc tests. For 
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The misuse of opioids has become a national and public health crisis with greater 
than 118 Americans dying from opioid overdose daily in 2016, 27% more deaths than the 
previous year (CDC Wonder). This crisis also carries a significant economic burden, 
estimated to be $78.5 billion/year (Florence et al., 2016). Significant efforts are underway 
to curb the misuse of opioids in adults, yet one understudied population in these efforts is 
pregnant women. Opioid use during pregnancy is on the rise (Epstein et al., 2013; Krans 
et al., 2015; Stover and Davis, 2015) and a significant need exists to improve treatments 
for neonates after maternal opioid use (Kraft et al., 2016). Maternal opioid use leads to 
neonatal abstinence syndrome (NAS), described as dysfunction in the central and 
autonomic nervous system, and gastrointestinal system in infants (McQueen and 




including; irritability, sleep disturbances, death, and respiratory disturbances (McQueen 
and Murphy-Oikonen, 2016). The respiratory disturbances are not well characterized, but 
increased apneas have been described (McQueen and Murphy-Oikonen, 2016; Ward et 
al., 1986). Yet, despite this increasing population of NAS infants, little is known about 
the effects of maternal opioids on developing neonatal respiratory control circuitry. 
At birth, neonates must have a functional respiratory system capable of robust, 
rhythmic breathing. Therefore, rhythmic neural activity, initiating at the preBötzinger 
complex (preBötC, the kernel for respiratory rhythmogenesis) (Smith et al., 1991) is 
required for development of neural circuitry, respiratory muscles, and the lungs (Greer, 
2012; Pagliardini et al., 2003). In rats, development of rhythmogenic respiratory neural 
networks begins around embryonic day 17 (E17) and continues until birth (Pagliardini et 
al., 2003). The preBötC is exceptionally sensitive to opioids and is responsible for many 
of the respiratory depressant effects of opioids (Montandon et al., 2011, 2016; Stucke et 
al., 2015). Since maternal opioids cross the placenta and delay neurodevelopment 
(Hauser and Knapp, 2018; Kopecky et al., 1999), they have the potential to suppress 
rhythmic respiratory activity from the preBötC, and thus, respiratory control networks 
need to compensate to maintain adequate respiratory function at birth (Gourévitch et al., 
2017). Interestingly, the parafacial respiratory group (pFRG) also has rhythmogenic 
properties during embryonic and early neonatal life (Onimaru and Homma, 2003; Thoby-
Brisson and Ramirez, 2001) and may be able to mitigate respiratory instability during 
early life (Feldman and Del Negro, 2006). However, controlled studies on neonatal 
breathing after maternal opioids are extremely limited. One study demonstrated 




rats (Gourévitch et al., 2017). Another study in guinea pigs shows enhanced hypercapnic 
ventilatory responses after prenatal opioids (Nettleton et al., 2008), suggesting changes in 
chemosensitivity after maternal opioids. To our knowledge, the present study is the first 
investigating changes in neonatal breathing after maternal opioid use in rats. For this 
study, we tested the effects of maternal methadone to model aspects of maternal opioid 
use since methadone is a standard of care treatment for maternal opioid dependence 
(Bhavsar et al., 2018). Additionally, NAS infants are typically treated acutely with 
opioids, such as methadone, to alleviate NAS symptoms (Davis et al., 2018; Kraft et al., 
2016; Pryor et al., 2017). However, opioids dangerously depress breathing in neonates 
and may cause lasting deficits in neurodevelopment (Attarian et al., 2014). Therefore, we 
hypothesized that repetitive, daily acute methadone would further destabilize breathing 
after maternal methadone. 
Understanding the acute effects of maternal opioid use is critical to developing 
more effective treatments for neonates exposed to perinatal opioids. We hypothesize that 
perinatal methadone exposure during development of the respiratory control system will 
destabilize neonatal breathing, blunt hypoxic ventilatory responses, and enhance 
hypercapnic ventilatory responses. Understanding how maternal opioid use alters the 
respiratory response to acute opioids will contribute to our understanding of how to 
alleviate the symptoms of NAS without severe respiratory dysfunction.  
 
Methods 
All experiments conformed to the policies of the National Institute of Health 
Guide for the Care and Use of Laboratory Animals and were approved by the 




pregnant Sprague Dawley Rats (Envigo Colony 217) were ordered to arrive at embryonic 
day 17 (E17) and were housed under standard conditions with a 12:12h light/dark cycle 
with food and water ad libitum.  
Maternal opioid exposure 
Since respiratory rhythm generation and fetal breathing movements begin on day 
E17 in fetal rats (Greer, 2012; Pagliardini et al., 2003), maternal methadone exposure 
began on E17 to mitigate other developmental effects of methadone and focus on the 
effects of opioids on developing respiratory circuitry. Each morning from E17 onward, 
dams were injected with methadone (5 mg/kg, Sigma-Aldrich, subcutaneous) and 
monitored for at least one hour. After parturition, daily maternal methadone injections 
continued until postnatal day 5 (P5) (Fig. 5.1). Control dams were injected daily with 
vehicle (saline, subcutaneous) or were un-treated to control for the potential stress of 
daily injections. Breathing in neonates (P0-5) born to maternal methadone (MM), 
maternal saline (MS), and maternal no-treatment (MN) were studied using 
plethysmography.  
In the first study, neonatal baseline ventilation, hypoxic, and hypercapnic 
ventilatory responses were assessed from P0-5 (Fig. 5.1). Since no differences were 
found between sexes (p > 0.05), male and female rats were combined for maternal 
methadone (MM: P0 = 8 female, 8 male, P1 = 8 female, 4 male, P2 = 9 female, 4 male, 
P3 = 7 female, 4 male, P4 = 7 female, 2 male, P5 = 7 female, 2 male), maternal saline 
(MS: P0 = 8 female, 5 male, P1 = 8 female, 7 male, P2 = 8 female, 7 male, P3 = 5 female, 




P0 = 10 female, 12 male, P1 = 7 female, 11 male, P2 = 4 female, 6 male, P3 = 7 female, 9 
male, P4 = 6 female, 8 male, P5 = 7 female, 7 male).  
In a separate group of neonates in the second study, the combined effects of 
maternal treatment with daily acute methadone (1mg/kg, i.p.) from P0-5 were assessed 
(Fig. 5.1). Injections began at P0 and were repeated each day in the same rats until P5. 
Thus, each neonate received a total of 6 acute, methadone injections by the time they 
reached P5. For each neonate, baseline breathing was measured for 10 minutes before 
acute methadone injection. The ventilatory response to acute methadone was monitored 
for one hour, followed by hypercapnic and hypoxic ventilatory responses. Since no 
differences were found between sexes, male and female rats exposed to daily acute 
methadone were combined from each maternal treatment (MM: P0 = 7 female, 7 male, 
P1 = 6 female, 8 male, P2 = 8 female, 5 male, P3 = 8 female, 7 male, P4 = 8 female, 7 
male, P5 = 7 female, 7 male; MS: P0 = 3 female, 6 male, P1 = 3 female, 6 male, P2 = 2 
female, 7 male, P3 = 2 female, 7 male, P4 = 3 female, 6 male, P5 = 5 female, 4 male; 
MN: P0 = 3 female, 4 male, P1 = 2 female, 4 male, P2 = 2 female, 4 male, P3 = 2 female, 
4 male, P4 = 2 female, 4 male, P5 = 2 female, 2 male).   
 
Neonatal whole-body plethysmography 
Ventilation was measured in awake, freely behaving neonates from P0-5 using 
custom built whole-body plethysmography. Neonatal rats were individually placed in an 
acrylic chamber (75 ml volume). Three mass flow controllers (Alicat Scientific) control 
the concentration of oxygen, nitrogen, and carbon dioxide at a total flow rate of 100 






Figure 5.1. Schematic of experimental paradigm for perinatal opioids. Pregnant dams 
were treated from E17-P5 with daily methadone injections (5mg/kg, s.c.). Control dams 
were untreated or injected with vehicle (saline). In study 1, baseline breathing, 
hypercapnic, and hypoxic ventilatory responses in neonates (P0-5) from each maternal 
treatment group were assessed by whole-body plethysmography. In study 2, neonates from 
each maternal treatment group were given daily acute methadone (1 mg/kg i.p.) from P0-
5. Baseline breathing, ventilatory responses to acute methadone, and hypoxic and 
hypercapnic ventilatory responses were assessed at P0-5 by whole-body plethysmography.  
 
 
thermoneutral (Eden and Hanson, 1987; Mortola and Dotta, 1992) by adjusting chamber 
temperature between 32-34°C with a heating pad (Kent Scientific). A differential 
pressure transducer (ADInstruments®) attached to the chamber via a dedicated port 
recorded pressure changes due to ventilation relative to pressure in an identical reference 
chamber. Data were recorded using LabChart software (PowerLab System, 
ADInstruments®/ LabChart). 
Hypoxic and Hypercapnic ventilatory responses 
Hypercapnic ventilatory responses (HCVR) and hypoxic ventilatory responses 




balance N2), inflow gas switched to 5% CO2 (10 minutes) to assess hypercapnic 
ventilatory responses. The HCVR response was assessed during the last two minutes of 
the hypercapnic stimulus and made relative to baseline VE taken during the preceding 5 
minutes before hypercapnic exposure. After hypercapnia, chambers were returned to 
normocapnia (21% O2, balance N2, 20 min) for neonates to recover (20 minutes). To 
evaluate hypoxic ventilatory responses, inflow gas was switched to 10% oxygen (10 
min). Peak, phase I, HVR was calculated as the maximum rolling average of 50 breaths 
during the hypoxic stimulus and made relative to baseline VE in the 5 minutes 
immediately preceding hypoxia. Phase II, hypoxic ventilatory decline was assessed as the 
average VE in the last two minutes of the hypoxic exposure and made relative to baseline 
VE in the 5 minutes immediately preceding hypoxia. 
 
Methadone-induced respiratory depression and quantal slowing 
Respiratory responses to acute neonatal methadone were measured daily in 
neonates from P0-P5 after MM, MS, and MN. Neonates were placed in the recording 
chamber for 10 minutes of baseline recordings. Neonates were removed from the 
chamber, injected with methadone (1 mg/kg, i.p.) and immediately returned the chamber 
for continuous recording (1 hour).  HCVRs and HVRs were measured one hour after 
acute methadone injections, as described above.  
 Quantal slowing is the reduction of breathing frequency by integer multiples of 
the basal breathing period in response to acute opioids (Mellen et al., 2003). To assess 




periods were used to identify the presence of breaths clustered at integers of breathing 
period.  
Data Analysis 
For all experiments, inspiratory frequency and VT were analyzed using peak 
analysis in LabChart (v8, AD Instruments®). Two respiratory variables, tidal volume (VT) 
and frequency (breaths/minute) are estimated from the amplitude and the frequency of the 
pressure recordings. Minute ventilation (VE) is calculated as the product of frequency and 
VT. VT and VE were normalized to body weight. Our custom-built plethysmograph is 
primarily effective for studying respiratory frequency and is not designed for absolute 
quantification of VT. Therefore, VT and VE are reported as changes relative to baseline. 
Apneas were identified as respiratory pauses lasting longer than 2.5 breaths. Post-
sigh apneas were defined as an augmented breath with at least twice the mean VT, 
followed by an apnea (Marcouiller et al., 2014). To assess respiratory rhythm variability, 
short-term (SD1) and long-term (SD2) variability were calculated from breath-to-breath 
intervals during baseline.  
Poincaré plots were constructed from a subset of breathing periods taken 25-40 
minutes after neonatal exposure to acute methadone. Normalized periods (n) and 
subsequent periods (n +1) were plotted. A blinded investigator visually coded each plot 
based on clustering of breaths at integer multiples of the normal breathing period, a 
feature consistent with quantal slowing. 
 Statistical comparisons and visualization for all data were performed using R and 




ANOVA with Bonferroni correction for multiple comparisons (α = 0.05). Values are 




Sex had no effect on any respiratory variables (p > 0.05); thus, male and female 
rats were combined for all analyses. Neonatal body weights were similar from P0-P5, 
regardless of maternal treatment. One exception was a significant reduction in MS P2 
weights compared to MM (p = 0.001, Table 5.1). 
Table 5.1. Maternal methadone does not alter neonatal weight. 
  P0 P1 P2 P3 P4 P5 
n MM  16 11  22  16  13 11 
 MS  13  9 10  14  15 11 
 MN 12  9 18  14  15 10 
Weight MM 5.3 ± 0.6  6.2 ± 0.5  7.0 ± 0.6 8.7 ± 0.6  10.1 ± 0.6  11.2 ± 1.0  
(g) MS 5.3 ± 0.6  5.9 ± 0.5 6.6 ± 0.6  7.7 ± 0.7  9.4 ± 0.5  10.7 ± 1.0  
 MN 5.5 ± 0.5  6.0 ± 0.7  8.0 ± 0.5  8.1 ± 0.9  9.1 ± 1.3  10.3 ± 1.3  
 
Mean ± SD; ANOVA-RM, Bonferroni post-hoc, # MN p<0.05 from MS. 
 
Maternal methadone destabilizes P0 respiratory rhythm. 
At P0, apneas were significantly more frequent after MM (p < 0.001 compared to 
MS and MN, Fig.5. 2A and B), indicating less stable breathing after MM. Apnea duration 
was greater in P0 neonates after MM and MS compared to MN (p = 0.002 and p = 0.008 
respectively, Fig. 5.2B). Additionally, post-sigh apneas were more frequent in P0 
neonates after MM compared to MS (p = 0.012) and MN (p < 0.001, Fig. 5.2B).  At P0, 
MM treated neonates had more sighs (5.1  2.5 min-1) compared to MN (1.1  0.6 min-1, 
p < 0.001), but the number of sighs was not significantly different from MS (1.9  1.4 
min-1, p = 0.086). The fraction of sighs followed by an apnea was not significantly 





Figure 5.2. Maternal methadone increases apneas at P0. Representative baseline 
plethysmography traces (A) show frequent apneas (↓) and post-sigh apneas (*↓) after 
maternal methadone (MM, dark bars). Group data (B) demonstrate MM increases the 
frequency (B, top) and duration of apneas (B, middle) at P0 compared to neonates after 
maternal saline (MS, grey bars) and maternal no-treatment (MN, light bars). MM also 
increased the frequency of post-sigh apneas compared to MS and MN neonates at P0 (B, 
bottom). By P1, the frequency and duration of apneas was not different between 
treatment groups. ANOVA-RM, Bonferroni post-hoc, * MM p<0.05 from MN, † MM 




Regardless of maternal treatment, overall baseline breathing was similar between 
groups, except at P0 (Table 2). At P5, breathing frequency after MM was increased 
relative to MN neonates (p = 0.005), but not MS (Table 2). MM increased VT at P0 
compared to MS (p < 0.001) and MN (p = 0.001), but VT was normalized by P1 (Table 
2). VE also increased at P0 after MM compared to MS (p = 0.017), but not MN (p = 
0.162, Table 5.2). 
Corresponding to the relative instability at P0 after MM, frequency CV was 
increased at P0 after MM compared to MN (p < 0.001, Table 5.2). Additionally, SD1 and 
SD2 were elevated in MM and MS at P0 compared to MN (p < 0.001, Table 5.2), 
suggesting both MM and MS cause greater variability in early neonatal breathing pattern.  
Maternal Methadone mitigates the hypoxic ventilatory decline at P0, but does not alter 
peak HVR or HCVR. 
To assess if MM altered chemosensitivity, the relative ventilatory response to 
hypoxia (10% O2) was analyzed. Phase I, peak ventilatory responses were not different 
within any age group (Fig. 5.3). However, the phase II hypoxic ventilatory decline was 
blunted at P0 in MM compared to MS (p = 0.036) and MN (p = 0.027, Fig. 5.3A and B). 
After P0, no differences in phase I or phase II HVRs were evident.  
The ventilatory response to 5% CO2 was not different between maternal treatment 








Table 5.2. Maternal methadone disrupts baseline breathing at P0.  
  P0 P1 P2 P3 P4 P5 
n 
MM  16 11  22  16  13 11 
 
MS  13  9 10  14  15 11 
 
MN 12  9 18  14  15 10 
Frequency MM 120.3 ± 27.3 155.6 ± 14.9 168.8 ± 30.1 165.4 ± 18.7 173.2 ± 29 202.2 ± 24.8* 
(breaths/min) MS 96.5 ± 17.1 138.0 ± 14.6 163.6 ± 19.4 155.6 ± 17 174.2 ± 22.4 183.5 ± 16.2 
 MN 104.7 ± 18.7 141.6 ± 14.2 150.9 ± 11.4 157.6 ± 14.9 178.6 ± 12.6 166.1 ± 25.7 
        
VT MM 0.81 ± 0.16*† 0.82 ± 0.19 0.67 ± 0.16 0.67 ± 0.16 0.79 ± 0.16 0.83 ± 0.20 
(ml/100g) MS 0.50 ± 0.10 0.76 ± 0.16 0.72 ± 0.18 0.66 ± 0.04 0.59 ± 0.10 0.64 ± 0.13 
 
MN 0.57 ± 0.15 0.73 ± 0.10 0.60 ± 0.07 0.66 ± 0.15 0.78 ± 0.22 0.75 ± 0.22 
        
VE MM 97.4 ± 28.1† 129.0 ± 30.3 117.3 ± 44.1 115.1 ± 35.1 141.7 ± 40.6 177.7 ± 67.8 
(ml/min/100g) MS 48.6 ± 14.8 104.4 ± 23.1 118.3 ± 35.4 104.7 ± 15.7 103.4 ± 25.9 123.0 ± 33.1 
 
MN 61.2 ± 24.2 102.6 ± 16.7 92.1 ± 14.6 104.1 ± 28.4 138.5 ± 40.8 126.3 ± 52.6 
        
Frequency  MM 0.92 ± 0.23* 0.64 ± 0.23 0.29 ± 0.11 0.35 ± 0.19 0.43 ± 0.42 0.29 ± 0.07 
CV MS 0.73 ± 0.20 0.42 ± 0.07 0.40 ± 0.17 0.35 ± 0.14 0.32 ± 0.1 0.29 ± 0.10 
 MN 0.55 ± 0.13 0.42 ± 0.16 0.37 ± 0.11 0.29 ± 0.1 0.27 ± 0.13 0.24 ± 0.07 
        
SD1 MM 0.48 ± 0.15* 0.21 ± 0.05 0.13 ± 0.03 0.14 ± 0.05 0.18 ± 0.14 0.10 ± 0.01 
 MS 0.50 ± 0.15
# 0.18 ± 0.03 0.16 ± 0.08 0.15 ± 0.03 0.13 ± 0.03 0.12 ± 0.02 
 MN 0.34 ± 0.12 0.18 ± 0.04 0.15 ± 0.02 0.13 ± 0.02 0.12 ± 0.02 0.13 ± 0.02 
        
SD2 MM 0.57 ± 0.19* 0.22 ± 0.08 0.11 ± 0.06 0.14 ± 0.10 0.19 ± 0.23 0.11 ± 0.03 
 MS 0.54 ± 0.21
# 0.16 ± 0.04 0.14 ± 0.09 0.13 ± 0.06 0.12 ± 0.05 0.11 ± 0.05 
 MN 0.34 ± 0.14 0.16 ± 0.06 0.14 ± 0.05 0.11 ± 0.04 0.11 ± 0.05 0.11 ± 0.04 
        
Ti MM 0.26 ± 0.08 0.14 ± 0.03 0.10 ± 0.02 0.1 ± 0.03 0.11 ± 0.06 0.08 ± 0.01 
(sec) MS 0.29 ± 0.06 0.13 ± 0.03 0.12 ± 0.04 0.1 ± 0.01 0.09 ± 0.01 0.09 ± 0.01 
 MN 0.24 ± 0.08 0.14 ± 0.03 0.11 ± 0.01 0.1 ± 0.02 0.09 ± 0.01 0.09 ± 0.01 
        
Te MM 0.53 ± 0.12 0.33 ± 0.03 0.30 ± 0.06 0.3 ± 0.06 0.31 ± 0.09 0.24 ± 0.04 
(sec) MS 0.57 ± 0.10# 0.35 ± 0.04 0.30 ± 0.05 0.32 ± 0.05 0.29 ± 0.05 0.27 ± 0.03 
 MN 0.47 ± 0.09 0.34 ± 0.03 0.33 ± 0.04 0.31 ± 0.04 0.27 ± 0.02 0.31 ± 0.05 
 
ANOVA-RM, Bonferroni post-hoc, * MM p<0.05 from MN, † MM p<0.05 from MS, # 









Figure 5.3. Maternal methadone blunts the phase II hypoxic ventilatory depression 
at P0. Average VE at P1 for maternal methadone (MM, dark circles, A, and bars, B), 
maternal saline (MS, grey boxes, A, and bars, B), and, maternal no-treatment (MN, light 
triangles, A, and bars, B) neonates. Phase I, peak hypoxic ventilatory responses (B, top) 
were unaffected by maternal treatment group or age. However, the phase II hypoxic 
ventilatory decline (B, bottom) was blunted at P0 after MM compared to MN and MS rats, 
suggesting impaired central hypoxic responses. ANOVA-RM, Bonferroni post-hoc, * MM 






Figure 5.4. Maternal methadone does not alter hypercapnic ventilatory responses 
(HCVR). Average VE for maternal methadone (MM, dark circles, A, and bars, B), maternal 
saline (MS, grey squares, A, and bars, B), and, maternal no-treatment (MN, light triangles, 
A, and bars, B) neonates demonstrates normal hypercapnic responses after MM (A). No 
differences in HCVRs after MM, MN, and MS neonates were evident at any age (B). 
ANOVA-RM, Bonferroni post-hoc, * MM p<0.05 from MN, † MM p<0.05 from MS, # 






Daily acute methadone blunts weight gain. 
In a separate group of rats from each maternal treatment group, neonates received 
daily injections of methadone (1 mg/kg, i.p.) starting at P0. After receiving four (P3) or 
five (P4) treatments with daily acute methadone, weight was blunted at P3 MM (p = 
0.049) and P4 MM (p = 0.001) neonates compared to MS (Table 5.3). However, no 
differences between MM and MS neonates or MS and MN neonates were evident at any 
ages. 
 
Table 5.3. Daily acute methadone reduces weight gain in P3 and P4 neonates after 
maternal methadone. 
 
  P0 P1 P2 P3 P4 P5 
n MM 14 14 13 15 15 14 
 MS 10 9 9 9 9 9 
 MN 8 6 6 6 6 4 
Weight MM 5.2 ± 0.7 5.6 ± 0.6 6.7 ± 0.7 7.3 ± 0.9 8.6 ± 1 10 ± 1.2 
(g) MS 5.6 ± 0.4 6.3 ± 0.4 7.2 ± 0.6 8.6 ± 0.6 10.3 ± 0.9 11.4 ± 1.5 
 MN 5.9 ± 0.9 6.4 ± 1.1 7.6 ± 0.6 8.6 ± 0.9 9.9 ± 0.7 11.8 ± 0.8 
 
Mean ± SD (n); ANOVA-RM, Bonferroni post-hoc, † MM p<0.05 from MS. 
Daily acute methadone does not alter neonatal breathing after maternal methadone 
exposure. 
 Daily acute methadone had no effect on baseline breathing in neonates regardless 
of maternal treatment (Table 4). Daily acute methadone had no significant effect on the 
frequency of apneas (p = 0.395), average apnea duration (p = 0.057), or frequency of 
post-sigh apneas (p = 0.430) between maternal treatment groups, which, contrary to our 
hypothesis, demonstrates daily acute methadone did not further destabilize neonatal 
breathing. Baseline frequency (p = 0.163), VT (p = 0.0737), VE (p = 0.060), or SD1 (p = 
0.379) were not different between maternal treatment groups after daily acute methadone, 




main effect of maternal treatment on SD2 (p < 0.001); however, no significant pairwise 
differences occurred. Ti and Te were also unaltered by daily acute methadone and 
maternal treatment group (p = 0.604 and 0.052 respectively, Table 5.4). 
 
Maternal methadone desensitizes P0-1 neonates from acute methadone-induced 
frequency depression. 
Next, we tested the hypothesis that MM desensitizes neonates to acute methadone-
induced respiratory depression. After daily acute methadone (1 mg/kg, i.p.), breathing 
frequency and VE were reduced at 20-60 minutes after all maternal treatments at all time 
points after acute methadone (p < 0.05, Fig. 5.5B). For neonates after MS or MN, acute 
methadone-induced respiratory frequency depression was not different across ages. 
However, after MM, methadone-induced respiratory depression was blunted in P0 
neonates compared to P3 and 4 (p<0.01) and blunted in P1 compared to P2-5 neonates (p 
< 0.01). Between groups, methadone-induced respiratory frequency depression was  
blunted at P0 and P1 in MM compared to MS and MN (Fig. 5.5A and B). MN neonates 
had a greater frequency depression in response to acute methadone at P2 compared to MS 
at 40 minutes (p = 0.028), and MM at 20 minutes (p = 0.025) and 60 minutes (p = 0.009). 
By P3, methadone-induced respiratory frequency depression was similar for all groups 
(Fig. 5.5B). A compensatory increase in VT occurred at P0 and P1 in MN and MS 
neonates relative to MM at 40 and 60 minutes (Fig. 5.5A and B). Despite differences in 
methadone-induced frequency depression, methadone-induced depressions in VE were 
similar for all maternal treatments (Fig. 5.5B) due to the compensatory increase in VT in 




reduced in MN neonates compared to MS neonates (p = 0.043), but not different from 
MM treated neonates.  
 
Table 5.4. Daily acute methadone does not change baseline breathing. 
 
  P1 P2 P3 P4 P5 
n MM 14 13 15 15 14 
 MS 9 9 9 9 9 
 MN 6 6 6 6 4 
Apneas/min MM 3.2 ± 2.0 0.7 ± 0.5   1.5 ± 2.7† 1.0 ± 0.8 0.5 ± 0.6 
 MS 2.9 ± 2.2 5.0 ± 8.2 1.0 ± 0.7 0.4 ± 0.3 1.1 ± 1.6 
 MN 4.4 ± 3.6 1.7 ± 2.5 0.8 ± 0.7 0.9 ± 1.3 0.6 ± 0.3 
        
Apnea MM 2.0 ± 0.4 1.3 ± 0.2 1.3 ± 0.4 1.1 ± 0.2 1.0 ± 0.4 
duration MS 2.3 ± 1.0 1.8 ± 0.6 1.4 ± 0.3 1.2 ± 0.3 1.2 ± 0.6 
(sec) MN 1.7 ± 0.5 1.5 ± 0.3 1.4 ± 0.5 1.3 ± 0.3 1.5 ± 0.6 
        
Post-sigh  MM 0.5 ± 0.6 0.1 ± 0.1 0.1 ± 0.2 0.1 ± 0.2 0.1 ± 0.2 
Apneas/min MS 0.3 ± 0.3 0.9 ± 2.00 0.2 ± 0.1 0.0 ± 0.0 0.3 ± 0.5 
 MN 0.6 ± 0.7 0.3 ± 0.6 0.0 ± 0.1 0.1 ± 0.1 0.0 ± 0.1 
        
Frequency MM 149.5 ± 23.4 176.9 ± 19.2 172.2 ± 20.8 192.0 ± 18.8 204.0 ± 40.0 
(Breaths/min) MS 141.4 ± 22.9 147.8 ± 24.1 166.5 ± 26.4 181.3 ± 24.5 210.8 ± 30.3 
 MN 156.7 ± 19.0 159.7 ± 13.0 168.3 ± 37.1 184.6 ± 22.4 203.6 ± 5.7 
        
VT MM 0.82 ± 0.13 0.81 ± 0.18 0.70 ± 0.15 0.85 ± 0.19 0.79 ± 0.19 
(ml/100g) MS 0.67 ± 0.10 0.76 ± 0.19 0.70 ± 0.09 0.70 ± 0.13 0.81 ± 0.13 
 MN 0.94 ± 0.18 0.67 ± 0.10 0.75 ± 0.15 0.67 ± 0.23 0.60 ± 0.09 
        
VE MM 121.5 ± 29.3 144.9 ± 42.5 124.4 ± 30.7 166.9 ± 42.5 159.6 ± 36.6 
(ml/min/100g) MS   98.1 ± 24.9 112.7 ± 41.0 118.6 ± 26.4 130.3 ± 30.7 175.7 ± 43.9 
 MN 149.3 ± 42.5 109.8 ± 22.0 130.3 ± 49.8 131.8 ± 61.5 124.4 ± 22.0 
        
SD1 MM 0.25 ± 0.08 0.12 ± 0.02 0.13 ± 0.03 0.12 ± 0.02 0.12 ± 0.05 
 MS 0.23 ± 0.10 0.20 ± 0.11 0.14 ± 0.03 0.11 ± 0.02 0.11 ± 0.04 
 MN 0.21 ± 0.09 0.15 ± 0.04 0.14 ± 0.04 0.14 ± 0.02 0.11 ± 0.01 
        
SD2 MM 0.33 ± 0.11 0.51 ± 0.29 0.7 ± 0.32 0.65 ± 0.35 0.57 ± 0.25 
 MS 0.83 ± 0.27 0.78 ± 0.44 0.65 ± 0.37 0.47 ± 0.19 0.86 ± 0.69 
 MN 0.86 ± 0.56 1.21 ± 0.48 1.13 ± 0.94 1.1 ± 0.54 0.72 ± 0.34 
        
Ti MM 0.15 ± 0.04 0.09 ± 0.01 0.1 ± 0.04 0.08 ± 0.01 0.09 ± 0.03 
(sec) MS 0.15 ± 0.04 0.13 ± 0.08 0.09 ± 0.01 0.08 ± 0.01 0.09 ± 0.03 
 MN 0.14 ± 0.04 0.11 ± 0.01 0.1 ± 0.02 0.08 ± 0.01 0.08 ± 0.01 
        
Te MM 0.36 ± 0.05 0.28 ± 0.04 0.29 ± 0.04 0.26 ± 0.03 0.25 ± 0.07 
(sec) MS 0.38 ± 0.08 0.37 ± 0.08 0.32 ± 0.07 0.28 ± 0.04 0.23 ± 0.04 
 MN 0.33 ± 0.06 0.31 ± 0.04 0.31 ± 0.08 0.30 ± 0.05 0.25 ± 0.01 
 








Figure 5.5. Maternal methadone blunts opioid-induced respiratory frequency 
depression at P0 and P1. Representative plethysmography traces (A) before (baseline) 
and 60 minutes after acute methadone at P0. Group data (B) for average breathing 
frequency, VT and VE after maternal methadone (MM, dark circles), maternal no-
treatment (MN, grey squares), and maternal saline (MS, light triangles) combined with 
daily acute methadone (1mg/kg, i.p.). Relative breathing frequency and VE were 
significantly reduced from 20-60 minutes after methadone injections in all groups (B, 
top). At P0 and P1, methadone-induced frequency depression and VT were blunted after 
MM compared to MN and MS (B). ANOVA-RM, Bonferroni post-hoc, * MM p<0.05 




Quantal slowing emerges at P2, regardless of maternal treatment.  
Quantal slowing is the slowing of respiratory frequency by integer multiples of 
the normal breathing period (Janczewski and Feldman, 2006; Mellen et al., 2003). 
Quantal slowing after acute methadone was observed in Poincare plots during the 15 
minutes of peak respiratory frequency depression (25-40 minutes post methadone 
injection, Fig. 5.6A and C). Poincare plots (Fig. 5.6B and D) demonstrated either 
distributed slowing of respiratory period in younger neonates (P0 methadone response, 
Fig. 5.6A and B) or quantal slowing in older neonates, evident as distinct groupings of 
breaths at integer multiples of the normalized period (P5 methadone response, Fig 5.6C 
and D). Regardless of maternal treatment, quantal slowing emerged at P2 (Fig. 5.6E). The 
percentage of animals exhibiting quantal slowing from MM, MS, and MN groups 
highlights the age-dependency of the emergence of quantal slowing (Fig. 5.6E).  
 
Discussion 
As the use of opioids during pregnancy increases, improving our understanding of 
how the neurorespiratory system develops in the presence of opioids is a critical step in 
understanding how to best treat infants with NAS. Here, we show maternal methadone 
destabilizes early neonatal respiratory rhythm by increasing apneas and desensitizes 
neonates to acute methadone-induced frequency depression. The respiratory rhythm 
instability was most severe in the first day of life after maternal methadone and 
normalized within the first two days. Contrary to our hypothesis, repeated daily acute 







Figure 5.6. During neurorespiratory development, quantal slowing emerges at P2, 
regardless of maternal treatment. Representative changes in breathing period at P0 (A 
and B) and P5 (C and D) after acute methadone (1 mg/kg, i.p.; ↑) demonstrate age-
dependent methadone-induced frequency depression. Grey highlighted regions (A and C) 
after methadone injection shown as Poincare plots (B and D respectively) to visualize 
quantal slowing. Quantal slowing is evident as periods clustered at quantal integers of the 
normal respiratory period at P5, but not P0. Group data highlight that regardless of 




baseline breathing. However, maternal methadone desensitized neonates to acute 
methadone-induced respiratory depression at P0-1. Interestingly, the desensitization was 
normalized rapidly between P1 and P2, the same age at which quantal slowing emerged. 
These data suggest a significant reorganization of respiratory rhythm generating circuits 
regardless of maternal treatment at P1-2. Overall, maternal methadone destabilizes the 
neurorespiratory control system early after birth; however, breathing is rapidly 




gestational exposure to methadone, there is an initial window of increased vulnerability 
to apneas, highlighting a particular window where treatment may be necessary.  
Maternal methadone increased the prevalence of apneas and post-sigh apneas, and 
destabilized breathing rhythm in neonates. Though the origin of apneas cannot be 
identified in this study, the prevalence of apneas suggests dysfunction of the respiratory 
control network after maternal methadone. This dysfunction could be a result of 
concentrated neonatal methadone since opioids are known to be higher in fetal tissues 
compared to maternal levels (Peters et al., 1972) and opioids inhibit rhythm generating 
regions (Montandon et al., 2011). Neonatal CNS methadone levels can even exceed 
maternal levels as methadone accumulates in fetuses (Hl and Vin Peters, 1975; Peters et 
al., 1972), likely due to blunted opioid metabolism in neonates. Furthermore, maternal 
opioids continue to be transmitted to neonates through breast milk (Hendrickson and 
McKeown, 2012) and some evidence suggests human neonatal apneas are the result of 
opioid exposure through maternal milk (Naumburg and Meny, 1988).  Therefore, 
maternal methadone may increase apnea prevalence as a result of high concentrations of 
methadone impairing neonatal respiratory neural circuitry. However, while concentrated 
methadone could induce apneas in neonates, methadone suppresses sighs (Bell et al., 
2011), which were elevated after MM in P0 neonates. Therefore, elevated neonatal 
methadone levels alone are unlikely to explain both the increase in apneas and increase in 
sighs. Since apneas are more common in preterm or very early neonatal infants (Greer, 
2012), maternal methadone could alternatively delay neurogenesis (Wu et al., 2014) and 
accelerate myelination (Hauser and Knapp, 2018; Vestal-Laborde et al., 2014). 




formation as maternal treatments began at E17, the day respiratory rhythm begins (Greer, 
2012). A relatively immature respiratory control system could also explain the increased 
prevalence of apneas after maternal methadone. 
Maternal methadone alone did not significantly reduce neonatal weight gain. 
Other reports (Byrnes and Vassoler, 2018; McLaughlin and Zagon, 1980) suggest longer 
maternal methadone treatments reduce neonatal weights, suggesting our exposure starting 
on E17, during a critical period for neurorespiratory development, is not inducing global 
developmental deficits. However, in combination with daily acute methadone, neonatal 
weights after MM were reduced at P3-4. Similarly, human infants withdrawing from 
methadone gain less weight in the first week of life, despite hyperphagia, suggesting 
altered metabolism after acute methadone (Martinez et al., 1999). Since we did not assess 
metabolism in our studies, it is unclear if maternal methadone alters neonatal rat 
metabolism. Further, it is unlikely maternal methadone induces long-lasting deficits in 
weight gain since adult weights are normalized in other studies with longer maternal 
methadone treatments (McLaughlin and Zagon, 1980). However, it remains unclear if 
adult weights are impacted by the combination of maternal methadone and daily acute 
methadone. 
 Peak hypoxic responses were unaffected by maternal methadone, demonstrating 
the respiratory control network can still respond appropriately to hypoxic stimuli. The 
phase I, peak hypoxic ventilatory response is typically attributed to activation of the 
peripheral chemosensors in the carotid body (Fung et al., 1996), which express opioid 
receptors (Ricker et al., 2015) and are inhibited by opioids in adults (Ricker et al., 2015). 




brainstem (Bailey et al., 2000; Pattinson, 2008), suggesting a balancing of peripheral and 
central effects. Thus, the results presented here suggest maternal methadone does not 
alter carotid body function. Regardless of maternal treatment, the phase I ventilatory 
response to hypoxia increased substantially in the first 6 days of life, similar to previous 
reports of HVR development (Liu et al., 2006). 
Unlike phase I, the phase II hypoxic ventilatory decline was significantly 
attenuated after maternal methadone. Phase II is known to be most severe in young 
neonates (Bissonnette, 2000; Liu et al., 2006; Moss et al., 1987) and is mediated by more 
complex mechanisms, likely involving changes in metabolism during hypoxia and 
brainstem signaling (Bissonnette, 2000). Purinergic signaling is significantly involved in 
hypoxic ventilatory depression, especially in young neonates (Elnazir et al., 1996; 
Gourine et al., 2005; Rajani et al., 2018), though it remains controversial (Funk and 
Gourine, 2018). The role of purinergic signaling in perinatal rats changes substantially 
from fetal to neonatal ages in rats (Huxtable et al., 2009), suggesting maternal methadone 
may alter the normal development of the purinergic system to blunt the hypoxic 
ventilatory decline after maternal methadone at P0. Interestingly, and contrary to our 
findings, human infants from mothers suffering from polysubstance abuse had 
significantly greater acute hypoxic responses and greater hypoxic ventilatory decline in 
the first week of life (Ali et al., 2016). However, these effects are confounded by the 
intake of multiple different types of drugs, which may independently or additively alter 
development (Nettleton et al., 2008). Thus, maternal methadone blunts the hypoxic 
ventilatory decline in neonatal rats, though whether this is physiologically advantageous 




 Maternal methadone did not alter hypercapnic ventilatory responses, suggesting 
the central networks sensing CO2/pH are not altered by maternal methadone. Unlike the 
response in rats, maternal methadone or morphine enhances the HCVR in guinea pigs 
(Nettleton et al., 2008). Contrary to ours and other animal findings, human infants 
chronically exposed to prenatal methadone have significantly blunted HCVRs, which 
persist for the first two weeks of life (Olsen and Lees, 1980). These differences in the 
HCVRs may be explained by species differences, the duration, or timing of maternal 
methadone exposure. Our paradigm had only 5 days of maternal methadone, while the 
others last for at least half of gestation, suggesting earlier developmental exposure to 
methadone may have differential effects on hypercapnic responses. 
Maternal methadone had no significant effect on baseline breathing responses to 
daily, repetitive acute methadone, but desensitized P0-1 neonates to acute methadone-
induced respiratory depression. There are at least three explanations for these changes in 
opioid sensitivity. Firstly, maternal methadone could downregulate expression of opioid 
receptors in neonates, thereby reducing preBötC sensitivity to opioids from P0-1 and 
blunting methadone-induced respiratory depression. Maternal buprenorphine 
downregulates µ-opioid receptors in P1 rat whole brains (Belcheva et al., 1998), 
demonstrating expression of µ-opioid receptors is influenced by gestational opioids. 
Additionally, µ-opioid receptors normally increase in the rat brainstem from P3-6 (Kivell 
et al., 2004) and, as opioid receptor expression increases, methadone-induced respiratory 
frequency depression likely also increases, potentially explaining the increase in 
methadone-responses at P3 after maternal methadone. Secondly, competing inhibitory 




respiratory depression at P0-1 after maternal methadone. While the preBötC rhythm is 
inhibited by opioids, the pFRG rhythm may be facilitated by opioids in P0-2 rats 
(Onimaru et al., 2006; Tanabe et al., 2005). Therefore, increased pFRG excitation could 
counteract depression in the preBötC to blunt methadone-induced frequency depression. 
Third, in utero exposure to methadone could impair preBötC activity during 
development, such that the respiratory network is more reliant on pFRG rhythm 
generation in the first two days of neonatal life. Thus, a rhythm generating network 
dominated by the pFRG would be less sensitive to opioid-induced respiratory depression. 
Future experiments assessing methadone responses of isolated respiratory circuitry and 
the developmental expression of opioid receptors would help delineate how maternal 
methadone alters methadone-induced respiratory depression. 
Interestingly, only maternal methadone treated neonates exhibited differential 
methadone responses over time, due to their blunted acute methadone sensitivity at P0-1. 
Previous studies are conflicting on the development of opioid-induced frequency 
depression in rodents. One study demonstrates early µ-opioid receptor-induced 
respiratory depression is blunted at P1 relative to P10 (Greer et al., 1995), while another 
suggests respiratory frequency depression is similar between P2 and P8 (Colman and 
Miller, 2001). Here, methadone sensitivity was unchanged over time in neonates from 
maternal saline and maternal no treatment groups, suggesting no developmental shifts in 
opioid sensitivity. However, here we used repetitive daily methadone injections in the 
same rats from P0-5 and, in many other physiological systems, opioids induce tolerance 
within the first few exposures in rodents (Ling et al., 1989). Tolerance in the respiratory 




has not been observed in other studies (Emery et al., 2016; Levitt and Williams, 2018). 
Here, we found no evidence for tolerance after repeated daily acute methadone exposure. 
Furthermore, it is widely thought the respiratory control system does not develop opioid-
induced tolerance (Emery et al., 2016; Levitt and Williams, 2018), which increases 
vulnerability of patients to lethal respiratory depression with opioid over-use.  
P0-5 is an important developmental period for respiratory rhythm generating 
mechanisms during which the dominance of the two respiratory oscillators switches 
(Huckstepp et al., 2016a). However, the precise timing of the switch is not clear. The 
phenomenon of quantal slowing represents a physiological means to probe the functional 
interactions of these two oscillators, whereby quantal slowing occurs when the two 
oscillators are in phase (Wittmeier et al., 2008) and the preBötC is the dominant 
inspiratory rhythm generator. Regardless of maternal treatment, quantal slowing emerged 
in the majority of rats at P2. This change likely reflects a network reorganization at this 
age irrespective of maternal treatment and suggests a strengthening in connectivity 
between the pFRG and preBötC. Previous work demonstrates pFRG activity precedes 
and drives preBötC activity in P0-1 rats (Onimaru and Homma, 2003) and then 
synchronizes with preBötC activity at P2 (Oku et al., 2007), suggesting quantal slowing 
may only emerge when the two oscillator’s activities are tightly coupled. Additionally, 
the changes in this coupling of activity may be related to the considerable maturation of 
neurotransmitter systems occurring at this developmental stage. These changes include 
large changes in chloride conductance and its inhibition of respiratory rhythm (Ren and 
Greer, 2008), increased preBötC GABA receptor expression at P2 (Liu and Wong-Riley, 




Such changes may strengthen connections between the preBötC and pFRG, coupling 
their activity, and contributing to the emergence of quantal slowing at P2. The emergence 
of quantal slowing and shifts in functional connectivity between oscillators may have 
important implications for interpreting rhythm generating mechanisms at different 
neonatal ages. Specifically, the majority of studies on respiratory rhythm generation 
occur in neonatal rodents in the first week of life; however, the precise age range varies 
between and within studies. Therefore, investigations of respiratory circuitry before and 
after P2 may reveal divergent results and should be interpreted with these developmental 
changes in mind.  
In our studies, maternal methadone treatment began on E17 because it is the first 
day of rhythmic respiratory neural activity, respiratory motor output, and fetal breathing 
movements in rats (reviewed in Greer, 2012). While other studies focused on the 
developmental impact of maternal opioids begin earlier to match the period when opioid 
receptors are first expressed in rodents (Byrnes and Vassoler, 2018), our experimental 
paradigm was intended to mitigate any other developmental effects of methadone and 
focus on this important period of neurorespiratory development. Methadone was chosen 
since it is commonly used as a clinical treatment in pregnant women and neonates 
(Bhavsar et al., 2018; Davis et al., 2018; Kraft et al., 2016; Pryor et al., 2017). However, 
methadone is also a non-competitive NMDA antagonist (Laurel Gorman et al., 1997), 
which may contribute to opioid-induced respiratory depression (Hoffmann et al., 2003). 
Furthermore, mice lacking NMDA receptors have more apneas in the first few days of 
life (Poon et al., 2000). However, central respiratory rhythm-generating networks develop 




apneas may be due to in utero alterations to  mechanosensory, chemosensory, or pontine 
respiratory areas (Funk et al., 1997; Poon et al., 2000). In our study, as we cannot 
determine the source of apneas, it is unclear if methadone antagonism of NMDA 
receptors is contributing to early-life respiratory instability. 
Endogenous opioid systems modulate neonatal breathing (Jansen and Chernick, 
1983) and may be altered by chronic methadone exposure. A surge of endorphins shortly 
after birth in neonatal brains (Jansen and Chernick, 1983) inhibits the preBötC, causing 
the pFRG to acutely dominate respiratory rhythm and maintain breathing rhythm 
(Feldman and Del Negro, 2006; Janczewski and Feldman, 2006). It is unclear if maternal 
methadone changes in the endogenous opioid system to impair respiratory instability at 
P0 or blunt early insensitivity to acute methadone. However, it is unlikely alterations in 
the endogenous opioid system explain the results presented here since maternal 
methadone in rats did not alter the endogenous opioid system in the neonatal rat ventral 
respiratory column (Gourévitch et al., 2017).  
Understanding how maternal opioids alter neurorespiratory development is 
important for enhancing treatments for neonates exposed to in utero opioids. Our data 
support the hypothesis that maternal methadone increases apneas and destabilizes 
neonatal breathing. This instability may be clinically relevant as apneas are more 
common in babies who die of sudden infant death syndrome (SIDS) (Franco et al., 2003; 
Kahn et al., 1992) and maternal methadone increases the risk of SIDS (Moon, 2016). 
Additionally, the hypoxic and hypercapnic ventilatory responses were unaffected by 
maternal treatment. However, in humans, maternal methadone depresses hypoxic 




suggesting differences in species or duration of in utero methadone exposure are 
important. Maternal methadone also blunted the acute response to neonatal methadone, 
suggesting neonates with NAS may have less respiratory depression after acute opioid 
treatments. Therefore, NAS infants potentially tolerate higher acute therapeutic doses to 
mitigate other symptoms of NAS, though the long-term impact of perinatal opioids 
remains to be determined. This protection from opioid-induced respiratory depression 
after acute methadone is lost rapidly in rats at P2, likely at the same time as the preBötC 
becomes the dominant respiratory rhythm generator. It is not clear if humans have a 
similar developmental trajectory of multiple respiratory rhythm generators as rodents.  
Importantly, the results presented here demonstrate neurorespiratory disruption by 
maternal methadone, which may be important for understanding and treating the 















CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
This discussion will summarize the key findings of each study, describe how the 
findings advance the current understanding of acute and developmental disruption to 
respiratory control, and discuss potential future experiments. 
 
 
Summary of Key Findings 
The four aims of this dissertation focus on acute and developmental disruptions to 
the neurorespiratory control system. The ability of the respiratory control system to adapt 
and maintain robust breathing is critical to preserving life (Feldman et al., 2010). 
Acutely, respiratory control is dominated by feedback control mechanisms, like the 
ventilatory response to hypoxia or hypercapnia. However, plasticity of the respiratory 
system is fundamental to longer term adaptations. A few physiological examples 
highlighting this function include acclimatization to altitude, breathing changes during 
pregnancy, and adapting to disease or injury (Fuller and Mitchell, 2017). In this 
dissertation, I investigated acute feedback control mechanisms and used phrenic long-
term facilitation (pLTF) as a model of respiratory plasticity.  
Chapters II and III focused on acute, adult inflammation and the mechanisms by 
which inflammation disrupts respiratory plasticity. Acute inflammation is common to 
almost all disorders, diseases, and injuries where breathing is compromised (Hunter, 




control during disease and injury limiting respiratory output (Strey et al., 2013). 
Therefore, advancing our understanding of how inflammation alters respiratory control is 
of immediate interest. Furthermore, respiratory plasticity is of particular interest for its 
therapeutic potential in treating obstructive sleep apnea (Mateika and Komnenov, 2017), 
facilitating recovery after incomplete spinal cord injury (Hayes et al., 2014; Tester et al., 
2014; Trumbower et al., 2012, 2017), and improving function during other motor 
disorders (Gonzalez-Rothi et al., 2015). All of these pathologies involve some element of 
inflammation (Arnold and Hagg, 2011; Meisel et al., 2005; Svensson et al., 2012). Thus, 
translation of these findings toward clinical conditions involving motor limitation and 
inflammation is major motivation for these studies. 
Chapters IV and V focus on perinatal disruption of respiratory control. The 
respiratory control system must develop and be fully functional at birth and continues to 
mature during the first two weeks of life, a critical period for neurorespiratory 
development (Greer, 2012; Liu et al., 2006). Insults to the perinatal respiratory control 
system can disrupt development and cause long-lasting alterations to respiratory control 
mechanisms (Bavis et al., 2004). In particular, early life inflammation, which acutely 
disrupts respiratory control (Poets et al., 1994; Poets and Southall, 1994) and is especially 
common in pre-term infants (Stoll et al., 2002, 2004), increases the risk of sleep apnea 
later in life (Tapia et al., 2016). Thus, Chapter IV investigates the lasting impacts of 
neonatal inflammation on adult respiratory plasticity and contributes to our basic 
understanding of how early-life insults can alter adult respiratory control. The findings 




investigating underlying mechanisms and the lasting consequences of early-life 
inflammation. 
Chapter V focuses on perinatal opioid exposure, a separate, yet increasingly 
common perinatal insult. Maternal opioid use is on the rise (Epstein et al., 2013; Krans et 
al., 2015; Stover and Davis, 2015) and results in infants born with neonatal abstinence 
syndrome (NAS) (Finnegan et al., 1975; Hudak et al., 2012). NAS is characterized by 
dysfunction of the central and autonomic nervous system (Kraft et al., 2016). The 
increase maternal use of opioids and risk of NAS has created a significant clinical need to 
improve treatments for infants perinatally exposed to opioids (Kraft et al., 2016). Opioids 
suppress the preBötC activity, which is responsible for respiratory rhythm generation 
(Smith et al., 1991) and must develop before birth (Greer, 2012).  As infants with NAS 
are more likely to have respiratory instability and apneas (Beckwith and Burke, 2015), 
Chapter V investigated the impact of maternal opioids on neonatal respiratory control 
mechanisms. These studies are the first to investigate respiratory control in rats exposed 
to maternal opioids and provide a basis for future research investigating short and long-
term effects of perinatal opioids on respiratory control mechanisms. Specifically, these 
studies provide novel data regarding the effects of maternal opioids destabilizing neonatal 
breathing and blunting acute opioid-induced respiratory depression. Understanding 
mechanisms by which perinatal opioids alter respiratory control will contribute to our 
ability to treat infants born to opioid-using mothers. 









Figure 6.1. Summary of major findings. Aim 1) Both peripheral and cervical spinal IL-
1R antagonism restores pLTF after acute, adult inflammation. These data demonstrate 
peripheral IL-1 signaling back to the CNS and local IL-1 signaling in the cervical spinal 
cord are both necessary to impair adult pLTF after peripheral inflammation. Aim 2) The 
viral mimetic polyIC induces inflammation and impairs Q-pathway, but not S-pathway-
evoked, pLTF. These data extend and generalize our understanding of the impairment of 
Q-pathway pLTF by inflammation and confirm the insensitivity of S-pathway pLTF to 
acute adult inflammation. Aim 3. A single bout of neonatal inflammation impairs adult 
Q-pathway and S-pathway evoked pLTF, demonstrating long-lasting deficits in adult 
respiratory control after early-life inflammation. Aim 4. Maternal methadone increases 






Aim 1) Interleukin-1 signaling after acute, systemic inflammation undermines adult 
respiratory motor plasticity (Fig. 6.1). 
Previous work has demonstrated inflammation undermines respiratory plasticity 
and is restored by anti-inflammatory treatment (Huxtable et al., 2013, 2015; Vinit et al., 
2011). The study, presented in Chapter II, was the first to demonstrate the importance of 
a single inflammatory cytokine receptor, IL-1R, in impairing pLTF after acute 
inflammation, adding to our mechanistic understanding of how systemic inflammation 
impairs neurorespiratory control mechanisms. Furthermore, these experiments 
demonstrate the necessity of IL-1R activation in the cervical spinal cord for impairing 
pLTF after peripheral inflammation. This is the first direct demonstration of local spinal 
inflammatory cytokines impairing respiratory plasticity, suggesting inflammation is 
transmitted from the periphery to the cervical spinal cord to impair plasticity. As IL-1R 
antagonism restored pLTF, we next tested the sufficiency of IL-1 in the cervical spinal 
cord to impair pLTF. IL-1 is an endogenous inflammatory cytokine activating IL-1R 
and has no known off-target binding. Exogenous spinal IL-1 was not sufficient to impair 
pLTF, suggesting other inflammatory signaling mechanisms, likely involving other 
inflammatory cytokines, are also required. LPS also upregulates other inflammatory 
cytokines in the cervical spinal cord, including iNOS and COX-2  (Huxtable et al., 2013), 
which may have additive effects and contribute to the impairment in pLTF after 
inflammation. 
Other IL-1R ligands could be involved in activating IL-1R after LPS-induced 
inflammation. IL-1 and IL-1 both activate IL-1R, and are thought have to identical 




inflammatory effects in the CNS through more potent activation of astrocytes (Liddelow 
et al., 2017). It is possible spinal IL-1, presumably still acting through IL-1R, is 
sufficient for impairing pLTF and should be the topic of future studies.  
In a separate model of inflammation induced by intermittent hypoxia, p38 MAPK 
activation, a kinase downstream of many inflammatory signaling pathways, is required to 
impair pLTF (Huxtable et al., 2015). Chapter II adds to a working model, whereby 
peripheral inflammation is transmitted to the cervical spinal cord, activating IL-1Rs 
which leads to p38 MAPK activation and impairment of pLTF. In the hippocampus, IL-
1β activates p38 MAPK and p38 MAPK activation is responsible for attenuating 
hippocampal plasticity (Curran et al., 2003; Kelly et al., 2003). However, to date, no 
studies have directly linked IL-1R activation with p38 MAPK activation in impairing 
respiratory plasticity and thus, should be the topic of future investigations. Additionally, 
the mechanism by which p38 MAPK impairs plasticity is unknown. One hypothesis 
suggests p38 MAPK activates protein phosphatase 1 (PP1), which is key to the pattern 
sensitivity of pLTF (Huxtable et al., 2018). Future studies could use available inhibitors 
for p38 MAPK and PP1 to further elucidate the mechanisms by which inflammation and 
IL-1 signaling impairs plasticity in the cervical spinal cord. 
 Taken together, Chapter II demonstrates the inflammatory impairment in pLTF is 
due to cervical spinal IL-1 signaling. Furthermore, these studies suggest a more complete 
working model by which IL-1 signaling activates downstream signaling pathways to 
impair plasticity. However, the specific cell-types involved in impairing plasticity remain 
unknown. IL-1R is primarily localized to endothelial cells in the cervical spinal cord (K. 




neurons after inflammation (Huxtable et al., 2015). Therefore, other intermediate 
signaling molecules may be responsible for linking IL-1R activation with downstream 
mechanisms like p38 MAPK activation to impair pLTF. Future investigations should 
target cell-specific mechanisms of the inflammatory impairment of pLTF. 
 
Aim 2) Viral mimetic-induced inflammation abolishes Q-pathway-evoked, but not 
S-pathway-evoked, adult respiratory motor plasticity in rats (Fig. 6.1). 
Inflammation arises from a variety of sources throughout our lives. Inflammation 
induced by either LPS or by intermittent hypoxia undermine pLTF (Huxtable et al., 2013, 
2015, 2017; Vinit et al., 2011). However, viral-induced inflammation is one of the most 
common sources of inflammation (Obasi et al., 2014). Chapter III demonstrated the 
inflammatory impairment of pLTF could be generalized to inflammation induced by a 
viral mimetic. Therefore, the inflammation-induced impairments in respiratory plasticity 
are generalizable to different sources of inflammation, suggesting diverse inflammatory 
stimuli are relevant to altering respiratory control. Additionally, viral infections are 
particularly common in patients with spinal cord injury (Bracchi-Ricard et al., 2016), 
which is the focus of using respiratory plasticity as a therapeutic agent (Hayes et al., 
2014; Tester et al., 2014; Trumbower et al., 2012, 2017).  
While Q-pathway-evoked pLTF is impaired by inflammation, the S-pathway is 
inflammation-resistant (Agosto-Marlin et al., 2017). Here, we support the findings of the 
inflammation-resistance of S-pathway using a distinct model of inflammation. This 
finding has important clinical significance as it suggests an alternative pathway to 




pathway could be targeted therapeutically with more severe AIH protocols to elicit 
beneficial responses in patients not responding to moderate AIH. However, clinicians are 
often concerned about exposing patients to severe hypoxia. Therefore, future pre-clinical 
studies should explore different AIH protocols, including more severe AIH, to investigate 
if more severe paradigms are safe and effective in humans. If more severe AIH is safe 
and effective, it may prove to be an effective strategy for eliciting plasticity in patients 
resistant to moderate AIH.   
Mechanistically, it is unknown if viral inflammation impairs plasticity via the 
same mechanisms as LPS or intermittent hypoxia-induced inflammation. Therefore, 
additional studies could build on our findings by investigating if IL-1R activation is also 
necessary after polyIC-induced inflammation and if mechanisms downstream of IL-1R, 
such as p38 MAPK, are also involved. Though these mechanism are likely similar, 
distinct mechanisms would suggest unique strategies may be needed to mitigate 
inflammation and elicit plasticity depending on the source of inflammation. However, to 
date, data suggest inflammatory mechanisms converge and respiratory plasticity can be 
restored by ketoprofen (Huxtable et al., 2013, 2015). Therefore, treatments targeting 
downstream inflammatory signaling are likely sufficient to inhibit inflammation and 
allow for respiratory plasticity regardless of inflammatory stimuli. 
Another potential avenue for future research is the role of sleep-deprivation in the 
inflammatory-impairment of respiratory plasticity. A proposed function of sleep, 
especially REM sleep, is to prepare for neuroplasticity related to learning and memory 
(Abel et al., 2013). Furthermore, REM sleep is reduced by each of the inflammation-




polyIC (Krueger et al., 1988), and intermittent hypoxia (Polotsky et al., 2006). Thus, 
sleep deprivation in these models could contribute to deficits in respiratory plasticity. 
REM sleep loss specifically disrupts cell-mechanisms of hippocampal long-term 
potentiation (reviewed in Abel et al., 2013), which share features involved in pLTF 
(Turner et al., 2018), such as cAMP dependence (Grosmark et al., 2012) and 
downregulated NMDA activity (McDermott et al., 2006). Therefore, REM sleep 
disruption could also contribute to the cellular mechanisms inhibiting pLTF. However, 
the precise mechanisms by which sleep deprivation alters cell functions involved in 
plasticity are unclear. REM sleep deprivation also causes inflammation in rats (Yehuda et 
al., 2009), suggesting REM sleep disturbances could impair plasticity by inducing 
inflammation. Future studies should investigate the role of sleep deprivation in impairing 
pLTF. Does sleep deprivation alone impair pLTF? Is the impairment dependent on 
inflammatory signaling? Understanding the impact of sleep alterations in regulating 
respiratory plasticity may be especially relevant in clinical conditions like sleep apnea, 
where sleep architecture is disrupted and respiratory plasticity may be a therapeutic 
strategy to reduce symptoms of sleep apnea (Mateika and Komnenov, 2017). 
 
Aim 3) One bout of neonatal inflammation impairs adult respiratory motor 
plasticity in male and female rats (Fig. 6.1). 
 Chapter IV shifts from acute inflammation in adults to studying the long-lasting 
effects of early-life inflammation. While the adult respiratory control system is known to 
be susceptible to other early-life stressors (Bavis et al., 2004; Fournier et al., 2011; 




perinatal inflammation has numerous effects on non-respiratory adult physiological 
systems (Bilbo, 2005, 2010; Bilbo et al., 2006, 2010; Grace et al., 2014; Hornig et al., 
1999; Mouihate et al., 2010; Rantakallio et al., 1997; Shanks et al., 2000; Spencer et al., 
2011; Wang et al., 2013). Chapter IV demonstrated, for the first time, a single bout of 
neonatal inflammation impairs Q- and S-pathways to adult respiratory plasticity. We 
hypothesize that respiratory plasticity compensates and stabilizes breathing in the face of 
conditions compromising breathing, such as injury or sleep apnea. Therefore, our 
findings suggest the respiratory control network is vulnerable to early-life inflammation, 
which may limit the capacity to compensate to disease or injury later in life and 
contribute to adult ventilatory control disorders. 
We found the impairment of Q-pathway plasticity in adults is dependent on acute 
inflammatory signaling. However, no lasting increase in adult inflammatory gene 
expression was evident in relevant CNS regions. It is possible cell-specific inflammatory 
signaling changes could be responsible for the inflammatory impairment of Q-pathway-
evoked pLTF. Future experiments are in progress to identify cell-specific changes in 
inflammatory signaling related to these findings. 
The impairment in S-pathway evoked plasticity was independent of acute 
inflammatory signaling. However, acute adenosine receptor agonism revealed S-pathway 
plasticity suggesting upstream impairments, such as the source of adenosine. Astrocytes 
are likely to be the primary source of adenosine during hypoxia (Angelova et al., 2015; 
Takahashi et al., 2010). Therefore, future studies implementing genetic strategies to 




2018) would be useful in elucidating the role of astrocytes and the source of adenosine in 
activating S-pathway-evoked plasticity.  
 Importantly, chapter IV is one of only a few studies investigating respiratory 
motor plasticity in females (Behan et al., 2002; Dougherty et al., 2017) and is the first to 
demonstrate a number of findings in female rats. This is the first report to demonstrate the 
presence of S-pathway-evoked pLTF in females, evoked by either severe AIH or 
adenosine receptor agonism. The S-pathway may be relevant for therapeutic uses as it is 
thought to act as an important backup pathway when Q-pathway is impaired. This is also 
the first demonstration in females of Q-pathway impairment by inflammatory signaling. 
Thus, though respiratory plasticity is estrus-cycle dependent (Dougherty et al., 2017), 
mechanisms stimulating or inhibiting respiratory plasticity do not differ by sex. Future 
experiments should continue to include females, especially translational studies using 
AIH therapeutically to improve breathing (Tester et al., 2014) and other motor functions 
(Hayes et al., 2014; Trumbower et al., 2012, 2017). 
 
Aim 4) Maternal methadone destabilizes early neonatal breathing and desensitizes 
neonates to acute methadone-induced respiratory depression (Fig. 6.1). 
 Maternal methadone is another common perinatal insult and directly inhibits 
respiratory rhythm generation. Chapter V demonstrates maternal methadone exposure 
during respiratory network development (E17-birth) (Greer et al., 2006; Pagliardini et al., 
2003), destabilizes neonatal breathing by increasing apneas and post-sigh apneas in P0 
neonates. Thus, infants born to opioid using mothers may have exacerbated respiratory 




common in babies who die of sudden infant death syndrome (SIDS) (Franco et al., 2003; 
Kahn et al., 1992) and maternal methadone increases the risk of SIDS (Moon, 2016). We 
also demonstrate a significant blunting of methadone-induced respiratory depression at 
P0-1 after maternal methadone. As neonates are commonly treated with methadone to 
mitigate symptoms of withdrawal, this finding suggests neonates may have blunted 
methadone sensitivity early in life and could tolerate higher doses, though this effect 
rapidly normalized at P2 in rats. However, higher acute doses in neonates should be 
balanced with the potential for long-term consequences of opioid exposure in neonates. 
Our investigation into the effects of perinatal methadone also provided an 
opportunity to understand the development of respiratory rhythm generating mechanisms 
in the first few days of life. During development, two rhythm generating regions 
contribute to breathing in neonates; the opioid-sensitive preBötC and the opioid-
insensitive pFRG (Huckstepp et al., 2016b; Mellen et al., 2003). P0-5 is an important 
developmental period during which the dominance of these respiratory oscillators 
switches (Huckstepp et al., 2016b; Onimaru, 2006; Onimaru and Homma, 2003), though 
the precise timing of this transition is unclear. Chapter V also provides evidence 
suggesting P2 is the age at which the preBötC and pFRG activity synchronize and 
therefore, quantal slowing emerges in the presence of opioids (Huckstepp et al., 2016b; 
Mellen et al., 2003; Wittmeier et al., 2008). Before P2, other reports suggest the pFRG is 
pre-inspiratory and may drive preBötC inspiratory activity (Onimaru et al., 2006). Thus, 
these findings provide important context for the interpretation of many studies of 
respiratory rhythm generation, which typically study rats in the first week of life. 




inspiratory rhythm is driven by pFRG and connections from preBötC to pFRG are 
relatively weak. After P2, pFRG activity continues to shift toward post-
inspiratory/expiratory activity patterns through the first week when it becomes 
predominately expiratory (Janczewski and Feldman, 2006).  
Future studies should focus on understanding the mechanistic effects of maternal 
methadone in isolated respiratory circuitry, the mechanisms driving breathing instability 
in P0-1 neonates, and the long-term consequences of perinatal opioid exposure. 
Experiments in isolated respiratory circuitry will be important for understanding the 
mechanisms involved in blunting opioid-induced respiratory depression after maternal 
methadone. Direct application of opioids on the preBötC and in brainstem spinal cord 
preparations could demonstrate if isolated respiratory circuitry is sufficient to replicate 
blunted opioid-induced respiratory depression or are other brain regions involved in this 
change in sensitivity. Next, the mechanisms responsible for respiratory instability and 
increased apneas after maternal methadone are unknown. One possibility is an increased 
endogenous opioid system. Upregulated opioid receptors or more available endogenous 
opioids would inhibit rhythm generation and contribute to breathing instability. 
Therefore, future studies with acute opioid receptor antagonists in P0-1 neonates after 
maternal methadone could demonstrate if changes in neonatal rhythm instability were 
due to elevated endogenous opioids. Finally, are there long-term consequences of 
perinatal opioid exposure on adult respiratory control? Neonatal opioids may induce 
opioid hypersensitivity in adults (Kennedy, 2014), making them more susceptible to 




(Wang et al., 2012), which could itself induce many long-lasting physiological changes 
as demonstrated in Chapter IV. 
The potential interplay between opioids and inflammatory signaling raises 
interesting questions and potentially unites the findings of Chapters II-V. Opioids activate 
Toll-like receptor 4 (TLR4), the pattern recognition receptor which is activated by LPS, 
and increase pro-inflammatory signaling (Hutchinson et al., 2009). The most well 
characterized opioid-induced inflammatory effects are from morphine; however, other 
clinically relevant opioids (e.g. methadone, oxycodone) also directly activate TLR4 
(Grace et al., 2015). Opioid-induced inflammatory signaling occurs in multiple species, 
whereby chronic intrathecal morphine upregulates spinal inflammatory cytokines in both 
rodents (Johnston, 2004) and in humans (Zin et al., 2010). These underappreciated opioid 
signaling pathways mechanistically link opioid actions with inflammation. Thus, 
perinatal opioids may induce inflammation and have long-lasting consequences, 
impairing adult respiratory plasticity as demonstrated in chapter IV.  Furthermore, acute, 
adult opioid exposure could induce inflammation and impair respiratory plasticity similar 
to the inflammatory impairments in pLTF in Chapter II and III.  Thus, opioid use in 
clinical scenarios, such as post-operative care, may limit the adaptability of the 
respiratory system after surgery. Potential acute opioid-induced impairments in 
respiratory plasticity may also be relevant for using AIH therapeutically, especially in 
chronic spinal cord injury patients who are likely to use opioids for pain management 
(Hand et al., 2018) and are a promising target population for therapeutic AIH (Fuller and 




Therefore, the interactions between opioids and inflammation in respiratory control are 
worthy of future investigation. 
 
Conclusions 
 The respiratory system must be adaptable in order to produce the necessary 
rhythmic motor output to drive ventilation. Respiratory plasticity is an important feature 
of this adaptability (Mitchell and Johnson, 2003). Importantly, basic science research into 
mechanisms of respiratory plasticity has directly led to development of promising 
therapeutic interventions to promote breathing and other motor function in patients with 
motor limitations (Fuller and Mitchell, 2017; Hayes et al., 2014; Tester et al., 2014; 
Trumbower et al., 2012, 2017). However, inflammation may limit the therapeutic benefit 
of respiratory motor plasticity. Thus, research furthering our understanding of respiratory 
plasticity, how plasticity can be undermined, and strategies to enhance the benefits of 
plasticity are critical for future clinical developments.  
 The research presented in this dissertation contributes to our fundamental 
understanding of how inflammation impairs adult respiratory plasticity, both acutely and 
after a single early-life exposure. It also builds on previous research (Agosto-Marlin et 
al., 2017), suggesting alternative pathways to evoking plasticity (such as severe AIH and 
S-pathway pLTF) may be beneficial for eliciting therapeutic plasticity in inflammatory 
conditions. Additionally, it lays the groundwork for future investigations in 
understanding how early-life inflammation causes lasting respiratory system 




pathway-specific changes after early-life inflammation will help us understand the lasting 
respiratory impairments after early-life inflammation.  
 Finally, the impact of maternal opioid use on neonatal breathing is of growing 
interest as the rates of maternal opioid use continue to rise (Epstein et al., 2013; Kraft et 
al., 2016; Krans et al., 2015; Stover and Davis, 2015). The research presented here lays 
the foundation for future studies investigating how perinatal opioids alter the developing 
endogenous opioid system, how isolated respiratory circuitry is altered by maternal 
opioids, and what the long-term consequences of perinatal opioids are for adult 
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